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ABSTRACT 
Antisera were prepared against pigeon thymus and bursa 
lymphocytes and against saline extracts of thymus and bursa. 
All unabsorbed sera were screened for differential reac-
tivity against thymus and bursa-derived tissue by several 
techniques. Selected sera were absorbed with thymus and 
bursa tissue to demonstrate specificity. One serum with 
specificity against thymus extracts was identified by 
immunodiffusion. The thymus specificity was absent from 
extracts of pigeon bursa, brain, liver and breast muscle, 
but present in spleen extracts. This thymus specificity 
does not appear analogous to lymphocyte specificities 
identified in other species. Shared tissue specificities 
and a possible quantitative antigenic difference among the 
tissue extracts were also demonstrated by immunodiffusion 
and absorption analysis. In lymphocytotoxicity tests, 
fresh rabbit normal serum is highly toxic for pigeon thymus 
and bursa cells. This toxicity, in general, resembles the 
natural antibody present in rabbit and guinea pig sera 
against heterologous thymus cells. A rabbit anti-pigeon 
gamma globulin serum was rendered specific for bursa cells 
by absorption with thymus cells. Some standard anti-
lymphocyte sera were shown to contain an antibody fraction 
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specific for thymus cells. Some or all of these reagents 
may be useful for distinguishing cooperating cell popula-
tions in a variety of innnune responses. 
An antigen was demonstrated on red cells from all 
pigeon squabs less than four days old. The antigen appears 
not to Jbe secondarily adsorbed to the red cells from the 
fluids of the egg or the embryo. In vitro, masking of the 
antigen by components of adult serum does not occur under 
the conditions tested. Although the squab antigen behaves 
similarly to a known fetal red cell antigen in doves, it is 
probably qualitatively different from that antigen and from 
the known chick red cell antigen. The squab antigen is not 
detectable on lymphocytes from the b ursa or the thymus. 
Virgin female CBA/J mice were obtained after a variety 
of treatments and observed for primary tumors until either 
tumor onset or death. Included were mice which were: 
(1) imrnunosuppressed as adults by injection of anti-
thymocyte serum (ATS); (2) injected with normal rabbit 
serum; (3) immunized with an irrevelant antigen or (4) 
untreated. Data were collected on tumor histology, inci-
dence and time of onset for all groups. No tumors appeared 
during the period of ATS-immunosuppression or for several 
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months following treatment. The most frequently observed 
subsequent tumor was the typical mammary tumor. Although 
the first tumors appeared in ATS-treated mice, the mean age 
at tumor onset was not significantly affected by ATS-
immunosuppression. No unusual tumors and no lymphomas 
were observed. Tumor incidences among groups of mice 
purchased at; different times were different, but unrelated 
to ATS-immunosuppression. The failure of ATS-immunosuppres-
sion to affect growth is consistent with the fact that 
cellular immunity to mammary tumors is often specifically 
compromised. 
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I. THYMUS AND BURSA SPECIFIC ANTIGENS OF THE PIGEON 
A. Abstract 
Lymphocytes of thymus-dependent and thymus-independent 
origins have separate roles in the immune response, but may 
cooperate in the antibody response to certain antigens. 
The lymphocytes look alike, but they can sometimes be 
distinguished from each other by serological means. The 
immune systems of birds are unique in that the functionally 
distinct populations of lymphocytes are anatomically sepa-
rated in the central lymphoid organs - the thymus and the 
bursa of Fabricius. The avian immune system is used as a 
model for understanding mammalian immune systems. Coopera-
tion between lymphocyte populations has been demonstrated 
in the avian antibody response although not with the two 
anatomically separate lymphocyte populations. Few sero-
logical markers are known for avian lymphocytes. Additional 
markers could more clearly identify distinct interacting 
cells and determine their roles in synergistic immune 
responses. 
Antisera were prepared against pigeon thymus and bursa 
lymphocytes and against saline extracts of thymus and bursa. 
All antisera were prepared in rabbits - some as standard 
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anti-lymphocyte reagents and some in rabbits injected neo-
natally with large doses of pigeon cells. The neonatal 
injections were made to reduce the rabbits' antibody 
response to species-specific antigens upon challenge with 
pigeon lymphoid tissue. 
All unabsorbed sera were screened for differential 
reactivity against thymus and bursa-derived tissue by 
passive hernagglutination, immunodiffusion, leukoagglutina-
tion and complement dependent lymphocytotoxicity. Sera 
identified in this manner were absorbed with thymus and 
bursa tissue to demonstrate specificity. One serum with 
specificity against thymus extracts was identified by 
immunodiffusion. The thymus specificity was absent from 
extracts of pigeon bursa, brain, liver and breast muscle, 
but present in spleen extracts. The thymus specificity was 
shared by extracts of thymus from two different breeds of 
pigeon but not extracts of chicken lymphoid tissue. This 
thymus specificity does not appear analogous to lymphocyte 
specificities identified in other species. 
Shared tissue specificities and a possible quantita-
tive antigenic difference among the tissue extracts were 
also demonstrated by immunodiffusion and absorption analysis. 
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In lymphocytotoxicity tests, fresh rabbit normal serum 
is highly toxic for pigeon thymus and bursa cells. This 
toxicity resembles the natural antibody present in rabbit 
and guinea pig serum against heterologous thymus cells. 
The activity against pigeon lymphocytes can be absorbed by 
pigeon thymus and bursa cells and is heat labile. Unlike 
the natural antibody against thymus cells of other species, 
the toxicity against pigeon lymphocytes could not be 
absorbed by agarose. 
A rabbit anti-pigeon gamma globulin serum was rendered 
specific for bursa cells by absorption with thymus cells. 
Some standard anti-lymphocyte sera were shown to contain an 
antibody fraction specific for thymus cells. 
Some or all of these reagents nay be useful for dis-
tinguishing cooperating cell populations in a variety of 
immune responses. Avian species, in addition to the chicke~ 
may provide additional data on the phylogeny of functionally 
distinct lymphocyte populations. 
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B. Introduction 
Avian species are unique in the animal world for their 
structural compartmentalization of the immune system. The 
central lymphoid organs, the thymus (T) and the bursa of 
Fabricius (B), provide cells and maturation hormones for 
the immune system. They develop in the late embryo~ and 
lymphocyte formation in these organs is maintained in the 
absence of antigen. The peripheral lymphoid organs - the 
spleen, lymph nodes, and circulating lymphocytes - require 
the presence of both central lymphoid organs for their sub-
sequent development. Cells of the peripheral lymphoid 
organs participate directly in specific immune responses. 
Cells within tre bursa or the thymus are not generally 
imrnunocompetent, although a small subpopulation may be 
imrnunocompetent. Both bursa and thymus are considered 
sites of maturation for stem cells of bone marrow origin. 
Once the cells become mature immunocompetent lymphocytes, 
they are seeded into the peripheral lymphoid structures 
where effective contact with antigen can occur. 
The demonstration that bursa and thymus are function-
ally distinct was obtained by hormonal or surgical removal 
of each central lymphoid organ from neonatal chicks. 
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Bursectomy and thymectomy produce non-identical deficits 
in immune responsiveness. Immune dysfunction is most 
marked when surgical removal is combined with a general 
immunosuppressive or lymphocytotoxic treatment. This 
latter treatment kills immunocompetent lymphocytes which 
have already left the central lymphoid organs. Thymectomy 
or bursectomy of older chicks without such additional 
immunosuppression has almost no immunosuppressive effect ~ 
No significant deviation from normal may be evident until 
the animal reaches advanced age. 
Neonatal thymectomy reduces all cell-mediated immune 
functions as measured by allograft survival and delayed 
hypersensitivity reactions. Circulating lymphocyte levels 
are severely reduced. Neonatal thymectomy depresses the 
primary antibody response to some antigens while response 
to other antigens remains intact. The secondary antibody 
response~ are not significantly affected. 
The complementary immune deficits are observed fol-
lowing neonatal bursectomy and x-irradiation of the chick. 
Specific antibody responses are severely depressed and 
serum immunoglubin levels are greatly reduced. Graft 
rejection and delayed hypersensitivity responses are 
virtually normal. 
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Surgical bursectomy of chick embryos at 19 days of 
incubation selectively prevents the later appearance of 
serum IgG immunoglobulins (16). If bursectomy is per-
formed even earlier in ovo, at 17 days of incubation, 
neither IgG nor IgM immunoglobulins appear in the serum. 
Developmentally in the chick, the capacity to produce the 
distinct immunoglobulin classes precedes from IgM to IgG 
to IgA (35). An intact bursa is required at least until 
hatching for the complete developmental sequence although 
when the serum immunoglobulins are measured, they are pro-
duced by cells then outside the bursa. 
The bursectomized and the thymectomized chicks are 
particularly useful models for understanding a dichotomy 
within the immune response which is partially observable 
in other species. The thymic role in cell-mediated immunity 
appears in many species to be equivalent to that in the 
chick. Neonatally thymectomized mice and cogenitally 
athyrnic mice and humans show severely impaired cell-
mediated immunity. Antibody responses are generally normal 
although they may be secondarily affected following severe 
infection. 
Congenitially agammaglobulinemic humans show the same 
impairment of humeral immunity as the imrnunoglobulin-
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deficient, bursectomized chick. No experimental equivalent 
has yet been found in mice because mammals do not possess 
a bursa of Fabricius or similar anatomical representation 
of the bursa. A thymus-independent or bursal equivalent 
is indicated in mice, though, since humoral antibody 
responses are generally unaffected by neonatal thymectomy. 
Chromosomal and serological markers in reconstitution 
experiments indicate that bone marrow can provide the 
thymus-independent lymphocytes in this species. 
A developmental progression of immunoglobulin c1asses 
as demonstrated by bursectomy in ovo, can be demonstrated 
in mice (38). In mice, neonatal injections of antisera 
specific for immunoglobulin class prevents the development 
of that immunoglobulin class and later developing classes 
of immu.noglobulins. In humans an apparently congenital 
immunodeficiency restricted to the IgA class of immunoglo-
bulins is known. In rats and mice, neonatal thymectomy 
decreases the IgA class of immunoglobulins. Congenitally 
thymusless mice also show depressed IgA levels (31, 40). 
This observation suggests that some functions of the avian 
thymus and bursa may be combined in the rat thymus and 
perhaps in other species as well. 
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No true equivalent of the bursa of Fabricius is known 
in mammals despite efforts to detect one. The properties 
of a potential bursa equivalent would be concentration of 
lymphocytes in close anatomical association with the gut and 
lymphocyte formation early in development of the lymphoid 
system. On this basis, tonsils, Peyer's patches and the 
appendix have been suggested as bursal equivalent structures. 
Attempts to demonstrate that these gut associated lymphoid 
tissues are functionally equivalent to the chick bursa of 
Fabricius have been unsuccessful. More likely, they are 
additional peripheral lymphoid organs. 
Two Australian rodents reportedly have 11dual thymuses•~ 
If it can be demonstrated that these two organs are not 
functionally identical to each other, these thymuses might 
be analogous to the central lymphoid organs of the chick 
or to'subpopulations of lymphocytes within either of those 
organs; or one "thymus" might be a peripheral, rather than 
central, lymphoid organ. 
Reptiles may have an anatomically closer representation 
of the avian immune system than do mammals. A few species 
of reptiles including the turtle have gut associated accumu-
lations of lymphocytes (58). As yet, there is no evidence 
9 
that these lymphoid accumulations are functionally equi-
valent to the bursa of Fabricius in chicks. 
Although the antibody response is generally considered 
a thymus-independent immune function, thymus-derived and 
bon e marrow-derived lymphocytes of the mouse cooperate in 
the antibody response to sheep red cells and certain other 
antigens. The specific antibody response when both lympho-
cyte populations are present is greater than the sum of the 
antibody responses attributable to either cell population 
separately. Separate roles for these two populations are 
still evident in that thymus-derived cells are required 
although they, themselves, do not produce appreciable an~i-
body. The specific antibody is produced almost exclusively 
by cells of bone marrow origin. An immunological role for 
the thymus-derived cells is .indicated because these cells 
are probably antigen specific. Synergism between thymus-
derived and bone marrow-derived lymphocytes has also been 
demonstrated in the antibody response to burro red cells 
and to heterologous serum proteins (13, 34, 63). These 
antigens have been called thymus-dependent antigens to 
distinguish them from antigens for which no thymus cell 
requirement could be demonstrated. Strong antigens, such 
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as polymerized flagella and bacterial endotoxin, are thymus-
independent (4). Endotoxin is a mitogen specific for 
thymus-independent lymphocytes, but non-specific as to the 
types of antibody the stimulated cells can produce. Graft 
versus host disease, which also causes non-specific lympho-
cyte proliferation, may partially replace the thymus-derived 
lymphocytes in antibody responses. Interaction between 
thymus-dependent and thymus-independent lymphocytes has also 
been demonstrated in cell-mediated immune responses such as 
graft versus host and delayed hypersensitivity responses. 
A variety of cell requirements have been demonstrated 
in both in vivo and in vitro immune systems. In vitro some 
cell requirements may be purely trephocytic. Cell coopera-
tion has been most extensively studied in the antibody 
response to sheep red cells. In this system at least three 
distinct cell populations cooperate in vivo and in vitro. 
The antibody response to sheep red cells is therefore used 
as a general inclusive model for cellular interactions in 
immune responses (14). Adherent cells interact with two 
distinct populations of lymphocytes. Adherent cells are 
separable from lymphocytes because they adhere to glass or 
plastic surfaces; lymphocytes do not. The adherent cells 
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may be phagocytic or otherwise retain quantities of antigens. 
The term adherent cell includes several histologically 
distinct types of cells. Functional diversity within the 
population of adherent cells is known, but identification 
and purification of the effective cells has not been accom-
plished. The existence of large numbers of non-essential 
cells does not interfere with the immune response or the 
demonstration of an adherent cell requirement. 
The amount of cell contact in vivo is difficult to 
estimate. The lymphocytes of the blood and lymphatic system 
recirculate constantly. The majority of these cells are 
thymus-derived, but a small population of recirculating 
thymus-independent cells exists. The structures of the 
lymphatic system including the peripheral lymphoid organs 
would appear to maximize contact between the recirculating 
cells, the stationary cells and antigen. Various degrees 
of cell contact have been observed between lymphocytes and 
adherent cells (29, 44, 56, 57). These observations provide 
evidence that several forms of cell contact can occur 
between adherent cells and lymphocytes. Jn. vitro culture 
conditions which maximize cell contact also maximize the in 
vitro immune response. 
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The adherent cell-lymphocyte interaction is important 
in the induction phase of an antibody response (21, 22). 
Adherent cells may concentrate antigen, process antigen into 
a more potent immunogen or transmit informational RNA for 
the production of specific antibody. Adherent cells may 
even be found in the center of hemolytic plaques, indicat i ng 
that they may secretE~ specific antibody. No evidence is yet 
available to determine whether the adherent cell synthesizes 
antibody or acquires antibody secreting properties after 
ingesting other cells. Adherent cells from nonimmunized 
donors or from tolerant donors are as effective in immune 
functions as adherent cells from immunized donors. The 
adherent cell has no inherent specificity for antigen. 
Phagocytosis and antigen processing are not identical func-
tions. The two processes may be disconnected by x-irradia-
tion; antigen processing is more radiation sensitive than 
is phagocytosis. 
In order to demonstrate a requirement for a particular 
cell population, those cells must be the limiting factor 
for the immune response. All peripheral lymphoid organs are 
mixtures of cell types, cells of different origins and cells 
in different states of differentiation. The primary 
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lymphoid organs - the thymus and the bursa of Fabricius in 
chickens or the bursa equivalent in mammals - contain the 
immature precursors of imrnunocompetent cells and are not 
themselves effector cells in the immune response. For this 
reason, it is necessa.ry to use immature cells and allow them 
to mature or to separate irnmunocompetent cells from comple·ix 
mixtures of cells. In the former situation, t he maturation 
steps and the interaction process are uncontrolled. In the 
latter, there may still be maturation steps which are anti-
gen dependent. 
Although the three cooperating cell populations are at 
least partially separable by their differential sensitivity 
to x-irradiation and different cell densities, these dis-
tinctions are not absolute (54). The adherent cell and the 
antibody secreting cell are generally of lighter densities 
than the lymphocyte and both are less sensitive to x-
irradiation than are the lymphocytes. Lymphocytes of both 
thymus and bone marrow origins are presumed to divide in 
response to antigen. In the differentiation to antibody 
secreting cells, the precursor cell may undergo four to 
seven division cycles. All cells in division are sensitive 
to the prior effects of irradiation. The cell producing 
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antibody rarely divides and is resistant to 20,000R x-
irradiation. Lymphocyte density is a function of the 
state of differentiation. Relatively immature or precurser 
cells may change density several times between antigen sti-
mulation and demonstration of an immune response. There 
may be interconversion of histological cell types during 
this interval as well. Thymus and bone marrow derived 
lymphocytes are not histologically distinct from each other. 
Lymphocytes may convert to an adherent cell morphology, but 
it is unknown whether these lymohocytes are stem cells or 
are thymus-dependent or independent cells. 
The cooperative effect between thymus-derived and 
thymus-independent lymphocytes has been demonstrated in 
mice, which species has no bursa of Fabricius. Although 
bone marrow cells of mice are often equated with bursal 
cell of chickens, synergism between cells of bursa and 
thymus origin in the chick has never been demonstrated. A 
recently published report indicates that, in the chick, 
synergism is demonstrable between bone marrow cells and 
thymus cells (43). The same experimental conditions failed 
to show significant synergism between bursa and thymus cells. 
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The failure to demonstrate synergism may be technical; for 
example, high background antibody production by bursal cells 
would obscure any synergistic effect of lesser magnitude. 
An alternative possibility is that chick bone marrow and 
bursa lymphocytes are not equivalent nor are the bone marrow 
cells of mammalian species necessarily equivalent to chick 
bursa cells. A cross species comparison of functional 
lymphocyte populations between avian and mammalian species 
rray now have outlived its usefulness for the understanding 
of immune mechanisms at a cellular level . 
There are limits to demonstrating a cell requirement 
especially for cell populations which are capable aE self 
replication. One is the number of cells within the mixed 
population which are able to interact and the second is the 
number of cells minimally needed to give a detectable 
response. Estimates of both have been determined for the 
adherent cell populations in vitro measures of immunity. 
Less than one in one thousand adherent cells effectively 
cooperates with lymphocytes in the antibody response. In 
the mixed leukocyte culture system in which cell-mediated 
immunity is assayed, less than one adherent cell per 
thousand lymphocytes will allow a positive response. In 
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migration inhibition tests, 2.5% lymphocytes in a population 
of adherent cells will determine the migration properties 
of the whole population. The effectiveness of small cell 
populations is increased by soluble mediators in the cell-
mediated responses. Although these estimates do not 
directly pertain to the antibody response to sheep red 
cells in vivo, it is obvious that minimal contamination of 
a cell population with cells of another type of different 
function can grossly effect either the immune response or 
the behavior of the majority of cells. There is a need for 
techniques or serological reagents which can identify 
single cells or distinguish cells of ditferent cell lineages. 
Subpopulations of thymus-independent lymphocytes may be 
distinguished by the class of immunoglobulin which the cell 
produces. Bursectomy in ovo as well as the observation that 
a single cell may have one class of immunoglobulin on its 
cell surface and another in the cell cytoplasm suggest that 
the switch in class of immunoglobulin production observed 
in the serum during specific immune response also occurs at 
the single cell level. 
Subpopulations of the thymus or of thymus-derived cells 
probably exist both as distinct states of differentiation 
and as functionally separate ce 11 populations { 12) . Only 
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10-15% of thymus cells in the mouse are immunocompetent in 
assays of cell-mediated immunity. The imrnunocompetent 
thymus subpopulation is identified as cortisone-resistant 
medullary lymphocytes. Immunocompetent thymus-derived 
lymphocytes in the periphery are sensitive to anti-
lymphocyte serum, cells in the thymus are unaffected. The 
difference in ALS-sensitivity is not a property of the cell, 
but is attributable to the blood thymus barrier. Adult 
thymectomy removes the primarily immature thymus cells, but 
not the thymus-derived cells in the peripheral lymphoid 
organs. Adult thymectomy and anti-lymphocyte serum treat-
ment deplete thymus and thymus-derived lymphocytes, respec-
tively. 
Two functionally distinct thymus-dependent lymphocyte 
populations show synergism in the graft versus host response. 
The two populations appear thymus-dependent because both are 
sensitive to anti-theta serum and complement. Theta is pre-
sent on both thymus cells and some immunocompetent cells in 
the periphery corresponding in location to the thymus-
dependent areas of the peripheral lymphoid organs. Anti-
theta is therefore used to distinguish thymus-derived 
immunocornpetent cells. Theta is a thymus specificity 
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although many anti-theta sera contain antibodies of other 
specificities. Autoanti-thymus antibody, anti-Ly antibody 
and anti-allotype antibody are often present in the standard 
preparations of anti-theta sera. The autoantibody and anti-
Ly are both directed against thymus cell specificities which 
are not detectable on lymphocytes in the peripheral lymphoid 
organs. Anti-allotype antibody, however, could kill thymus-
independent cells in the presence of complement. The pre-
sence of this antibody in anti-theta reagents must temper 
the interpretqtion that the interacting cell$ are both of 
thymus origin when sensitivity to anti-theta is the only 
criterion of thymus origin. 
Apparent thymus specificity may be indicative only of 
a state of lymphocyte differentiation rather than an inde-
pendent line of lymphocytes (54). The so-called thymus 
specificities may be masked in cells of thymus-independent 
origin. Neuraminidase treatments of non-thymus-derived 
lymphocytes makes these cells sensitive to anti-theta serum 
and complement. The Lna specificity associated with the 
immune response locus, Ir-1, in mice is distinct from theta 
specificity, but is also present on peripheral immuno-
competent cells (20). Anti-Lna reagents are not exclusively 
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thymus-dependent or thymus-independent reagents. They 
probably contain two or more specificities. 
Thymus-independent cell markers include the anti-
immunoglobulin, anti-MBLA and anti-PC-1. Anti-PC-1 appare Af y 
is present only on cells actively secreting antibody and not 
on antibody forming cell precursers. MBLA is apparently 
present on precurser cells as well as on secreting cells. 
Of the two cellular interactions described for the 
antibody response, the interaction between the thymus-
derived and bone marrow derived lymphocytes appears to be 
the more restrictive interaction. Both lymphocyte popula-
tions must possess the same major h.istocompatibility 
r 
antigens for synergism in the antibody response to persi~s 
(36). If the cells are mismatched or only semi-allogeneic, 
as in parental and Fl hybrid combinations, synergism as 
rreasured by hernolysin response may be variabl~ detectable 
in the first two weeks, but not thereafter. The inter-
action between adherent cells and lymphocytes on the other 
hand, does not require that the cell participants be histo-
compatible. Adherent cells and lymphocytes interact 
adequately even if they are of different histocornpatibility 
types. 
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This requirement for histocompatibility may be a func-
tional reflection of the close genetic linkage between some 
immune response genes and the major histocompatibility locus 
of the species. Such linkage is well established in the 
rnous·e and is indicated in other species as well. Except ions 
to this association exist; they reflect genetic blockage at 
different levels within complexities of the immune response. 
Serological narkers may help to identify interacting cell 
populations, but differences at some markers may in fact 
interfere with the interaction one wishes to study. It is 
therefore necessary to have at hand as many narkers as 
possible both to identify the cell populations and possibly 
to determine the molecular basis of cellular interactions 
in the immune response. 
The immune systems of birds other than the chicken 
have not been studied extensively, but the bursa of Fabri-
cius appears to be the central lymphoid organ controlling 
the development of humeral immunity in these species as 
well. Because the Orders of birds diverged from each other 
between 60,000,000 and 120,000,000 years ago, differences 
may well exist among the immune systems of avian species. 
Subtle differences in the structure and function of the 
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avian immune systems would provide additional information 
on the phylogeny of immune mechanisms and perhaps provide 
additional insight into functionally distinct populations 
of lymphocytes. 
Pigeons and chickens belong to separate Orders. At 
hatching, pigeons are considerably less mature than chicks. 
If the functional development of the immune system is also 
slower, the bursa-dependent and the thymus-dependent 
immunological functions may be more accessible to experi-
mental manipulation. Pigeon eggs are laid in clutches of 
two -which hatch at approximately the same time. Paired 
squabs provide for an excellent control on age and environ-
ment for many experimental procedures. 
In this thesis, serological markers were sought for 
the lymphoid cells and organs of the pigeon as a means of 
identifying functionally distinct cells in an avian immune 
system. In the synergistic response observed with avian 
thymus and bone marrow lymphocytes, the unique contribution 
of each population or of subpopulations can not be deciph-
ered as long as the various lymphocytes are indistinguish-
able. The most useful serological markers would be the 
discriminating lymphocyte markers. Small antigenic dif-
ferences may distinguish bursa and thymus lymphocytes or 
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their subpopulations or their immunocompetent descendants. 
Serological markers of less specificity, such as blood 
group antigens or histocompatibility antigens, could be 
useful in reconstitution experiments or in in vitro systems 
where cells from antigenically distinct individuals may 
interact. 
Because bursa and thymus lymphocytes are so similar, 
they are expected to share many of the same antigens - from 
species-specific antigens to some possibly lymphocyte-
specific antigens. In immunizations between individuals of 
the same species, species-specificities would not be anti-
genic, but individual differences could be. Smaller anti-
genic differences could be recognized by alloirnrnunization. 
In cross species immunizations, species-specificities 
are often thought to be the most antigenic. Strong antigens 
may compete with and obscure the immune response to weaker, 
more subtle antigenic differences. Most species specifi-
cities would not discriminate among lymphocyte populations, 
although many organ specific antigens are detectable by 
heterologous antisera. 
Numerous antisera were prepared in rabbits against 
pigeon bursa, thymus and spleen cells and against saline 
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extracts of these organs. Because species specificities may 
be a problem in heterologous antisera, a number of the anti-
sera were prepared by a method which could reduce the 
species specificity. Fifteen newborn rabbits were injected 
with large doses of pigeon cells, in an attempt to induce 
tolerance to antigens common to all pigeon tissues and 
thereby reduce the antibody directed against these antigens. 
Challenge immunizations were done with pigeon lymphoid tis-
sues or cells which were generally different from those used 
in the tolerizing phase of the inoculations. Three addi-
tional sera were prepared following a standard procedure 
for anti-lymphocyte sera. The specificity of standard 
anti-lymphocyte sera is usually demonstrated by in vivo 
immunosuppression of cell-mediated immunity. The lympho-
cyte antigen(s) recognized by ALS have not been identified, 
in any species. Antisera against the saline extracts of 
lymphoid organs were prepared in three adult rabbits in 
order to identify the large number of antigens which are 
certainly present in such extracts. Not all of these anti-
gens would be expected to be recognized by the sera from 
neonatally tolerized rabbits. A summary of the sera pre-
pared for this study is presented in Tables la and lb. 
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Rabbits Tolerized as Neonates 
Number 













1 rbc (K30) b 
a. abbreviations used in this table: 
B: bursa of Fabricius cells 
T: thymus cells 
S: spleen cells 
h: Saline homogenate of lymphoid organ 
rbc: red blood cells 
wbc: peripheral white blood cells 














wbc (K30) b 
TABLE la. SUMMARY OF ANTISERA PREPARED AGAINST 
PIGEON LYMPHOID TISSUES 
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* abbreviations used in this Table: 
B: bursa of Fabricius cells 
T: thymus cells 
S: spleen cells 
h: saline homogenate of lymphoid organ 
TABLE lb. SUMMARY OF ANTISERA PREPARED AGAINST 
PIGEON LYMPHOID TISSUES 
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Serum samples were taken from the rabbits before antigen 
challenge, after challenge and after reimmunization. The 
antisera were tested for specificity against both soluble 
and membrane antigens. Passive hemagglutination, immuno-
diffusion and immunoelectrophoresis were used for the 
detection of antibody against soluble antigens. Leukoag-
glutination and complement dependent lymphocytotoxicity 
tests were performed to assay specificity for membrane 
associated antigens. These tests were chosen to take 
advantage of the different properties of antibody popula-
tions including ability to precipitate or agglutinate the 




The pigeon colony at Caltech contains two distinct 
breeds of pigeons - Tumblers and Kings. The colony was 
started with three mated pairs of each breed. These mated 
pairs were housed separately in mating cages and fed grains, 
grit and water ad libitum. Progeny of these mating were 
banded and placed in fly pens after weaning. Nests were 
provided in each fly pen, but mated pairs were not sepa-
rated. The two breeds were not housed in separate fly pens, 
but matings between the two were rare. Individual pigeons 
were identified by leg band numbers, preceded by Tor K to 
identify the breed. 
Bleeding Larger Squabs and Adults: 
Blood was taken from the wing vein of larger squabs 
and adult birds into a syringe containing either an iso-
tonic NaCl-sodium citrate solution {isocitrate) or 
Alsever's solution. Isocitrate was used if the cells were 
to be tested that day. If cells were kept longer, collec-
tion was done in Alsever's solution. All blood was stored 
at 4°C until use. Adult cells were used within a week. 
Squab cells were kept only overnight. 
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Preparation of Antisera in Neonatally Tolerized Rabbits: 
Three pregnant New Zealand white rabbits were kindly 
supplied by Dr. Justine Garvey. 
Newborn rabbits were injected with .5-1.0 ml of 108 -
2 x 108 pigeon cells in Hank's Balanced salt solution from 
the day of birth and every day thereafter for fourteen days 
(69). Cells were injected subcutaneously and intraperi-
toneally. Pigeon red cells, bursa cells or thymus cells 
were used in this phase of the injection schedule. Because 
there were not sufficient amounts of thymus and bursa cells, 
pigeon red cells from the same squabs providing the bursa 
and thymus cells were used. Rabbits receiving pigeon red 
cells were injected with 35% suspension of red cells on the 
first day and 20% suspension of red cells on the succeeding 
days. Squabs used as tissue donors were between a week and 
one month of age. Bursa follicles were broken up by passage 
through syringe needles of decreasing size to maximize the 
number of free bursa cells. Ont injection of bursa cells was 
substituted by an injection of a 15% bursa follicle suspen-
sion. All rabbits were bled at three months of age just 
prior to the challenge injections. For antigen challenge 
two ml of 1:1 saline extract of bursa or thymus were 
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injected subcutaneously once a week for three weeks. Ten 
days after the last injection all rabbits were bled for 
ant isera. 
Antisera Prepared in Adult Rabbits: 
Antisera against bursa, thymus or spleen were prepared 
in adult female rabbits following a standard method for 
preparation of anti-lymphocyte serum (39). Rabbits were 
bled seven days after the last injection. 
Antisera to lymphoid organ homogenates were prepared 
by thrice weekly injections of two ml of saline extracts of 
bursa, thymus or spleen. Injections were continued for 
three weeks. Rabbits were bled ten days after the last 
injection. 
Rabbit Antiserum to Whole Pigeon Serum: 
An adult female New Zealand rabbit received footpad 
injections of 1 ml of pooled pigeon serum in one ml of 
Complete Freund's Adjuvant. One month later, the rabbit 
was injected intraperitoneally with 1 ml of pigeon serum and 
intravenously with .5 ml two and five days later. The 
rabbit was bled ten days after the last injection. 
Rabbit Antiserum to Pigeon Gamma Globulin: 




Rabbits were reimmunized according to the availability 
of antigen. They were desensitized with an intraperitoneal 
injection of tissue extract or a subcutaneous injection of 
cells in a dose at least equivalent to the largest single 
dose of antigen the rabbit had recieved previously. Two 
and five days later, the cells or tissue homogenates were 
injected subcutaneously or intravenously. The rabbits were 
bled ten days after the last injection. 
Rabbit Normal Serum: 
Rabbit normal serum was obtained from an uninjected 
litterrnate of the "tolerized" rabbits or as preirnmune 
serum from those rabbits subsequently inununized as adults. 
Serum Handling: 
Serum from individual bleedings was split into two 
aliquots. Aliquots for use in agglutination and complement 
dependent lytic tests were heat inactivated at 56°C for one 
hour. Sera for immunodiffusion and immunoelectrophoresis 
tests were not heated. All sera were stored at - 20°C. 
Pr€paration of Cells Suspensions: 
Red cells, bursa and thymus cell suspensions were pre-
pared. Red cells were separated from whole blood in anti-
coagulant by light centrifugation and remova1 of the buffy 
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coat cells. Thymus and bursa were minced between scalpel 
blades to release the lymphocytes. When large quantities 
of cells were required the bursa tissue was forced through 
syringe needles of decreasing bore size to release addi-
tional cells from the bursa follicles. Cells were washed 
three times in medium and counted in a hemocytometer. 
Tissue Extracts: 
Fresh pooled tissue and an equal volume of saline were 
homogenized in a Waring blender for two minutes in thirty 
second intervals. The crude homogenates were centrifuged 
at 4°C at 17,000 rpm for 30 minutes and at 15,000 rpm for 
one hour, dialyzed overnight against at least twenty 
volumes of saline, centrifuged at 10,000 rpm for twenty 
minues. The supernatants were centrifuged at 105,000x g 
for 2 hours at 4°C. The lipid layers at the tops of the 
supernatants were discarded and the fluid pipetted off the 
pellets. The extracts were stored at - 20°C. 
Concentration of Antisera and Organ Homogenates by Ammonium 
Sulfate Precipitation: 
Saturated ammonium sulphate was added to the solution 
to be concentrated up to a final concentration of either 33% 
or 50% (11). The precipitate was stirred for several hours 
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at room temperature, then pelleted at 1400 g for 30 minutes 
at room temperature. The precipitate was re-dissolved in 
borate-buffered saline (pH= 8.4) and dialysed against 
borate-buffered saline at 4°C until sulphate ions were no 
longer detectable in the dialysate. The material was 
clarified by centrifugation at 1400xg for 30 minutes at 
4°C and stored at - 20°c. 
Concentration of Extracts by Pressure Dialysis: 
The extracts were concentrated at room temperature by 
pressure dialysis using U.MlO membranes (Arnicon Corporation) 
at 20 psi. Concentrated extracts were stored in small 
aliquots at - 20°C. 
Standardization of Extract Concentration: 
Extracts were adjusted to 60 O.D. 280 with saline. 
Chickens: 
White Leghorn chicks were obtained from Kimber Farms 
at one day of age and sacrificed for tissue when needed. 
Micro-Hemagglutination: 
Hemagglutination assays were performed in microtiter 
plates. 25 µl of normal rabbit serum diluent (1% normal 
rabbit serum in saline) was added to each well. Doubling 
dilutions of the antibody were made with a Takatsy micro-
titrator. 25 µl of a 2% suspension of washed red cells was 
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added to each well. Plates were covered to prevent evapora-
tion. Contents of the well were mixed by gently agitation 
of the entire plate. Agglutinations were read after three 
hours,at that time all the cells had settled to the bottom 
of the wells. 
Reading Hemagglutination Assays: 
Each individual well was observed and the degree of 
agglutination scored from - to++++ (59). 
The titer of the antiserum is the reciprocal of the 
last serum dilution which shows positive agglutination. 
For convenience the results were recorded as the titer 
log 2 which is the same as the number of the last positive 
well. 
Passive Hemagglutination: 
Two techniques for the attachment of soluble extracts 
to tqnned sheep red cells were used. A single sheep was 
used as the red cell donor in all cases. The procedures 
were the same as described by Kabat and Mayer (33) and by 
Nowonty (49). Identically prepared extracts of bursa, 
thymus and brain from pools of like organs from the same 
birds were used as antigen. 
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Immunoelectrophoresis: 
A layer of 1% agar in Barbital buffer, ionic strength 
= 0.078, ph = 8.6 was allowed to solidify on a microscope 
slide. Antigen was placed in a well cut in the agar. The 
slide was electrophoresed at 6 ma per slide (about 60 volts) 
for two hours. Troughs parallel to the direction of electro-
phoresis were filled with antiserum and allowed to diffuse 
in a moist chamber for at least 24 hours. 
Immunodiffusion: 
Immunoelectrophoresis agar was allowed to solidify on 
clean microscope slides. The appropriate pattern of wells 
was cut with a gel punch and the agar plug removed by 
suction. Antibody and antigen were placed in the appro-
priate wells and the slides were stored in a moist chamber 
at least overnight. 
Photographs : 
Polaroid photographs were taken and kept as a record 
of the irnmunodiffusion or immunoelectrophoresis patterns. 
Ficoll-Isopague Separation of Lymphocytes: 
Ten parts of 33.9% Isopaque (Nyegaard and Co.) and 24 
parts of 9% ficoll (Pharmacia Fine Chemicals) were mixed 
at 4°C for several hours (64). Density of the mixture was 
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determined to be 1.073. The mixture was dispensed in 2 ml 
aliquots in clear plastic centrifuge tubes and stored at 
4°C ·until use. Not more than six ml of cell suspension were 
layered on the gradient. Gradients were centrifuged for one 
half hour at l0°C. The gravitational force at the interface 
was 400 g. The white cells remained at the interface while 
red cells, dead cells, and cell aggregates pelleted. Cells 
were removed from the gradient immediately after separation. 
Complement: 
Complement from a number of sources was tested for 
toxicity and complement activity. Absorbed rabbit serum was 
used in most assays. Fresh rabbit serum was absorbed with 
pigeon thymus and bursa cells as described by Boyse et al. 
{10). One volume of .1 M EDTA was added to nine volumes of 
whole rabbit serum. For every seven volumes of treated 
rabbit serum one volume of packed cells was used for absorp-
tion. Cell suspension and washings were done in Hank's 
Balanced Salt Solution lacking ca++ of Mg++. Absorptions 
were done at 4°C for 20 minutes with frequent mixing. The 
absorbing cells were removed by centrifugation and the 
complement activity was restored with one volume of .1 M 
cac12 • The absorbed complement was stored in small aliquots 
at - 70°C until use. 
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Complement Titration: 
Complement was titrate~ for residual toxicity against 
both bursa and thymus cells. Complement activity was 
determined with a dilution of unabsorbed rabbit antiserum 
which would kill 100% of bursa or thymus cells in the 
presence of adequate complement. The complement dilution 
which was twice the last doubling dilution to give 100% 
killing of both bursa and thymus cells was subsequently 
used in the lymphocytotoxicity tests. 
Trypan Blue: 
The trypan blue solution was made from 3 ml of a 
stock solution of 1% trypan blue in distilled water to 
which 7 ml of a 2% solution of EDTA in the culture medium 
(pH= 7.2) was added (3). 
Lymphocytotoxicity: 
Complement dependent lymphocytotoxicity was determined 
by dye exclusion using essentially the two stage micro-
cytotoxicity method described by Amos (3). Modifications 
of medium and incubation times were necessary for pigeon 
cells. The general medium adopted for pigeon cells was 
Eagle's Minimum Essential Medium in autoclavable form 
{Grand Island Biological Company). The medium was prepared 
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according to package directions, one-tenth volume of 1.25% 
gelatin was added and the medium autoclaved. Before use for 
bursa and thymus cells, dextran (200,-300,000MW, Clinical 
grade; Nutritional Biochemicals Corp.) was added to a final 
concentration of 2%. For peripherial blood leukocytes, 1% 
heat inactivated chick serum was added. One µl of an anti-
serum dilution was incubated with one µl of a 2 x 106 
cells/ml suspension at room temperature in microtiter plates. 
After 30 minutes the wells were filled with medium and the 
cells allowed to settle for ten minutes. The excess fluid 
was removed by quickly flicking the plate. One µl of 
absorbed rabbit complement was added to each well. The 
plates were then incubated at 37°C in a water saturated, 
5% co2 atmosphere. After 20 minutes the wells were filled 
with a 0.3% solution of trypan blue. The cells were allowed 
to settle for ten minutes. Plates were read immediately 
under an inverted phase microscope. Pach well was counted 
and the percentage of dead cells recorded . The serum titer is 
the reciprocal of the serum dilution which kills 50% of the 
cells. The percentage of dead cells in the absence of 
either antiserum or complement should be less than 15%. 
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Leukoagglutination: 
A rnicroagglutination test similar to the one described 
by Kissrneyer-Nielsen and van Rood was used (37). Two µl of 
antiserum dilutions and 2 µl of a suspension of 2 x 106 
cell/ml of culture medium were added to the wells of a 
microtest plate. The plates were gently agitated to mix, 
and incubated for one and a half hours in a water saturated, 
5% co2 atmosphere. At the end of the incubation, the wells 
were filled with trypan blue solution. Cells were allowed 
to settle · for 10 minutes. Plates were read immediately with 
an inverted phase microscope. Plates were not scored if 
more than 10-15% of the cells were dead. 
A second method of leukoagglutination was also used 
(53). For this assay cells had to be pipetted onto a 
microscope slide to determine the degree of agglutination. 
Pigeon Normal Serum: 
Serum samples from ten or more adult pigeons were 
pooled and heated at 56°C for one hour. The pooled serum 
was stored at - 20°C. 
Lipid Extraction of Serum: 
Pigeon serum was extracted with chloroform:rnethanol 
at 4°C (2, 23), centrifuged at lOOOx g for five minutes 
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and the aqueous layer retained. The extraction was repeated 
three times. The extracted serum was dialysed overnight 
against phosphate buffered saline pH= 7.2. 
Solid Irnmunoabsorbants: 
Solid immunoabsorbants of serum were prepared by cross-
linking serum conponents with _2.5% glutaraldehyde (6). 
Serum was first dialysed overnight against saline at 4°C. 
Pigeon serum was also lipid extracted. The serum pH was 
adjusted to 5.0 with 1 M acetate buffer. Glutaraldehyde 
was added and the mixture allowed to stand at room tempera-
ture for several hours. The gel-like material was cut with 
a spatula and forced through a syringe to obtain smaller 
uniform pieces. The immunoabsorbant was washed with saline 
until the washes no lo~ger absorbed at 280 mµ. 
KCl Extractions of Pigeon Tissue: 
Ten or more pigeons were exsanguinated by cardiac punc-
ture and their thymuses, bursas and brains removed immedi-
ately. The tissues were washed in saline and like tissues 
pooled. , Tissues were minced between scalpel blades into 
pieces about mm3 • Two hundred ml of 3M KCl in .01 M 
phosphate buffer at pH; 7.4 were used for each pool of 
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tissue (52). The tissue-KCl mixture was stirred overnight 
at 4°C, then centrifuged at 17,000 rpm for 30 minutes and 
at 15,000 rpm for an additional hour. The supernatant was 
dialysed against saline for 48 hours. The dialysed material 
was centrifuged at 10,000 rpm for 20 minutes and then stored 
at - 20°c. 
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D. RESULTS 
Bursa and thymus cells should supply the most homo-
genous lymphocyte populations available from any lymphoid 
organs although there may still be minor subpopulations of 
cells derived from the other central lymphoid organ. The 
most easily quantitated cell subpopulation in bursa and 
thymus cell preparations consists of red cells. The oval-
shaped avian red cells are nucleated and larger than lympho-
cytes. When the bursa and thymus lymphocytes are counted 
under the microscope, red cells are sometimes observed. 
Red cells are always less than two percent of the total cell 
population. Contamination of peripheral blood leukocytes 
preparations with red cells may be as high as 25% when cells 
are separated by centrifugation only. Separation on Ficoll-
Isopaque gradients reduced the red cell content of the peri-
pheral blood leukocytes preparations to about two percent. 
Spleen cells were injected without separation of the red 
and white cells. 
Saline extracts of pigeon bursa, thymus and brain 
contain serum components which can be visualized in the 
concentrated extracts by immunoelectrophoresis. Inclusion 
of serum components is probably unavoidable for all tissue 
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extracts. Serum components are generally antigenic in 
heterologous species and immunization may pick up low level 
antigenic contaminants in the immunizing mixture. Antibody 
to serum components may be present in any antiserum pre-
pared against crude tissue extracts. 
Extracts used in injections and in the first screening 
of antisera by passive hemagglutination were not ultra-
centrifuged and therefore contained more membraneous material 
than the ultracentrifuged preparations. Ultracentrifuged 
preparations were used in all other passive hemagglutination 
experiments, in immunodiffusion, immunoelectrophoresis and 
in serum absorptions with soluble extracts. 
All sera were screened by passive hemagglutination, 
irnmunodiffusion, leukoagglutination and complement-dependent, 
lymphocytotoxicity tests for differential reactivity against 
thymus or bursa tissue. The greatest difference in serum 
titers are denoted by boxes in the data tables. 
In passive hemagglutination soluble antigens are 
attached to red cells. Upon reaction with the corresponding 
antibody directed against the soluble antigen, the red cells 
agglutinate and thereby make the antibody-antigen reaction 
visible. The extracts used in passive hemagglutination were 
43 
unconcentrated and were further diluted for attachment to 
tanned sheep red cells. Two slightly different methods of 
attachment of soluble antigen to tanned red cells were used 
(Tables 2, 3a-3d). The method described by Nowonty as the 
Boyden Method yielded moderate titers, but clear negatives. 
Agglutinations observed with the preimmune sera were similar 
to those obtained with normal serum from adult rabbits. 
· Serum from an uninjected littermate showed no agglutina-
tion with any of the extracts in either technique for anti-
gen attachment. This serum was obtained at three months 
of age. Agglutination of red cells with attached pigeon 
extracts by adult rabbit serum at a 1:4 dilution or less 
suggest that adult rabbits may have low levels of natural 
antibody reactive with pigeon tissue extracts. 
The method described by Kabat and Mayer yielded higher 
titers against thymus and bursa extracts while the titers 
observed with all rabbit normal sera remained low. Sheep 
cells with brain extract attached, howevei , spontaneously 
aggluntinated even in the absence of serum. Serum concen-
trations higher than used in the diluent only slightly pro-
tected the cells from spontaneous agglutination. Compari-




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































were not possible when this technique was used for antigen 
attachment. 
Rabbit antiserum to whole pigeon serum strongly agglu-
tinated sheep red cells with bursa and thymus extracts 
attached by this latter method, but not by the former 
method. The agglutination patterns observed with this tech-
nique could be due in part to serum components in the 
extracts~ 
Passive hemagglutination titers for the preimmune sera 
using both techniques of antigen attachment are given in 
Table 2. Experiments 1 and 2 were done with red cells pre-
pared as described by Nowonty (49) and experiment 3 with 
cells prepared as described in Kabat and Mayer (33). Dif-
ferences in titer of two wells or less is within the error 
of the technique. The results of experiments 1 and 2 are 
consistent with each other except for W 19 serum. W 19 
serum gave higher titer against thymus extract than against 
bursa extract in experiments 1 and 3, but equivalent titers 
in experiment 2. With this possible exception there are no 
other indications of specificity for bursa or thymus in the 
unabsorbed preimmune sera by passive hemagglutination. The 
reactivities of each individual serum sample against paired 
bursa and thymus extracts were nearly identical. 
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Passive hemagglutination by irranune sera for the same 
three cell preparations is shown in Tables 3b, 3c and 3d. 
There were no sera with consistent differences in titer 
against thymus and bursa extracts for all three experiments. 
Serum W 14 (first immunization) shows a higher titer for 
bursa extract than thymus extract in two of the three experi-
ments. The higher titer against bursa extract is consistent 
wit~ the fact that rabbit W 14 was immunized with bursa 
extract. Sera from W 1, W 4, W 5, W 19, and R 36 show dif-
ferences in only one of the three experiments. Differences 
in titer in a consistent direction were observed with 
lat~r bleedings of W 5, W 19 and R 36, (for W 19 see pre-
immune serum). Again the differences are consistent with 
a higher titer against the tissue used for immunization. 
In the case of W 19 one must assume that the peripheral 
white cells in the original red cell preparations used to 
"tolerize" W 19 acted to immunize that rabbit against 
thymus-derived cells or cell components. 
In experiment 3 ten sera from seven rabbits show a 
difference in titer of three or more wells between bursa 
and thymus. Eight of the ten react more strongly with bursa 
extracts than with thymus extracts. A similarly high titer 
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against bursa extract was noted with the rabbit anti-whole 
pigeon serum antiserum. The fact that most of the dif-
ferences are in one direction and do not necessarily cor-
respond to the immunizing material suggest that the increase 
in bursa reactivity may not indicate anti-bursa specificity. 
This method may increase the attachment of bursa antigens 
(or possibly serum antigens shared by bursa cells) to red 
cells. Alternatively, red cells with sufficient attached 
bursa extract may have a greater tendency to agglutinate 
with low levels of antibody than cells with attached thymus 
antigens. 
Bursas from two day old chicks were extracted for 
passive hemagglutination tests. Chick thymus tissue at this 
age did not provide enough material for testing. Chick 
bursa extract was used as an indication of the cross reac-
tivity between avian species. Passive hemagglutination 
titers against pigeon brain and chick bursa extracts were 
generally of the same order as against lymphoid tissue 
extracts. Several exceptions in which the reactivity is 
either lower or higher are noted in Tables 3a through 3d. 
Absorptions were performed on six of the sera to 
separate the possible specificities indicated in screening 
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of the unabsorbed preimmune and immune sera (Tables 4 and Sl 
Sera were absorbed with the pelleted material obtained in 
preparation of the extracts. This insoluble material was 
used because large quantities were available which were from 
the same pool of birds as the extracts, and absorptions 
could be performed without diluting the antibody. The 
pellets were stored at - 20°C and washed in saline before 
use. as absorbants. The sera were multiply absorbed at room 
temperature and at 4°C. The pelleted materials were gener-
ally effective in absorbing out all reactivity against the 
corresponding soluble extracts. The pellets also absorbed 
reactivity against the other extracts tested. Those which 
only partially absorbed the corresponding specificity 
lowered the titers against other extracts as well. There 
was no indication of differential absorption of reactivity 
against the corresponding antigen. In none of the sera 
tested by absorption analysis and passive hernagglutination 
techniques (W 1, W 4, W 5, W 11, W 14, W 19) could tissue 
specificity be detected. If the possible specificity in 
some of these sera were against membrane components, as 
suggested by their titers in experiment 1, but not the fol-
lowing experiments, the membrane specificity was also 
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Rabbit Tolerogen Irnmunogen Absorbing 
Number** Source* Source* Tissue* 
W 4 a T Bh none 
B 
T 








W 19 a rbc T none 
B 
T 
* abbreviations used in this Table: 
B: bursa of Fabricius 
T: thymus 
Bh: bursa homogenate 
Br: brain 
rbc: red blood cells 
** a and b: successive immunizations 
Passive Hemag-
glutination 






















Rabbit Tolerogen Immunogen Absorbing 
Titer log2 
Against 
Number* Source** Source** Tissue** Bursa Thymus 
W 5 b rbti_0 Bh none 10 > 12 
B 0 0 
T 0 0 
w 14 a T Bh none 9 9 
B 0 0 
T 2-3 2 
w 1 a B Th none 11 12 
B 0 0 
T 0 0 
W 11 a T T none 11 > 12 
B 4 5 
T 0 0 
W 19 a rbc T none 8 9 
B 4 2+ 
T 0 2+ 
* a and b: successive immunizations 
** abbreviations used in this Table: B: bursa of Fabricius; 
T: thymus; Bh: bursa homogenate; Th: thymus homogenate; 
Br: brain; rbc: red blood cells 
TABLE 5. PASSIVE HEMAGGLUTINATION BY ABSORBED SERA 
(ME'IHOD FROM KABAT AND MAYER) 
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absorbed out by the pelleted material. It is also possible 
that the pelleted material non-specifically absorbed out all 
antibodies. There was no control on this possibility 
except that the sera were also tested for specificity in 
imrnunodiffusion. 
Immunodiffusion is less sensitive than passive hemag-
glutination for detecting low levels of antibody against 
soluble antigens. The technique has the advantage of 
separating the reactions to different antigens. The results 
are not seen as a single sum of the individual antibody-
antigen reactions. 
All sera were initially tested against the unconcen-
trated soluble extracts. Precipitin bands were not observed 
unless the antigen and antibody wells were refilled. 
Refilling wells may create artifactual precipitin bands. 
Both the antisera and the soluble extracts needed to be 
concentrated. 
Saline extracts of bursa, brain and thymus were con-
centrated by two different methods - pressure dialysis and 
ammonium sulphate precipitation. The supernatants from 
ammonium sulphate precipitation were retained, dialysed 
against saline and concentrated by pressure dialysis. The 
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ammonium sulphate precipitable material was redissolved, but 
precipitated on dialysis against saline and was discarded. 
The concentrated nonprecipitable material formed a diffuse 
concentric halo around the antigen well in imrnunodiffusion 
tests. Precipitation in diffuse concentric patterns in the 
absence of antibody is generally indicative of aggregated 
or high molecular weight material. Such halos obscure pos-
sible precipitin bands which might be formed by antigen-
antibody precipitation. 
A method of antigen extraction other than making saline 
homogenates was attempted for preparing possibly simpler 
tissue extracts. Hypertonic KCl was used as a mild treat-
ment for extraction of cell membrane antigens. Extraction 
of pigeon bursa, thymus, and brain with 3M KCl yielded 
material which, like the ammonium sulphate treated extracts, 
formed concentric halos when tested in immunodiffusion. 
Hypertonic KCl was not a useful extraction procedure. 
Crude saline extracts concentrated only by pressure 
dialysis precipitated only in the presence of antibody and 
were used in subsequent irnmunodiffusion assays. For 
screening the unabsorbed antisera, larger antibody wells 
and greater volumes of antisera were used as a substitute 
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for concentrating each antiserum. All sera were tested 
against thymus, bursa and brain extracts, and normal pigeon 
serum. The concentration of the extracts was adjusted to 
the same on280 level. Pigeon serum was more concentrated, 
but was used undiluted for the assays. No precipitin bands 
were observed with normal rabbit serum with the exception 
of R 36 preimmune serum. That serum formed a diffuse band 
against pigeon normal serum, but not against any of the 
tissue extracts. All preirnrnune sera and sera from rabbits 
immunized with whole cells produced no bands or faint pre-
cipitin bands. · Immune sera prepared against the tissue 
extracts produced precipitin bands against all test fluids. 
Irnrnunodiffusion patterns showing an additional band and pos-
sible specificity for thymus extracts were obtained from 
single bleedings of rabbits W 1, W 4, W 5, W 6, W 14, W 15, 
W 16, R 61 and R 62. Possible specificity was indicated in 
two bleedings from W 6 and from W 16. W 1, W 6, W 16 and 
R 62 had been immunized with thymus extract. W 4, W 14 and 
W 15 received thymus cells neonatally. W 5 was injected 
neonatally with pigeon red blood cells and R 61 was 
immunized with spleen extract. Thymus specificity would 
not be inconsistent with any of these injections. No serum 
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showed a pattern suggesting possible bursa specificity. 
Only R 61 and R 36 had been injected with bursa extract or 
bursa cells with no subsequent injection of thymus tissue 
or tissue containing a minor population of thymus component~ 
Each serum showing possible specificity was concentrated by 
ammonium sulphate precipitation and absorbed with soluble 
extracts. An equal volume of the extract was added directly 
to the antiserum. Each serum was separately absorbed with 
pigeon normal serum, thymus, bursa and brain extracts. 
The absorptions showed several common features. First, 
absorption with thymus removed activity against all of the 
tissue extracts. In almost every case an indistinct pre-
cipitin band remained against normal pigeon serum. Second, 
absorption with pigeon normal serum removed all activity 
against pigeon serum, but most sera showed two or three 
faint precipitin bands against the tissue extracts. 
The bands remaining in W 1 serum were slightly stronger 
than with most of the sera. This serum produced two bands 
of identity for thymus, bursa and brain extracts (Figure 1). 
The first immune serum from W 16 was unusual in that it 
showed a distinct unique band against thymus extract. This 
specificity will be considered more extensively following 
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Absorption with brain extract removed all activity 
against brain extract, but in most cases left in faint 
reactivity to normal serum, thymus and bursa extracts. 
Absorption with bursa extract removed all activity 
against bursa extract, but left in a faint band against 
thymus extract. Both bleedings of W6 were exceptional in 
that reactivity against thymus extract was completely 
remqved by absorption with bursa extract. Faint reactivity 
remained against brain extracts in serum from W 1, W 14, 
and the last bleeding of W 16. 
In general, the precipitin bands remaining after 
absorption were too faint and did not extend far enough to 
determine reactions of identity or nonidentity in the 
several extracts and pigeon serum. Two exceptions to this 
generalization are W 1 and W 16 serum. Although\-:W~\'l . 
identified two specificities shared by bursa, thymus and 
brain extracts, the two specificities behave differently 
in absorption analysis. One specificity can be· completely 
absorbed by each of the three extracts. The second specifi-
city is partially absorbed by the bursa extract, more so by 
the brain extract and completely absorbed by the thymus 
extract. The first specificity appears the same in all 
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extracts tested. The second specificity may be present in 
different quantities in the three extracts although quanti-
tation by immunodiffusion is usually difficult. 
Serum from W 16 shows a quite distinct pattern, both 
unabsorbed and absorbed, (Figures 2a through 2d). Absorp-
tion of W 16 with pigeon serum removes several specifi-
cities common to serum and tissue extracts. The same 
absorption leaves two precipitin bands - one fused band 
against thymus, bursa and brain extracts and a second which 
recognizes only thymus extract. Sequential absorptions were 
not performed on this serum because each absorption further 
dilutes the antiserum. The precipitin band for the common 
specificity is located closer to the antigen well than the 
band for thymus specificity. The common tissue specificity 
is also present in liver and muscle extracts (Figure 2b). 
The thymus specificity identified by this reagent is present 
in saline extracts of spleen, but not in saline extracts of 
liver or breast muscle, (Figure 2b). These results are 
indicated directly by irnrnunodiffusion and confirmed by 
absorption analysis. 
Because the thymus specific antigen appears to be a 
major antigen ic component of the thymus extract, this 
W 16 
O: Antiserum W 16 
Q: Antigen Extract 
():Absorption 
B : Bursa. 
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reagent was tested against the various extracts and pigeon 
serum in immunoelectrophoresis. The unabsorbed serum fails 
to reveal the thymus specificity as distinct from the 
several common specificities in the unabsorbed reagent 
(Figure 2c). Absorption with pigeon serum again indicates 
a thymus specific component (Figure 2c). Neither the 
thymus specificity nor the common tissue specificity 
mig~ates under the conditions of immunoelectrophoresis. 
The absorbed reagent recognized the thymus specificity 
in extracts of King thymus (Figure 2d). It was non-reactive 
with bursa extracts from King pigeons and both thymus and 
bursa extracts from chickens. The shared tissue specifi-
city appeared to be absent from the King thymus extract. 
later bleedings of W 16 failed to show an increased 
thymus specificity and recognized a more complex pattern of 
reactivity against the common tissue specificities (Figure 
2e). 
Direct agglutination of pigeon red cells was used as 
an indication of the depth of tolerance, the possible breed 
specificity and generalized membrane reactivity in the 
unabsorbed reagents. 
Tumbler squabs had been used as the major sources of 
antigens - both cellular and soluble. A deliberate 
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exception was made for rabbit W 10. Rabbit W 10 was neo-
natally injected with red cells from a single adult King 
pigeon donor, K 30, and later challenged with K 30 peri-
pheral white blood cells. 
In the unabsorbed reagents, generally no difference in 
titer was observable between Tumbler and King red cells 
(Tables 6 and 7a through 7c). Preimmune sera from the neo-
nat~lly injected rabbits indicated that tolerance if it 
existed at the time of bleeding was incomplete. Rabbits 
injected neonatally with red cells showed higher titers 
against red cells of both types than did rabbits which had 
been neonatally injected with thymus or bursa cells. The 
highest titer for a pre-immune serum, W 19 serum, was as 
high as might be expected from hyperimmune serum prepared 
against pigeon red cells. The high red cell titers are not 
necessarily indicative of specificity for the corresponding 
antigen, but could represent a dosage effect. The concen-
trations of red cells used in neonatal injections were 
higher than the concentrations of bursa and thymus cells. 
The immune sera from these same rabbits showed a more 
restricted range of anti-red cell titers. The titers 






Rabbit Tolerogen Tumbler (Tl0) c King (K30) c 
Number Cell Source Red Cells Red Cells 
w 1 B (Bursa) 1 1 
w 2 B 0 0 
w 3 T (Thymus) 0 0 
w 4 T 1 1 
w 5 rbc (red blood cells) 5 4 
w 6 rbc 7 8 
w 7 rbc 5 5 
w 10 rbc (K30)c 7 6 
w 11 T 2 3 
w 12 B 1 2 
w 13 rbc 5 5 
w 14 T 0 1 
w 15 T 0 1 
w 16 T 4 3 
w 19 rbc 11 10 
w 21 nonea 0 0 
R 35 noneb 0 0 
R 35 noneb 0 0 
R 45 noneb 0 0 
a. untreated litter mate 
b. pre-immune sera 
c. identification of pigeon cell donor 




Titers (log2 ) 
Against 
Tumbler King 
Rabbit Tolerogen Inununogen Red Cells Red Cells 
Number* Cell Source** Source** (TlO) (K30) 
w 1 a B Th 5 5 
w 1 b 3 4 
w 1 C 5 5 
w 2 a B T 3 4 
w 3 a T B 3 2 
w 4 a T Bh 2 4 
w 4 b 6 6 
w 5 a r .bc Bh 7 6 
w 5 b 6 5 
w 6 a rbc Th 7 7 
w 6 b 7 7 
w 6 C 6 7 
w 7 a rbc s 8 7 
w 10 a rbc (K30) wbc (K30) 5 4 
w 11 a T T 4 4 
* a, b, care successive immunizations 
** abbreviations used in this Table: B: bursa of Fabricius 
cells; T: thymus cells; S: spleen cells; h: saline homo-
genate of lymphoid organ; rbc: red blood cells; wbc: 
peripheral white blood cells 




Titers (log 2 ) 
Against 
Tumbler King 
Rabbit Tolerogen Immunogen Red Cells Red Cells 
Number* Cell Source** Source** (Tl0) (K30) 
w 12 a B Th 5 6 
w 12 b 5 5 
w 12 C 6 5 
w 13 a rbc B Q] I]] 
w 14· a T Bh 5 6 
w 14 b 6 6 
w 15 a T Sh 6 6 
w 15 b 5 5 
w 16 a T Th 8 6 
w 16 b 7 6 
w 16 C 7 8 
w 19 a rbc T 7 8 
R 35 a none T 7 6 
R 35 b 8 7 
R 36 a none B 10 8 
R 36 b 5 7 
* a, b, care successive immunizations 
** abbreviations used in this Table: B: bursa of Fabricius 
cells; T: thymus cells; S: spleen cells; h: saline homo-
genate of lymphoid organ; rbc: red blood cells; wbc: 
peripheral white blood cells 




Titers (log2 ) 
Against 
Tumbler King 
Rabbit Tolerogen Imrnunogen Red Cells Red Cells 
Number* Cell Source Source** (Tl0) {K30) 
R 45 a none s 11 9 
R 45 b [gJ rn 
R 60 a none Bh 7 6 
R 60 b 6 6 
R 61 a none Sh 7 6 
R 62 a none Th 7 7 
R 62 b 8 6 
* a, b, care successive immunizations 
** abbreviations used in this Table: B: bursa of Fabricius 
cell~; T: thymus cells; S: spleen cells; h: saline homo-
genate of lymphoid organ; rbc: red blood cells; wbc: 
peripheral white blood cells 
TABLE 7c. DIRECT AGGLUTINATION OF PIGEON RED CELLS BY 
IMMUNE SERA 
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dropped to a level similar to that of other sera. The 
previously nonreactive or low titer rabbit sera showed 
increased serum titers, although some were still low. 
The red cell titers of immune sera from some rabbits 
injected as neonates were comparable to titers obtained 
with sera from rabbits injected as adults with pigeon white 
cells. The highest titer obtained was from R 45 which had 
been injected as an adult with spleen cells. This was the 
only rabbit showing a higher titer against Tumbler red cells 
than against King red cells. Spleen cell preparations 
contain both red and white cells. Unabsorbed W 10 serum 
gave similar titers against both King and Tumbler red cells. 
Rabbits immunized with whole cells did not form a group 
distinct from rabbits immunized with tissue extracts, on 
the basis of the anti-red cell titers of their unabsorbed 
sera. 
Leukoagglutination assays were pe~formed by two dif-
ferent methods. In the method described by Schmid and 
Thein (55), the agglutination mixture must ·be pipetted onto 
a microscope slide to be scored. In this procedure the cell 
aggregates are disturbed and this could introduce errors in 
scoring agglutination. In the second technique described by 
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Kissmeyer-Nielsen and van Rood (37), it was not necessary 
to disturb cell aggregates to score agglutination. Cell 
aggregates in positive agglutination controls ranged from 
three to ten cells. Numerous free cells were also present . 
The small size of the cell aggregates and the large , propor-
tion of free cells made leukoagglutination assays difficult 
to score. All the unabsorbed reagents were screened by 
leukoagglutination using one or the other of these two 
techniques. The leukoagglutination titers were lower and 
showed fewer differences in titer than did complement 
dependent lymphocytotoxicity. The initial screening of 
sera in lymphocytotoxicity tests were done in medium which 
was less than optimal for cell survival. The background of 
dead cells was high and tests were scored only relative to 
the high background. These titers are relative and not 
directly comparable t b titers obtained in later studies ' 
when the background was low. Investigations of selected 
sera were performed with supplemented medium, in which the 
background was reduced. 
The conditions used in the lymphocytotoxicity tests had 
to be modified for testing pigeon lymphoid cells. Isolated 
pigeon bursa cells are generally less stable than isolated 
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pigeon thymus cells. The nonspecific bursa cell and thymus 
cell death was reduced by addition of 2% dextran to the 
medium. Cytotoxicity tests still had to be read soon after 
the final addition of medium or background levels of dead 
cells again rose to unacceptable levels. At 5% dextran 
levels both thymus and bursa cells were protected from non-
specific death, but antibody mediated cell killing was also 
prevented. Dextran was found less toxic and more protective 
than fetal calf serum at serum dilutions from .5% to 20%. 
Peripheral blood white cells and red cells were more stable 
under the same conditions than bursa or thymus cells. 
In preliminary experiments, a variety of complement 
sources were tested for toxicity and for complement activit~ 
Fresh rabbit serum from five different rabbits, rabbit serum 
absorbed with agarose, rabbit serum absorbed with pigeon 
lymphoid tissues, lyophilyzed guinea pig serum and fresh 
pigeon serum were tested. Unabsorbed sera from all rabbits 
and the lyophilyzed guine~ pig complement were highly toxic 
for both pigeon bursa and thymus cells even at dilutions of 
1/20 or 1/40. There were no complement dilutions at which 
the toxicity was reduced below 10% and the complement was 
fully active with the rabbit antibody. Agarose absorption 
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of the rabbit serum did not reduce the natural toxicity of 
the rabbit serum to usable levels. 
Undiluted fresh pigeon serum from the same pigeon whose 
cells were used for testing was nontoxic, but less than 90% 
of the cells were killed by the rabbit antibody and this 
complement. The antibody was unabsorbed rabbit anti-pigeon 
thymocyte serum from R 35. Complement dependent cytotoxi-
citY. dropped sharply with only a single doubling dilution 
of pigeon serum. The sharp fall in complement activity sug-
gests that pigeon complement is not very active with rabbit 
antibody in this system rather than that the small volume 
of pigeon serum absorbs significant antibody activity. 
Rabbit normal serum absorbed at 4°C with pigeon bursa 
and thymus tissue was nontoxic and was used as the comple-
ment source in all lymphocytotoxicity tests. The natural 
toxicity of fresh rabbit serum for pigeon thymus and bursa 
cells disappeared after the serum had been heated for one 
hour at 56°C. The serum remained nontoxic when rabbit serum 
absorbed with pigeon lymphoid tissue was added as the 
complement source. 
Each individual rabbit reagent was tested for lympho-
cytotoxicity against thymus and bursa cells from the same 
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pigeon. Successive bleedings of the same rabbit were also 
tested against cells from the same pigeon. Serum samples 
from different rabbits were not necessarily tested against 
cells from the same pigeon donor. Preimmune serum samples 
from six rabbits injected as neonates showed similar titers 
against both thymus and bursa cells (Table 8). Preimmune 
sera from W 11, W 16, and W 19 showed higher titers for 
thymus cells than for bursa cells. Preimmune sera from 
rabbits W 2, W 3 and W 14 showed higher titers against 
bursa cells than against thymus cells. Higher bursa 
reactivity in W 3 and W 14 sera may result from the lower 
stability of bursa cells. These two rabbits had been 
injected only with thymus cells before the serum was taken. 
The immune sera gave generally similar titers against 
thymus and bursa cells (Tables 9a and 9b). No immune serum 
showed a significantly higher titer against bursa cells than 
against thymus cells. Serum from rabbits W 12 and W 19 gave 
differences in titers against thymus and bursa cells of more 
than three wells. Both sera indicated possible thymus 
specificity and both had been immunized with thymic material. 
In some instances, the serum dilution series were not 
carried to the point of 50% toxicity for the test cells. 
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Lymphocytotoxicity Titers 
(log 2 ) Against 
Rabbit Tolerogen 
Number Cell Source Bursa Cells Thymus Cells 
w 1 B (Bursa) < 5 6 
w 2 B ~ D 
w 3 T (Thymus) > g' 6 
w 4 T 3C < 5 
w 5 rbc (red blood cells) 4C 7 
w 6 rbc 8 8 
w 7 rbc < 5 5-6 
w 10 rbc (K30) 9 9 
w 11 T ~ ~ 
w 12 B 4C 4 
w 13 rbc > 8 8 
w 14 T LI [TI 
w 15 T 8 7 
w 16 T 6 7-9 
w 19 rbc rn ~ 
w 21 nonea < 5 < 5 
R 35 noneb < 5 < 5 
R 36 noneb < 3 < 3 
R 45 noneb 4 < 3 
a. untreated litter mate 
b. pre-immune sera 
c. no clear end titers 
TABLE 8. COMPLEMENT DEPENDENT LYMPHOCYTOTOXICITY TITERS FOR 
PRE-IMMUNE SERA 
(This experiment was part of an immunology class experiment 
performed by Jonathan Fuhrman, Ken Pischel and the authorJ 
Rabbit 
Number* 
w 1 a 
W 1 b 
W 1 C 
W 2 a 
W 3 a 
W 4 a 
W 4 b 
W 5 a 
W 5 b 
W 6 a 
W 6 b 
W 6 C 
W 7 a 
W 10 a 
W 11 a 
W 12 a 
W 12 b 
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* a, b, care successive immunizations 
** abbreviations used in this Table: B: bursa of Fabricius 
cells; T: thymus cells; S: spleen cells; h: saline homo-
genate of lymphoid organ; rbc: red blood cells; wbc: 
peripheral white blood cells 
TABLE 9a. COMPLEMENT DEPENDENT LYMPHOCYTOTOXICITY TITERS 
FOR IMMUNE SERA 
Rabbit Tolerogen 
Number* Cell Source** 
W 13 a 
W 14 a 
W 14 b 
W 15 a 
W 15 b 
w 16 a 
W 16 b 
W 16- C 
W 19 a 
R 35 a 
R 35 b 
R 36 a 
R 36 b 
R 45 a 
R 45 b 
R 60 a 
R 60 b 
R 61 a 
R 62 a 
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* a, b, care successive immunizations 
** abbreviations used in this Table: B: brusa of Fabricius 
cells; T: thymus cells: S: spleen cells; h: saline homo-
genate of lymphoid organ: rbc: red blood cells: wbc: 
peripheral white blood cells 
TABLE 9b. COMPLEMENT DEPENDENT LYMPHOCYTOTOXICITY TITERS 
FOR IMMUNE SERA 
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Although possible specificity was indicated for some 
of the preimmune sera in lymphocytotoxicity tests, immune 
sera did not appear as promising. Seven sera were selected 
for further study in lymphocytotoxicity assays. They were 
W 10, W 16, ~ 35, R 36, R 45, R 61 and rabbit anti-pigeon 
gamma globulin. W 16 was chosen because of its specificity 
for thymus in imrnunodiffusion tests. W 10 was selected 
because it was the only serum prepared against peripheral 
white cells and it could possibly show specificity for 
irnrnunocompetent peripheral lymphocytes rather than lympho-
cytes of the central lymphoid organs. R 35, R 36 and R45 sera 
were chosen as standard anti-lymphocyte reagents prepared 
against thymus, bursa and spleen cells, respectively. Con-
flicting reports in the literature indicate that such sera 
may have specificity for bursa or thymus lymphocytes (24, 
32, 42, 50). R 61 was chosen as a strong reagent in which 
there might be many specifities. Rabbit anti-pigeon garrana 
globulin was selected mainly because the thymus independent 
cells of the mouse are recognized by their cell surface 
irnmunoglobulin determinants. 
W 10 serum samples were absorbed with red cells from 
K 30, the same pigeon that had donated cells for injection 
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of W 10. Red cells used for absorption were centrifuged 
free of the buffy coat cells and then centrifuged on a 
Ficoll-Isopaque gradient andwashed in medium three times 
to further free the red cells of contaminating white cells. 
Unabsorbed preirranune and immune W 10 sera gave titers of 
10,240 and 320, respectivelY, in lymphocytotoxicity tests 
against K 30 peripheral white cells. Absorptions of the 
imm~ne serum at 4°C and at room temperature with K 30 red 
cells reduced the toxicity against K 30 white cells to less 
than 10% above background at the lowest serum dilution 
tested (1:10). At the serum dilutions tested there appeared 
to be no specificity for peripheral white blood cells in 
the irranune serum. Identical absorptions of the preimmune 
reduced its titer to 320 and still agglutinated K 30 red 
cells. Four further absorptions with K 30 red cells reduced 
the titer to 20. The absorbed serum at this point was 
simila~ly toxic for peripheral blood leukocytes from Tumbler 
93 and for Tumbler bursa and thymus cells. Two additional 
absorptions with K 30 red cells decreased the complement 
dependent toxicity to 25% above background at 1:10 serum 
dilution. Higher serum dilutions were not cytotoxic. The 
absorbed serum alone at 1:10 dilution J:aised the background 
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to 17%. As for the preimmune serum, there is no indication 
of leukocyte specificity. 
Anti-lymphocyte sera prepared in adult rabbits against 
pigeon thymus, bursa and spleen cells were tested in lympho-
cytotoxicity tests against thymus and bursa cells. The 
three unabsorbed sera were highly toxic for both types of 
cells. Absorptions of the three sera with thymus cells 
remc;,ved all the activity against both thymus and bursa cells . 
Absorptions with bursa cells removed all activity against 
bursa in the anti-thymocyte and the anti-bursa cell sera. 
Absorption of the anti-spleen cell serum was incomplete. 
In the anti-thymus cell and anti-bursa cell sera, absorption 
with bursa cells did not remove anti-thymus cell activity. 
In the anti-spleen cell serum there was no evidence to sug-
gest differential absorption of the toxicity against either 
bursa or thymus. The results must be regarded as only 
indicative, because the background levels of dead cells for 
both bursa and thymus were high. 
Rabbit anti-pigeon gamma globulin contained specifi-
cities for a number of pigeon serum components in addition 
to gamma globulin. Immunoelectrophoresis demonstrated 
specificity for gamma globulin as well as for two or three 
84 
serum components found in the region of the antigen well and 
a minor component in the S-globulin region. The unabsorbed 
anti-gamma globulin was toxic for both bursa and thymus cells 
at a titer of 320. The serum was absorbed once at 4°C with 
thymus cells. The absorbed serum was no longer toxic for 
thymus cells, but retained specificity for bursa cells. In 
this case, the cell donor for absorptions was not identical 
to the target cell donor. The immunoelectrophoretic pattern 
of the absorbed serum was indistinguishable from that 
obtained with the unabsorbed serum. If the bursa cell 
specificity of this serum is due to anti-gamma globulin or 
other serum specificity, many of the sera may show the same 
specificity after absorption. As noted in the immunodif-
fusion tests, all immune sera prepared against pigeon tis-
sue extracts and one normal serum from an adult rabbit had 
precipitating activity against pigeon serum components. 
Distinct anti-gamma globulin activity was detectable by 
immunoelectrophoresis only in the final bleedings of R 61 
and R 62. 
A third bleeding of R 61 was absorbed at 4°C with K 30 
red cells that had been separated on Ficoll-Isopaque 
gradient. The absorptions with red cells reduced the titer 
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against both bursa and thymus cells. The absorbed serum 
titers against bursa and thymus cells were very similar. 
The absorption with red cells was not meant to be complete, 
but only to reduce the amount of bursa and thymus cells 
needed for absorption. Subsequent absorption with thymus 
completely absorbed specificity for thymus cells; the titer 
against bursa cells remained high. Absorption with bursa 
cells was incomplete. 
Aliquots of W 16 serum which showed thymus specificity 
in immunodiffusion were absorbed with thymus cells and with 
bursa cells. Complement dependent toxicity was reduced for 
both bursa and thymus target cells although neither absorp-
tion was complete. There was no indication of differential 
absorption by either population of lymphocytes. Absorptions 
with soluble extracts of thymus and bursa as used in immune--
diffusion reduced the serum titer against both types of 
lymphocytes. This effect appeared to be an anti-comple-
mentary effect of the extracts. Additon of more comple-
ment increased the apparent titer of the absorbed sera 
without increasing the background of dead cells. 
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E. DISCUSSION 
Antibody specificity ·against possibly weak antigens in 
a mixture of strong competing antigens may be difficult to 
obtain. The unwanted antibodies may be reduced by the 
induction of immunological tolerance to strong common anti-
gens. This approach has been somewhat successful in pre-
paring antisera to tumor specific antigens (8, 69), and 
was .one method used in this study for the preparation of 
anti-pigeon lymphocyte sera in rabbits. The antigen pre-
parations, tissue homogenates or cells, are complex mixtures. 
The immunogenicity and the concentration of the individual 
antigenic specificities within the mixture are unknown but 
important parameters. Tolerance is highly dependent upon 
the presence of antigen and antigen dose. 
The levels of contaminating minor antigen populations 
within the antigen preparations are important because anti-
gen dosage can determine the balance between immunity and 
tolerance. The form of the antigen, either cellular or 
soluble, is also important because tolerance is more dif-
ficult to induce against cellular antigens. For these 
reasons, some antigens in /the preparation may immunize 
while others may induce tolerance. The soluble extracts of 
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pigeon bursa, thymus ' and brain contain serum components and 
probably some membrane specificities. These contaminants 
are difficult to quantitate. The importance of serum con-
taminants is indicated by the fact that a rabbit antiserum 
to pigeon gamma globulin was specifically cytotoxic for 
pigeon bursa cells after absorption with thymus cells. 
Serum contamination of antigen preparations could evoke 
anti-pigeon serum antibodies including some with anti-gamma 
globulin specificity. Serum from all rabbits that were 
immunized against pigeon tissue extracts contained pre-
cipitating antibodies against pigeon serum, but only three 
hyperimmune sera had demonstratable specificity for pigeon 
gamma globulin. 
The inclusion of minor cell populations in the cell 
inocula can explain the anomalous reactivity of some unab-
sorbed antisera. Red cells included in bursa and thymus 
cell preparations represented less than 2% of the total cell 
population. Cross contamination of bursa and thymus cells 
in the pigeon cannot be assessed in the absence of distin-
guishing cell markers. For the chick, reciprocal bursa-
thymus cell contaminations are estimated at approximately 
5% (3, 42, 50). If some antigens present in the cell 
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inocula given neonatal rabbits immunized the rabbits, sub-
sequent immunizations with antigenically different inocula 
could adversely affect the antibody specificity of the anti-
serum. The specificities and the titers of antisera from 
different bleedings of the same rabbit could be very dif-
ferent. Such differences were, in fact, observed in dif-
ferent bleedings of the same rabbit. 
_ Antigen presence is required for tolerance maintenance. 
The timing of the immunizing series of injections coincided 
with the time the rabbits would be expected to have a 
spontaneous break in tolerance. The one serum showing anti-
thymus specificity in irranunodiffusion was prepared in a 
rabbit that received neonatal injections of thymus cells 
followed by injections of thymus extract. The specificity 
observed with this particular serum suggests that the tissue 
source of the tolerizing antigens need not be different from 
that used later for immunization. 
All unabsorbed rabbit antisera reacted against pigeon 
serum, red blood cells, bursa and thymus cells, and saline 
extracts of many pigeon tissues. Tolerance to pigeon cells 
in the neonatally injected rabbits was incomplete. Titers 
of the unabsorbed sera against bursa or thymus or their 
extracts were often similar. Such sera may have contained 
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specificities which would not be apparent until specific 
absorptions were performed. 
Titers obtained in passive hernagglutination tests 
measure the total reaction between all antibodies and their 
corresponding antigens. This technique is very sensitive; 
less than 50 antibody molecules per cell can cause aggluti-
nation. Only a very small percentage of the soluble antigen 
ava~lable is actually adsorbed to the tanned red cells. 
Because tissue extracts are highly complex antigenic mix-
tures, antigens within the mixture may compete for attach-
ment to tanned red cells. All antigenic specificities would 
not necessarily be represented on these cells. This pheno-
menon could explain the high anti-bursa extract titers in 
one set of passive hemagglutination tests. 
A totally different technique, inununodiffusion, was 
also used for detection of soluble antigens. Irnmunodif-
fusion screening of the unabsorbed antisera identified 
eleven sera with possible anti-thymus extract specificity. 
No anti-bursa extract specificity was indicated for any of 
the sera by immunodiffusion. The thymus extract was more 
effective in absorbing antibody than were the other tissue 
extracts. All sera prepared against soluble extracts showed 
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reactivity against all tissue extracts and against pigeon 
serum. One antiserum after absorption with pigeon serum 
demonstrated a shared tissue specificity and a possibly 
quantitative antigenic difference among the thymus, bursa 
and brain extracts. 
Lymphocytes from mouse thymus show quantitative anti-
genic differences from peripheral, apparently thymus-derived 
lymphocytes for both theta and H-2 specificities (54) . 
Theta is high on thymus cells, H-2 is low. The reverse 
quantitative relationship is true for the peripheral blood 
lymphocytes. These quantitative antigenic differences 
coincide with a difference in functional capacity between 
these lymphocyte populations. The murine TL antigen is 
present only on thymus cells in normal individuals. Normal 
lymphocytes outside the thymus do not express TL. The Ly 
and MSIA markers are present on peripheral lymphocytes and 
are lymphocyte specific (54). The H-2, theta, PC, H-14 and 
the natural specificity in normal guinea pig sera are not 
lymphocyte specific markers, although they can distinguish 
between thymus-dependent and thymus-independent lymphocytes 
(54). 
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A pigeon thymus specificity was detected by immunodif-
fusion in one rabbit antiserum. This reagent recognizes 
the same specificity in spleen extracts. The pigeon thymus 
specificity is not unique to the less differentiated state 
of lymphocytes in the thymus. This reagent did not react 
with pigeon brain extracts and therefore may not be the 
pigeon counterpart of the mouse antigens, H-2, theta, H-14 
or the natural specificity recognized by normal guinea pig 
sera which are all present in brain. These mouse antigens 
are membrane antigens. The pigeon thymus reagent did not 
appear specific for intact thymus cells although the absorp-
tions with soluble material were incomplete. Absorption 
with insoluble thymus tissue pellets removed all activity 
against thymus extract. 
McArthur et al. (42) and Potworowski et al. (50) 
recently reported serological markers for both chicken 
thymus and bursa cells in complement dependent lymphocyto-
toxicity tests. The reagents of Potworowski et al. and of 
McArthur et al. were also cytotoxic for some lymphocytes 
in tissues other than the central lymphoid organs. 
Jankovic et al. {32) were unable to demonstrate bursa or 
thymus specificities by lymphocytotoxicity, leukoagglutina-
tion or passive hemagglutination techniques. Some in vivo 
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specificity was demonstratable in these latter sera by 
injection into chick embryos with guinea pig complement. 
Forget et al. (24) identified bursa and thymus specifi-
cities by immune adherence tests. The nature of these test 
systems suggests that the identified specificities are pre-
sent on the cell membranes. No comparison of the various 
reagents has been reported so that the number of unique 
spec~ficities may be no greater than two. 
Malchow et al. (41) prepared antisera against crude 
membrane fractions of chick thymus and bursa cells. They 
identified two specificities shared by bursa and thymus and 
a unique specificity cells for each central lymphoid organ. 
The unique specificities were not detectable on lymphocytes 
from other tissues. The present study with pigeon lympho-
cytes was successful in detecting solublizable specificities 
for thymus and also two shared specificities. 
The pigeon thymus antigen reagent could possibly be 
a useful typing reagent because the antiserum gives clear 
positive and negative reactions. It is not, however, a 
strong reagent and at present can be used only on pooled and 
concentrated extracts. A high titer reagent might be pre-
pared because the antigen is separable from a number of 
serum specificities by its electrophoretic mobility. 
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Tissue extracts used for testing and for immunizations 
could also be freed of many pigeon serum specificities by 
absorption with insolublized antiserum to whole pigeon serum. 
Preliminary experiments indicated that rabbit antiserum to 
pigeon serum was easily rendered insoluble by glutaraldehyde 
treatment, the procedure used to insolublize pigeon serum. 
No prior extraction of lipids was necessary. Soluble anti-
gens are particularly intriguing because they are, in general, 
more amenable to chemical analysis than are membrane anti-
gens. 
Strong reagents against pigeon lymphocytes may be 
obtained from rabbit antiserum to whole pigeon serum as 
well as by the procedures used to obtain standard anti-
lymphocyte reagents. The former serum can be made bursa 
cell specific by absorption with pigeon thymus cells. This 
bursa specificity is consistent with the proposed role of 
antibody as the antigen specific receptor molecule on the 
cell membrane of imrnunocompetent cells, particularly of 
thymus-independent derivation. Some anti-lymphocyte sera 
can be made thymus-specific by absorption with pigeon bursa 
cells. 
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The molecular specificities of these sera are, in 
general, unknown, although heterologous anti-gamma globulin 
should be directed against the constant region of the 
immunoglobulin molecule. The natural antibody in hetero-
logous serum against thymus cells of many species appears 
by inhibition studies to be directed against carbohydrate 
moieties. 
Natural toxicity to heterologous thymocytes has been 
reported in normal serum from rabbits and from guinea pigs. 
Evidence that this toxicity is mediated by natural anti-
bodies is that the toxicity can be absorbed out by thymo-
cytes, and the toxicity can be isolated in the 7s and 19s 
serum fractions where IgG and IgM are found. Antibody to 
IgG removes the toxicity. Absorption with agar or agarose 
removes the toxicity without affecting the complement 
levels and is consistent with a carbohydrate specificity 
as indicated in inhibition studies. The toxicity is also 
heat labile. 
The natural toxicity of rabbit serum for pigeon lympho-
cytes is similar to these previously reported systems in 
several ways: the toxicity is present in normal serum of 
rabbits and is more toxic for thymus and bursa cells than 
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for peripheral lymphocytes, is absorbed from the serum by 
thymus and bursa cells and is heat labile. A possibly 
significant difference from the preceding systems is 
that the toxicity for pigeon cells is not absorbed by 
agarose. If the natural toxicity depends on antibody in 
this case, the antibody specificity would be different 
than that for mouse and human thymus cells. 
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F. Summary 
Antisera were prepared against pigeon thymus and bursa 
lymphocytes and against saline extracts of thymus and bursa. 
All antisera were prepared in rabbits - some as standard 
anti-lymphocyte reagents and some in rabbits injected neo-
natally with large doses of pigeon cells. The neonatal 
injections were made to reduce the rabbits' antibody 
response to species-specific antigens upon challenge with 
pigeon lymphoid tissue. 
All unabsorbed sera were screened for differential 
reactivity against thymus and bursa-derived tissue by 
passive hemagglutination, immunodiffusion, leukoagglutina-
tion and complement dependent lymphocytotoxicity. Sera 
identified in this nanner were absorbed with thymus and 
bursa tissue to demonstrate specificity. One serum with 
specificity against thymus extracts was identified by 
imrnunodiffusion. The thymus specificity was absent from 
extracts of pigeon bursa, brain, liver and breast muscle, 
but present in spleen extracts. The thymus specificity was 
shared by extracts of thymus from two different breeds of 
pigeon but not extracts of chicken lymphoid tissue. This 
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thymus specificity does not appear analogous to lymphocyte 
specificities identified in other species. 
Shared tissue specificities and a possible quantitative 
antigenic difference among the tissue extracts were also 
demonstrated by immunodiffusion and absorption analysis. 
In lymphocytotoxicity tests, fresh rabbit normal serum 
is highly toxic for pigeon thymus and bursa cells. This 
toxicity resembles the natural antibody present in rabbit 
and guinea pig sera against heterologous thymus cells. 
The activity against pigeon lymphocytes can be absorbed by 
pigeon thymus and bursa cells and is heat labile. Unlike 
the natural antibody against thymus cells of other species, 
the toxicity against pigeon lymphocytes could not be 
absorbed by agarose. 
A rabbit anti-pigeon gamma globulin serum was rendered 
specific for bursa cells by absorption with thymus cells. 
Some standard anti-lymphocyte sera were shown to contain an 
antibody fraction specific for thymus cells. 
Some or all of these reagents may be useful for distin-
guishing cooperating cell populations in a variety of immune 
responses. Avian species, in addition to the chicken, may 
provide additional data on the phylogeny of functionally 
distinct lymphocyte populations. 
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II. DEVELOPMENTAL RED CELL ANTIGEN IN THE PIGEON 
· A. Abstract 
Several fetal red cell antigens are described in the 
literature for species other than the pigeon. In this 
study, a fetal red cell antigen was sought as a possible 
serological marker for white cells as well. There are 
several reasons for thinking that such an antigen might 
be present on white cells. First, these two cell types 
are derived from a common stern cell. Second, a number 
of other antigens are known to be shared by white cells 
and red cells. In addition, the thymus and the bursa of 
Fabricius, which are the primary lymphoid organs in birds, 
are transient sites of erythropoiesis. Both lymphoid 
organs could be classified as developmental structures. 
At least one fetal red cell antigen in known to exist on 
cells other than mature red cells and to persist in these 
sites even after the antigen is no longer detectable on 
red cells. 
The studies reported in this thesis did, in fact, 
reveal an antigen on red cells from all pigeon squabs 
less than four days old. The antigen appears not to be 
secondarily adsorbed to the red cells from the fluids of 
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the egg or the embryo. In vitro, masking of the antigen 
by components of adult serum does not occur under the 
conditions tested, nor can the antigen be made to reap-
pear in the adult after frequent bleedings. Although the 
squab antigen behaves similarly to a known fetal red cell 
antigen in doves, it is probably qualitatively different 
from that antigen and from the known chick red cell anti-
gen.-
The squab antigen is not detectable on lymphocytes 
from the bursa or the thymus by either leukoagglutination 
or complement dependent lymphocytotoxicity. The antigen 
does not appear to be a lymphocyte marker. It is, however, 
an additional developmental antigen. If it is like other 
developmental antigens, it could be an interesting marker 
in both normal development and some disease states. 
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B. Introduction 
An interesting subset of the developmental antigens 
are those present on red blood cells of the embryo and the 
neonate, but absent from normal adult red cells. Heterol-
ogous antisera have been used to demonstrate fetal red cell 
antigens in humans, chickens and doves (5, 6, 9, 10). The 
common fetal red cell antigen of humans, the i antigen, is 
detected by alloantisera. The relationship between this 
antigen and the one detected by rabbit antiserum is unknown 
(5, 11). Only in humans has an adult counterpart, I, of 
the fetal antigen been identified (11). The amounts of I 
and i present on human red cells are reciprocally related. 
Avian blood is a particularly useful tissue for the 
study of developmental antigens because it is readily 
accessible and radical changes occur in both cellular and 
plasma factors between the time the blood first appears 
and the fully developed embryo hatches. The differences 
observed during embryonic development are both quantita-
tive and qualitative (13, 14). The concentration of 
circulating red blood cells increases rapidly as hatching 
approaches, while the white cell levels rise more slowly. 
The first red cells in the avian embryo are a primitive 
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strain. Red cells in progressive stages of differentiation 
appear in the circulation of the chick embryo for the first 
six days of incubation. These cells are subsequently 
replaced by red cells of the definitive strain. These 
latter red cells quickly become the major type of red cells 
in the circulation, although primitive red cells may be 
found in the blood for as long as two weeks after hatching. 
' While changes in circulating red cells are occurring, 
the site of hernatopoiesis is also changing (13). The pro-
gression is from yolk sac to fetal liver to spleen and bone 
marrow. The avian thymus and bursa of Fabricius are also 
minor sites of erythropoiesis. Erythropoiesis is observed 
in the bursa during the last days of incubation and ceases 
within several days after hatching. The avian thymus is 
even less involved in erythropoiesis. The circulating red 
cells and white cells of the blood appear to be derived 
from a common stem cell. The bursa and thymus which are 
minor sites of erythropoiesis are at the same time major 
and continuing site of lymphopoiesis. The thymus is the 
first lymphoid organ to develop and the first in which 
lymphopoiesis is observed. In the chick, the thymus 
develops at eight days of incubation. The bursa develops 
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2-4 days later and lymphocytes begin to appear in the bone 
marrow at about the same time. Small lymphocytes are 
found in the spleen 2-3 days later. 
Red cells and white cells of the adult animal share 
many, but not all cellular antigens (23). The human blood 
group antigens A, B, M, N, S, Tja and probably the Rh 
complex are present on human leukocytes. These antigens 
are ·more difficult to detect on leukocytes than on red 
cells. Anti-leukocyte antibodies are more often found 
coincident with anti-erythrocyte antibodies than expected 
by chance in sera from multiparous or multiply transfused 
persons. In the mouse, the H-2 system, which was origin-
ally detected as a red cell antigen, not only is detectable 
on lymphocytes, but also is the major leukocyte antigen 
system in this species. In the chicken, the B blood group 
locus is that species' major leukocyte antigen system. 
A chicken fetal red cell antigen, while absent from 
adult mature red cells, was detectable on other adult 
tissues (15). Spleen, liver, kidney and bone marrow cells 
of either adult or young chickens were able to absorb 100% 
of the hemolytic activity from the anti-chick cell reagent . 
In fluorescent antibody tests, adult red cells were nega-
tive, but blood leukocytes were fluorescent. 
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The I antigen of humans is absent from lymphocytes 
as indicated by the failure of anti-I sera to agglutinate 
or lyse lymphocytes in the presence of complement (21). 
One anti-I serum did lyse some lymphocyte samples, but 
lysis did not occur with all strong anti-I reagents. 
Lysis in the anomalous case was probably due to a con-
taminating antibody of different specificity. Absorption 
tests were not reported. The fetal antigen in chicks 
persists in adult tissues other than circulating red cells. 
If either the I or i antigens were present on human lympho-
cytes, the fetal antigen, rather than the adult counterpart, 
might be the more probable specificity. Anti-i was not 
tested against adult human lymphocytes. 
The composition of the blood plasma may be important 
in determining the antigens on the red cells (19). There 
is a large positive association between blood group anti-
gens and serum isoenzymes in several species (24). This 
association does not imply a mechanism of red cell anti-
gen determination. The reason for the correlation remains 
to be explained. In vitro, red cells can adsorb bacterial 
and blood group specificities from the surrounding medium 
(19). Stormont demonstrated that the J antigen on cattle 
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red cells is, in fact, normally adsorbed to the cells 
from J+ plasma (20). 
The composition of the plasma changes radically with 
development in the chick embryo (14). In the early embryo, 
the plasma solids are predominantly lipids. The concentra-
tion of serum protein increases especially in the week 
before hatching, and by hatching exceeds the concentration 
of serum lipids. The physical properties of the plasma 
also change. The pH changes from acidic to basic. The Cu 
and Fe levels and the Ca/Mg ratio increase. 
All of these components - the physical properties of 
the serum, the composition of the plasma and the internal 
environment of the embryo (16) - may affect the expression 
of red cell antigens. 
In the present study, because of the close develop-
mental relationship between red cells and white cells, 
fetal red cell antigen(s) were looked for in lymphocytes 
of both thymus and bursa! origin. The chicken fetal red 
cell antigen is present in tissues which at some time 
contain elements of both the white cell and red cell 
series. The bursa and thymus can both be regarded as 
developmental organs because of their early influence 
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on the development of the immune system, the transient 
erythropoiesis in both organs in the embryo, and the 
decrease in organ size and immune function in advanced age. 
The possibility of polymorphism in fetal antigens is 
suggested from the I antigen system in humans (11). Clear 
polymorphisms exist for the i antigen and polymorphism in 
I may also exist. Even if no difference were observed 
between the bursa and thymus expression of a squab fetal 
antigen, there might be genetic differences among indi-
viduals within the breeds of pigeons or between breeds. 
The relationship between the various red cell fetal 
antigens of different species is unknown. The chicken 
and pigeon systems are not expected to be necessarily 
identical or even equivalent. These two species are 
evolutionarily far removed and developmentally distinct. 
Pigeons belong to the altricial group of birds - those 
which hatch in a very immature state and develop slowly 
and require parental care. Pigeons, along with doves, 
are unique even among the altricial birds, in that parents 
produce crop milk to feed the very young bird. 
The existence and nature of a fetal red cell antigen 
/ 
in pigeons is revealed in the following study. Its 
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relationship with the known chick and dove fetal red 
cell antigens is discussed. 
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C. Methods 
Preparation of Antiserum: 
An adult female New Zealand rabbit was injected in 
the toepads with .5 ml of a 20% suspension of washed 
squab red blood cells mixed with an equal volume of 
·Freund's Complete Adjuvant. One month later an intra-
peritoneal injection of 1 ml of 20% squab cells in saline 
was given. 'lwo and five days later the rabbit was 
injected intravenously with .5 ml of 20% squab cells in 
saline. Two reimmunizations, repeating the intraperi-
toneal and intravenous injections, were made at later 
times. The rabbit was bled ten days after the last 
injection in each series. Only the last serum sample was 
demonstrated to have specificity for squab cells after 
absorption with red cells from adult pigeons. Serum 
was heated for 1 hour at 56°C and stored at - 2O°C. 
Absorption with Adult Pigeon Cells: 
The rabbit antiserum was absorbed at room tempera-
ture and at 4°C with washed, packed red cells from four 
adult pigeons. Three of these were the offspring of the 
three original Tumbler mating pairs and the fourth was 
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an adult King. Absorptions were repeated until the anti-
serum no longer agglutinated red cells from these same 
four pigeons. 
~: 
Eggs are normally laid in a clutch of two, the second 
egg is laid somewhat less than two days after the first (l). 
Pigeons were checked three times a week or daily when more 
accurate ages and incubation times were necessary. Incuba-
tion times were determined from the time the second egg 
was laid because the first eggs are usually not adequately 
incubated until the female has finished egg laying. The 
two eggs often hatch the same day. 
Bleeding Embryos: 
The shell over the air sac was carefully removed to 
expose the internal fibrous membrane below (9) . ·The 
membrane was flooded with a warm (37°C) isotonic NaCl-
sodium citrate solution (isocitrate). A sharp scalpel 
was used to nick the visible surface blood vessels and 
the blood-citrate mixture was removed with a pipette. 
Bleeding Squabs and One Day Old Chicks: 
Small squabs and one day old chicks were bled 
terminally by cardiac puncture. 
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Chickens: 
One day old (Kimber Farm) White Leghorn male chicks 
were obtained after use in short term learning trials. 
A single adult rooster which had been immunized to 
the phage PM2 was used as an adult red cell donor. 
Hemolytic Assays: 
Hemolytic tests with pigeon red cells were performed 
as described for chicken red cells (15). Dilutions of 
antiserum were mixed with one-half volume of 2% washed 
red cells. Complement was added and the tubes were 
incubated at 37°C in a shaking water bath. The tubes 
were centrifuged and the degree of hemolysis estimated. 
Complement: 
Fresh normal rabbit serum was absorbed with agarose 
at 4°C for one hour (1). One rabbit was chosen as a 
complement source because its serum was less toxic for 
mouse thymocytes than were other rabbit sera. The 
absorbed serum was divided into small aliquots and 
stored at - 70°C until use. The complement was titrated 
in the hemolytic assay against both squab red cells and 
adult red cells. 
117 
Collection of Allantoic Fluid: 
A fertile egg which had been incubated 8 days was 
candled. A pencil cross was made on the shell about one 
quarter inch below the air chamber and away from large 
blood vessels. A syringe needle was inserted through the 
shell at the pencil mark and allantoic fluid withdrawn. 
Saline Extracts: 
A one to two day old squab was sacrificed shortly 
after feeding, the crop was opened and the milk removed 
with a spatula. The egg yolk and egg white from an 
infertile egg were separated. Equal volumes of the egg 
yolk or egg white or crop milk were shaken with an equal 
volume of .OOlM MgCl in saline. The extract was spun 
down in a clinical centrifuge at top speed and the super-
nant collected and stored at - 20°C. 
Incubation of Red Cells with Fluids or Extracts: 
20 µl of washed adult pigeon red cells were incubated 
with 2 ml of appropriate fluid or extract at 37°C. Red 
cells for a two day old squab were similarly incubated in 
adult serum. After forty minutes the incubation mixtures 
were centrifuged and the fluid removed. The cells were not 
washed, but the fluid was replaced by enough saline to 
make a 2% suspension of red cells. 
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Serum Absorption with Chicken Cells: 
The squab specific reagent was absorbed four times 
with red cells from one day old chickens. Absorptions 
were performed for five minutes at room temperature, fol-
lowed by a five minute absorption at 4°C. 
Additional Methods: 
Additional methods may be found in the methods 
section of the preceding chapter. 
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D. Results 
Absorption of the antiserum with red cells from a 
single adult pigeon removed most of the antibodies directed 
against adult red cells, but the serum still agglutinated 
red cells from some adult pigeons at low serum dilutions. 
No agglutination was observed when the absorbed serum was 
tested against red cells from the same pigeon as used for 
the · absorptions. Absorption of the antiserum for detection 
of a possible squab antigen was not considered complete 
until the antiserum no longer agglutinated red cells from 
the four pigeons used to provide red cells for absorptions. 
The antiserum was also tested against red cells from the 12 
bi~ds used to start the pigeon colony. At no time did the 
absorbed antiserum agglutinate red cells from these addi-
tional adult birds. The parents of the positive squabs 
were also found to be negative, although the parents were 
not tested in every case. 
The absorbed antiserum always agglutinated red cells 
from squabs between hatching and four days of age (Table 
1). Because the Tumbler pigeons reproduce faster than the 
King pigeons, most of the squabs tested were Tumblers. 








































































































































































































































































































































































































generally positive at serum dilutions of 1:128. Cells from 
embryos between 11 and 17 days of incubation were agglu-
tinated although the reactivity was somewhat less than that 
observed for the newly hatched squabs. Reactivity was 
heterogeneous for individual squabs between five and eight 
days after hatching. Some squabs reacted with the same 
serum dilutions as the very young squabs, and others were 
negative. Heterogeneity persisted until 16 days, but the 
deg~ee of disparity between individuals decreased. Posi-
tive cells were agglutinated only with serum dilutions of 
1:8 or less. There may be two prototype patterns of 
reactivity -which are indistinguishable until four days 
after hatching when the reactivity disappears in one and 
is diminished in the other. Heterogeneity in the persis-
tence of reactivity was also noted in individual squabs 
which were bled every other day until their cells were 
no longer agglutinated by the antiserum (Table 2). Absorp-
tions with red cells from individual squabs were limited 
because of the amount of material needed for the absorp-
tion and the volume of antiserum necessary to perform the 
tests. Complete absorptions were obtained with cells from 
two different squabs. Tests of the absorbed sera against 
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Age of Squab 





2 5 - 0 
3 
} sibs 
4 6 7 7 
4 8 7 7 0 
a. not done 





red cells from other one to two day old squabs indicated 
that absorption with cells from a single donor did not 
remove reactivity to all other squab cells, but did reduce 
the serum titer significantly. Reciprocal absorptions were 
not performed. 
Immunodiffusion tests were performed with the anti-
serum against saline extracts of egg yolk and of egg white 
and of crop milk and one to two day squab serum in Alsever's 
solution and allantoic fluid. Embryo red cells were mixed 
with some allantoic fluid during bleeding. The unabsorbed 
serum strongly precipitated a component in allantoic fluid, 
and weakly precipitated a component of squab serum and of 
milk extract. No precipitin bands against the egg white 
extract were observed. Egg yolk was highly opaque to an 
extent which made · it impossible to distinguish any precipi-
tin bands. Absorptions with adult red cells removed pre-
cipitating activity against all extracts and fluids except 
the allantoic fluid. The percipitin reaction with allan-
toic fluid was considerably reduced. 
Because specific agglutination was observed in intact 
red cells, the antigen was assumed to be present on the cell 
surface. Attempts were made to attach or to reveal the 
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antigen on adult red cells. Incubation of adult cells in 
squab serum, allantoic fluid and saline extracts of egg 
white and egg yolk, failed to confer a positive reaction 
on adult cells. 
Squab red cells are less stable when stored in Alsever's 
solution than are adult cells. They are more susceptible 
to lysis in distilled water and to complement mediated anti-
body lysis indicating that they are more fragile and perhaps 
that the additional red cell antigens of the adult confer 
stability upon the red cells and mask expression of the 
fetal antigen. Incubation of the squ~b red cells with serum 
from an adult bird did not prevent agglutination when the 
squab red cells were subsequently tested with the squab 
specific antiserum. 
The adult serum did protect the squab red cells from 
spontaneous agglutination. Squab cells incubated with 
saline under identical conditions of incubation sponta-
neously agglutinated even in the absence of antibody, 
whereas those incubated with adult serum agglutinated only 
with the antiserum and only with the dilutions of ~ntiserum 
to which they were normally reactive. 
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Red cells from a frequently bled adult bird were less 
stable than normal adult red cells upon storage at 4°C in 
Alsever's. These red cells formed less compact cell buttons 
in the absence of the antiserum, but still failed to agglu-
tinate with the squab specific reagent. No evidence was 
obtained that the squab specific antigen was secondarily 
adsorbed to the squab red cells or that the antigen was 
present but masked in the adult red cell. 
The unabsorbed antiserum reacts strongly in immunodif-
fusion with saline extracts of thymus and of bursa. These 
extracts also contained adult serum components. Passive 
hemagglutination which is more sensitive for the detection 
of soluble antigens than immunodiffusion showed some low 
level reactivity for extracts of thymus and bursa (Table 3). 
No reproducible difference in reactivity between extracts 
from thymus or bursa was found. The nature of these reac-
tions or the antigens responsible are unknown. The anti-
gens may not be membrane antigens. Specificity for intra-
cellular soluble antigen, either common to both organs or 
unique, would not have been absorbed by intact adult red 
cells. 
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TABLE 3. SPECIFICITY OF RABBIT ANTISERUM FOR 
BURSA OR THYMUS EXTRACTS AND CELLS 
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A single absorption of the squab reagent with bursa 
cells failed to reduce the titer of the serum when tested 
against red cells from the same newly hatched squab. Bursa 
and thymus cells tested in either leukoagglutination or 
lymphocytotoxicity tests for comparative purposes were 
always from the same individual. Individual differences 
would therefore not be detected, but organ specific dif-
fe~ences could be detected, if present. Bursa and thymus 
cells from squabs over a week old failed to react with the 
squab specific reagent in leukoagglutination or in comple-
ment dependent lymphocytotoxicity tests (Table 3). The 
unabsorbed rabbit antiserum tested against the same cells 
was used as a positive control. 
The squab reagent agglutinated red cells from one day 
only chicks, but not from adult chickens (Table 4). The 
titer against chick cells was slightly lower than against 
red cells from one to four day squabs. Absorption of the 
reagent with chick red cells removed all reactivity against 
chick cells without significantly affecting the titer 
against squab cells. This cross reactive specificity could 
account for the red cell heterogeneity in squabs between 
five and sixteen days of age, but this possibility was not 
pursued. 
Red Cell Donor 
adult chicken 
one day old chicken 
one day old squab 
a. not done 
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TABLE 4. AGGLUTINATION OF RED CELLS FROM ADULT AND ONE 
DAY OLD CHICKENS BY SQUAB SPECIFIC REAGENT 
129 
E. Discussion 
Absorption of the rabbit antiserum with red cells from 
a single adult pigeon failed to remove reactivity against 
red cells from all adult pigeons, but substantially reduced 
the titer against adult red cells. Because the antiserum was 
prepared against red cells from newly hatched squabs, those 
red cells must have already expressed some adult red cell 
alloantigens. These observations are in agreement with more 
extensive developmental studies of adult pigeon red cell 
antigens (2, 3). Of the five identified pigeon red cell 
antigens, three are already present at hatching and two are 
detected at one week after hatching. Adult antigen levels 
are not reached until one to three weeks after hatching. 
During embryonic life and before adult antigen levels 
are reached, the red cells may express fetal antigen(s). 
Rabbit anti-squab red cell antiserum absorbed with adult 
red cells specifically agglutinates squab red cells. The 
strongest agglutination reactions are observed in red cells 
of embryos and squabs less than four days old. The tran-
sient appearance of the squab antigen as detected by hemag-
glutination is very similar to the time interval during 
which the known dove embryo antigen was detectable on dove 
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red cells. Ousterhoudt and Irwin reported that a dove 
embryo antigen was present on red cells from all embryos 
and disappeared four days after hatching (9). They tested 
thirteen pigeon embryos between six and thirteen days of 
incubation for the presence of the dove antigen, but no 
antigen was detectable. 
The obvious developmental structures coincident with 
squab antigen expression are the egg yolk, allantoic fluid , 
egg white and primitive red cells. Incubation of adult red 
cells with extracts of egg structures and embryo fluids 
were performed to determine if the antigen could be adsorbed 
onto the red cells from the embryonic environment. The 
squab reagent weakly precipitates a component of allantoic 
fluid. Red cells of many species adsorb lipoproteins and 
serological specificities both in vitro and in vivo. The 
present experiments indicate that the squab specificity 
could not be adsorbed by adult red cells from fluids and 
extracts, at least under the conditions of the tests. 
The primitive red cells are only a very small percentage 
of the circulating red cells in the newly hatched chick. If 
the same is true in pigeons, there are not enough primitive 
red cells to account for the strong agglutination pattern 
observed with this reagent. 
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Because the squab cells are more fragile than adult 
pigeon red cells to hypotonicity and complement dependent 
lysis, the squab antigen could be present in the adult red 
cells but masked from reaction with specific antibody. 
Incubation of squab red cells in adult serum does not 
support this possibility. Frequent bleeding of an adult 
bird also did not change the non-agglutination of adult 
red cells with this reagent. 
Both adsorption of serological specificity and masking 
of fetal specificity have been observed in other species 
and other red cell antigen systems (19). Sanders and Wright 
observed that papain treatment of red cells from adult brown 
trout revealed a specificity characteristic of red cells 
from yearling trout (18). Similar papain treatment of adult 
chicken red cells failed to reveal the fetal red cell speci-
ficity (15). Sanders demonstrated that the expression of 
the chick fetal antigen was not changed by in vitro or in 
vivo experiments in which the antigen might become covered 
and inaccessable to antibody. The antigen expression was 
apparently dependent upon a neonatal internal environment. 
The time of appearance of the chick fetal antigen did not 
correlate with observed quantitative differences in macro-
globulin or lipid in the young chick and the adult chicken. 
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Levi and Schechtman reported that fluids and tissues from 
chick embryos failed to inhibit agglutination (6). 
Ousterhoudt and Irwin found that the dove fetal red 
cell antigen was not removed from positive cells after 
washing, or treatment of the cells with either hyaluroni-
dase or trypsin (9). The three avian fetal red cell anti-
gen systems are similar in that simple direct mechanisms 
of antigen loss cannot be demonstrated. Sanders suggested 
that the antigen expression in the chick system might be 
determined by differential gene expression (15). 
Although the chicken fetal antigen was detected on 
bursa and thymus cells of one day old chicks, the squab 
antigen could not be detected on squab bursa or thymus 
cells by either leukoagglutination or lymphocytotoxicity. 
Sapders et al. found that not all cells of the neonatal 
chick bursa and thymus express the chick fetal antigen (17). 
If the positive cells were stem cells (17), the squab anti-
gen might also be present in thymus and bursa but not 
present on lymphocytes. The squab antigen does not appear 
to be a useful l y~phocyte marker. 
The squab specific reagent reacts with red cells from 
one day old chicks but not from an adult chicken. Agglu-
tination of chick red cells is due to cross reactive 
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antibodies in the rabbit antiserum. Absorption with chick 
cells removes all reactivity to chick cells but has no 
significant effect on the agglutination of squab cells. It 
is not known if the specificity detected by this cross 
reactive antibody is the same as the reported chick fetal 
red cell antigen. 
Because reactivity against chick cells was not neces-
sary for the specific a~glutination of squab red cells, the 
chick specific antigen is probably different from the major 
antigen detected on squab cells in this study. The squab 
antigen appears to be different from that reported in dove 
red cells because the dove embryo reagent did not agglu-
tinate red cells from any of the pigeon embryos tested (9). 
Because the dove antigen cannot be detected on pigeon 
embryo red cells and the squab reagent can be rendered 
nonreactive to chick cells without affecting its squab 
specificity, the squab antigen appears distinct from the 
other avian red cell developmental antigens. 
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F. Blood Group Antigens in Ontogeny, Phylogeny and 
Disease States 
The embryo specific red cell antigens which have been 
described in the literature are all present, at least neo-
natally, on the red cells of all individuals of the species. 
These are cell surface antigens, but their role, if any, in 
ontogeny is unknown. Since red cells are freely circulating, 
the ·antigens are not likely to function in cell interactions 
or in morphogenetic movements. They are not required for 
the formation or function of fetal hemoglobin. In humans, 
the i antigen and fetal hemoglobin are present concur-
rently in normal development. The rate of synthesis of the 
Schain of fetal hemoglobin does not correlate with the 
rate of synthesis of the I antigen (21). The two events are 
presumed to be under different regulatory control. In the 
rare adults whose red cells express the i antigen, adult 
hemoglobin - not fetal hemoglobin is found (11). In 
normal adults whose red cells contain fetal hemoglob~n 
the I antigen is present on the cell surface. In chickens, 
the fetal red cell antigen and the fetal hemoglobin are 
not present at the same times even in normal development 
(15). The presence of a normal fetal component in the 
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adult apparently is not necessarily indicative of a return 
to the fetal state in a genetic sense. 
The significance of the fetal expression of some anti-
gens is clouded by the fact that so-called fetal antigens 
may be fetal antigens only for a defined species. In one 
species of doves, for example, an antigen has been found on 
red cells for only a short period of development. In a 
second species the same specificity continued to be present 
in - the adult (9). 
The species distribution of fetal red cell antigens, 
or indeed of red cell antigens in general, are not neces-
sarily indicative of evolutionary relationships among the 
species. Tha AB human blood group specificities are 
found throughout the plant and microbial species as well 
as in animal species other than humans (11). The relation-
ships among the various fetal red cell antigens is unknown 
and only the Ii system has been looked for extensively in 
other species (25). Both I and i are widely distributed. 
The fetal i specificity is detectable in adults of some 
infrahuman species. The distinction between adult and 
fetal red cell antigens may have no significance outside 
the reference species. 
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In humans, the I antigen, unlike the other human blood 
group antigens is absent from fetal blood and from cord 
blood (11). It is, in that respect, late in developing, 
but it reaches adult levels by 18 months of age. The A and 
B, P and Lua human blood group antigens while present in 
human fetal blood may not reach steady adult levels until 
three, seven or fifteen years, respectively, after birth 
(11). The level of a particular antigen is not necessarily 
less than full adult level during that time. It may exceed 
adult levels and subsequently return back to adult norms. 
The A and B specificities in human fetuses are cross reac-
tive with the A and B specificities of adults, but not 
identical. 
The common ABO blood group polymorphisms in humans 
have been studied by many investigators in hopes of finding 
an association between antigen and disease susceptibility 
or resistance. Because individuals are tolerant of their 
own antigens and because a number of micro-organisms carry 
antigens highly cross reactive with the A and B blood group 
substances, it was thought that difference in ABO type might 
be responsible for a difference in fitness between indi-
viduals. Many small but significant associations between 
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ABO type and noninfectious and infectious disease have been 
reported (22), including diseases of older adults. Selec-
tive pressure for maintenance of polymorphism would have to 
occur prior to or coincident with reproductive capability. 
A significant influence of ABO type has been reported in 
very young children with regard to hospital admittance for 
gram negative infections (12), in spite of the fact that the 
AB antigens do not reach adult levels until three years of 
age and the fetal A and B substances are quantitatively and 
qualitatively different from the adult A and B substances. 
ABO incompatibilities between mother and fetus have 
been suggested in association with early fetal death. A 
recent study by Hiraizurni et al. failed to demonstrate any 
significant correlation between ABO maternal-fetal incompati-
bilities and fetal death (4). They did report a significant 
effect of fetal genotype on fetal survival. Type A fetuses 
seemed to be favored. The advantage of blood group A indi-
viduals was less significant for infants in the first month 
after birth. 
A different and more direct influence of blood type on 
disease is indicated in those diseases with recognizable 
antibodies directed against blood group substances. 
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Antibodies against the Rh factors are directly responsible 
for erythroblastosis fetalis. Rh is already expressed on 
the red cells in the human fetus. Autoimmune anti-I anti-
bodies are responsible for the cold type autoimmune hemo-
lytic anemia and a reexpression of the i antigen in the 
affected individuals (11). The complementary antibody, 
anti-i, was identified in several patients with reticulosis. 
Most individuals with either anti-I or anti-i in their serum 
have been detected because of attendant hematological dis-
orders. Natural antibodies to trese specificities are rare. 
These autoantibodies represent an apparent break in toler-
ance to either normal adult or normal fetal antigens. 
Expression of fetal cellular antigens at least in some 
disease states may be modified by environmental influences 
direqtly, without modification of gene action. 
Malignancies directly affecting blood cells may change 
antigen expression on red cells. The reactivity of human 
red cells to a number of typing sera, including those 
having A, B or I specificity, is altered by leukemia (11). 
The natural antibodies to the A and B antigens are also 
altered. The antibody change is possibly a secondary 
effect of altered expression of the autologous antigens. 
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In chickens, the fetal red cell antigen reappears in 
leukos is (17). 
The occurrence of fetal antigens in normal ontogeny 
and in some disease states has suggested to many investi-
gators that these antigens may be useful in elucidating 
the relationship between environmental influences and 
cell surface specificities, the mechanism of differential 
gene expression or identifying the target cell for parti-
cular disease processes. The identification of new develop-
mental antigens may provide additional markers for eluci-
dating these processes. 
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III. EFFECT OF IMMUNOSUPPRESSION ON PRIMARY TUMORS 
A. Abstract 
If immune surveillance suppresses spontaneous tumors 
which result from somatic mutation, environmental carcino-
gens, and oncogenic viruses, anti-thymocyte serum treatment 
should increase ihe tumor incidence and shorten the latent 
period. It might also allow the expression of tumors not 
normally seen in unsuppressed populations. 
Virgin female mice of a single inbred strain, CBA/J, 
were obtained after a variety of treatments and observed 
for primary tumors until either tumor onset or death. 
Included were mice which were: (1) immunosuppressed as 
adults by injection of rabbit anti-mouse thymocyte serum 
(RAMTS), (2) injected with normal rabbit serum, (3) immu-
nized with an irrelevant antigen (mouse serum S-lipoprotein) 
or (4) untreated. Data were collected on tumor histology, 
incidence and time of onset for all groups. 
No tumor.s appeared during the period of ATS-immuno-
i 
suppression or for several months following treatment. 
There was no evidence from this study or from the litera-
ture that anti-thymocyte serum has any carcinogenic effect 
in the absence of oncogenic viruses or carcinogens. 
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This strain carries mammary tumor virus as a result 
of neonatal infection via milk from infected mothers. 
The most frequently observed tumor, the mammary tumor, 
appeared at an average age of slightly less than two years. 
Although the first tumors appeared in ATS-treated mice, 
the mean age at tumor onset was not significantly affected 
by ATS-immunosuppression. No unusual tumors and no 
lymphomas were observed. 
Tumor incidences among groups of mice purchased at 
different times were different, but unrelated to ATS-
immunosuppression. Tumor incidence was not depressed by 
failure of mice to reach tumor age; the mean life span of 
non-tumor bearing mice was as long as or longer than that 
of tumor-bearing mice. Cause of the fluctuation in tumor 
incidence is not known. 
Although tumor immunity reportedly exists at a time 
when palpable mammary tumors are present, immune surveil-
lance does not appear to be the determining factor in the 
long tumor latent period. This conclusion is supported 
by published data from other laboratories which indicate 
that cellular immunity to mammary tumors is often compro-
mised by immunological tolerance and/or the presence of 
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blocking factors in the serum. The failure of ATS-
irnmunosuppression to affect mammary tumor growth is 
consistent with these observations. 
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B. Introduction 
1. Histocompatibility - Necessity for Immunosuppression 
Major histocornpatibility loci have been identified in 
a number of vertebrate species and homology between these 
systems is often assumed (59, 66). The H-2 system in mice 
is the best studied and has been used to elucidate the 
basic principles of transplantation biology. The histo-
compatibility antigens, like blood group antigens, are 
expressed coridominantly and are present to some degree on 
most tissues. If a graft donor has histocompatibility 
antigens different from those of the recipient, the graft 
will be rejected. Graft rejection is normally an immune 
phenomenon triggered by antigen-specific, thymus-dependent 
lymphocytes. It is associated with leukocyte infiltration 
and can be passively transferred by lymphoid cells, but not 
by serum. Damage appears to result from contact between 
"killer" lymphocytes and the target graft. For these 
reasons graft rejection is termed a cell-mediated immune 
response. 
In humans, HL-A - a leukocyte antigen system, and ABO 
the blood group antigens, function as histocompatibility 
antigens (65). Graft donor and recipient are cross-matched 
for ABO as they would be for a blood transfusion. 
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Significantly longer skin graft survival is observed 
when related donor-recipient pairs are HL-A matched. In 
unrelated individuals there is no correlation between HL-A 
compatibility and skin graft survival. If individuals are 
presensitized to a particular HL-A antigen, they will reject 
grafts bearing that antigen more quickly than they will 
grafts lacking the antigen. The effect of preimmunization 
demonstrates the potent antigenicity of HL-A and its 
importance when grafts are exchanged between unrelated 
persons. The difference in rejection times and the ratio-
nale for tissue matching prior to transplantation is that 
an individual usually reacts immunologically against only 
those antigens which he/she does not possess. 
Sensitization to HL-A antigens is sometimes noted in 
multiply transfused or multiparous persons. Serum from 
such persons is the source of most HL-A typing reagents. 
Most potential graft recipients have been multiply trans-
fused and therefore may be presensitized to some HL-A 
specificities. Circulating antibody to HL-A antigens has 
resulted in hyperacute rejection of kidney grafts carrying 
the corresponding HL-A antigens. Experiments in rabbits 
have confirmed the role of antibody in this unusually severe 
type of graft rejection. 
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Kidney grafts to immunosuppressed recipients who are 
matched to donor HL-A type function better and longer in 
proportion to the degree of HL-A matching. This result 
holds for unrelated as well as related donor-recipient 
pairs and has been observed both prospectively and retro-
spectively. The ability to match recipient and donor at 
HL-A is greatly impaired by the high degree of polymorphism 
associated with this locus. 
An estimate of the number of alleles at HL-A was made 
from mixed leukocyte culture (MLC) data (7). In vitro as 
well as in vivo leukocytes respond to antigenic challenge 
by clonal expansion of the antigen-specific lymphocytes and 
of non-specifically activated leukocytes. Histocompati-
bility antigens are unique in that 40-60% of unsensitized 
lymphocytes respond in this way to allogeneic lymphoid 
cells. In the mixed leukocyte reaction, the mitotic 
activity of co-cultured allogeneic leukocytes is compared 
with that of the separately cultured leukocytes. Signifi-
cantly increased incorporation of 3H-thymidine is associated 
with HL-A differences between the leukocytes. ABO dif-
ferences do not stimulate label incorporation under these 
conditions. Bach and Bach observed that 28% of mixed 
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leukocyte cultures from sibling pairs failed to stimulate . 
No instance of non-stimulation was observed in the 700 
MLC between pairs of unrelated individuals. 
The percentage of nonstimulation for sibling pairs is 
consistent with genetic data indicating that HL-A is a 
single genetic locus. From the frequency of non-stimulation 
in both cases, the effective number of alleles present in 
the- test population is a minimum of twenty and more probably 
greater than thirty. 
There is no simple relationship between the number of 
histocompatibility alleles and number of histocompati-
bility antigens (66). In H-2 there are at least 19 alleles 
and 36 H-2 associated antigenic specificities. 
a 
The H-2 
allele includes ninteen specificities and other alleles 
include varying, but lesser numbers of specificities in 
various combinations. These data are based on experiments 
with inbred strains of mice, most of which are related in 
origin. Preliminary results from Klein's laboratory indi-
cate that wild mouse populations, presumably more repre-
sentative of outbred populations, carry the known H-2 
alleles and at least twenty additional H-2 alleles. 
So far, HL-A is antigenically less complex than H-2 
(65, 66). There are 11 internationally recognized HL-A 
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antigens. These antigens fall into two segregant series 
on the basis of apparent antigen exclusion. The present 
two subloci model does not account for all the data on 
HL-A, but is the prevailing model. Errors in the model 
are expected to be on the simplistic side. Refinement of 
HL-A serology will probably reveal hidden specificities in 
the present typing reagents - adding to the number and 
diversity of HL-A antigens. 
If hidden specificities are present in typing sera, 
then individuals typed as identical for a given antigen 
could be antigenically identical for only a subset of the 
antigenic specificities. The serology would indicate more 
identity than really exists and would emphasize sameness. 
In transplantation it is the differences which are 
important and which result in graft rejection. Serologi-
cally defined differences do not indicate the strength of 
the antigenic differences as recognized by graft rejection 
in vivo. There are no data in humans to indicate that 
certain serologically defined differences may be responsible 
for more vigorous cell-mediated responses. In mice, H-2 
differences within the K region have been reported to be 
stronger stimulators of cellular immunity than differences 
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confined to the D region (112). The difference may be 
related to an additional locus within the H-2 region 
(5, 78). 
Recognizing the deficiencies of the two sublocus model 
and its possibly oversimplistic representation of HL-A, 
Kissm~yer-Nielsen and Thorsby have used the model to make 
a minimum estimate of the number of possible HL-A pheno-
types (65). Considering the 11 officially recognized 
HL-A antigens and 8 other antigens recognized by their own 
reagents and assuming a minimum of null alleles, they 
calculated that 4725 HL-A phenotypes are possible. In 
their population studies the most frequent HL-A phenotype 
was present in only 1-2% of the population. If a single 
antigenic difference is allowable, then an acceptable match 
for the most frequent phenotype would occur at random 11% 
of the time. The probability of a match declines rapidly 
when other phenotypes are considered. The chance of a 
perfect HL-A match between siblings remains one in four 
because recombination within HL-A is infrequent. 
The fitness of a match between unrelated individuals 
is becoming an increasingly important medical problem. 
Prior to 1959 less than 10 transplants were performed 
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annually in the world. By 1971 that number was greater 
than 4000. The percentage of living donors, mostly 
relatives, has decreased from 54.5% to 32.8% over the same 
time interval. The corresponding increase in donors has 
been in unrelated, cadaver donors (1). 
Polymorphism in minor histocompatibility loci affects 
the transplantability between related individuals as well 
as between unrelated individuals. In mice it has been 
demonstrated that differences at minor histocompatibility 
loci can act additively and resemble a major histocompati-
bility locus difference - causing rapid graft rejection 
(45). Humans, undoubtedly, have as yet unidentified minor 
histocompatibility loci. 
With the difficulties in HL-A matching, the existence 
of minor histocompatibility loci and perhaps other antigenic 
stimuli, rejection is a virtual certainty for the graft 
recipient. Although matched related donors could alleviate 
the HL-A incompatibilities, rejection is also indicated. 
Skin graft survival time for an HL-A identical match is 
significantly prolonged compared to the survival time for 
a mismatched graft, but even then rejection occurs within 
twenty days - indicating far from infinite survivals e 
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Kidney may not be as antigenic as skin as illustrated by 
somewhat longer survival times for kidneys than for skin 
in both mouse and human; nonetheless, the antigenic dis-
parity is sufficient to cause rejection. 
Survival of a functioning transplanted organ requires 
suspension of the normal immune response. This occurs 
naturally in the case of corneal transplants or in the 
normal maternal-fetal relationship where the fetus may be 
considered comparable to an antigenically foreign trans-
plant. The common feature of these two examples is that 
the circulating immunocompetent cell fails to recognize or 
be stimulated by the foreign antigens. For the cornea, 
this is a fortunate consequence of normally poor vascu-
larization and small graft size (58). The fetus may be 
protected from effective contact with the immune system by 
the high sialomucin content of the trophoblast (58, 120). 
There is also some evidence that the pregnant female is 
specifically less reactive to histocompatibility antigens 
of paternal origin than to histocompatibility antigens not 
present on paternal cells (15). The specificity suggests 
an immunological reaction similar to immunological toler-
ance. Kidney, heart, lung, liver, bone marrow cells and 
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peripheral blood lymphocytes are subject to rejection and 
are not privileged transplants. Graft survival in these 
cases must be artificially prolonged by direct interference 
with the immune system rather than by masking or protecting 
the graft itself. 
2. Methods of Immunosuppression 
The ideal mode of immunosuppression would be specific 
immunological tolerance to donor histocompatibility anti-
gens. In a state of tolerance an individual fails to 
respond to the tolerizing antigen but responds normally to 
all other antigens. Although there is evidence of partial 
tolerance or tissue adaptation in long term graft recipi-
ents, that population may be highly selected for reduced 
immunity. 
Experiments with mice have demonstrated that tolerance 
to cellular antigens is much more easily established in 
neonates than in even slightly older individuals (69). 
Maintainence of tolerance requires that the individual be 
chimeric for lymphoid tissue of the two histocompatibility 
types. Since human transplants are performed on individuals 
past the neonatal stage, any scheme requiring identification 
155 
and treatment of the graft recipient as a neonate is 
impractical and unrealistic at this time. 
In mice, induction of tolerance or immunity to soluble 
antigens depends upon the antigen dose. Tolerance can 
occur at dosages well below or above those which immun ize . 
The amount of material per unit body weight necessary to 
induce high zone tolerance is equivalent in neonate and 
adults. The necessity and difficulties in identifying 
histocompatibility differences between donor and recipient 
are the same as previously discussed. The current pre-
parations of soluble histocompatibility antigens are far 
from supplying the quantities and specificities required 
both for the induction and maintainence of tolerance. 
In human transplantation, the risk and consequences 
of sensitizing the individual are much greater than the 
chance of establishing tolerance. Sensitization results 
in rapid second set or acute rejection which is more 
difficult to control than a first set rejection. 
A generalized state of immunosuppression is more 
easily and reliably obtained. Immunosuppression may even 
facilitate tolerance induction. The immune response can 
be blocked at any point up to and including the r eac t ion of 
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immune cells or antibody with antigen. Its effectiveness 
may depend upon the ability of the immune response to 
compensate for perturbations in other parts of the system. 
The target may be antigen-specific lymphocytes or non-
specifically activated lymphocytes and macrophages. The 
block may occur in antigen recognition, antigen processing, 
lymphocyte activation by antigen, lymphocyte differentia-
tion, cell recruitment and mitosis, release of soluble 
mediators, antigen expression or in any required synthetic 
process along the way. 
There are five major groups of immunosuppressants 
which are therapeutically practical. They are antimetabo-
lites, corticosteroids, x-irradiation, anti-lymphocyte 
serum (ALS) and surgical removal of lymphoid organs (26, 
73, 131). Most antimetabolites are effective immuno-
suppressants at dosages which interfere with cell division 
although individual agents differ in their kinetics of 
inducing imrnunosuppression and their direct cytotoxic 
effects. The selective value of these agents is a result 
of the selective division of antigen reactive cells upon 
contact with antigen. Because of this division, immuno-
competent cells become more sensitive to the toxic effects 
157 
of these drugs. The transplant patient is exposed to 
numerous environmental antigens as well as foreign histo-
compatibility antigens. At immunosuppressive doses the 
antimetabolites can also be toxic for other physiological 
systems. Because of the general toxicity of these drugs, 
it is likely that at least some antimetabolites interfere 
with normal immune processes at several levels simulta-
neously. The resultant immunosuppression is generalized 
and is not antigen specific. 
The corticosteroids are lymphocytolytic and anti-
inflammatory in rodents and therefore are potentially 
active both on central and peripheral elments of cellu-
lar immunity. In humans, steroids appear to act primarily 
by reducing inflammatory responses. Continued steroid 
treatment can cause a severe imbalance in a number of 
physiological systems. 
X-irradiation causes chromosomal damage in both dividing 
and non-dividing cells, and results in cell lethality during 
cell division. It is therefore less specific in its action 
than are most other antimitotic agents. Sublethal doses of 
x-rays induce a persistent generalized immunosuppression. 
Because of their respective requirements for cell division 
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(clonal expansion), primary immune responses are more 
sensitive to x-irradiation than are secondary responses. 
Thymectomy removes both a source of lymphocytes and 
hormone(s) - necessary for the maturation of precurser 
lymphocytes into immunocompetent cells. Cells within the 
thymus are not generally immunologically competent. They 
are considered to represent a precurser or immature form of 
the lymphocytes which are active in cell-mediated immunity 
in the periphery. The thymus-derived cell is equivalent to 
an immunocompetent cell active in cellular immunity. 
The cells or precursers of cells which directly produce 
antibody are not affected by thymectomy and are therefore 
termed thymus-independent cells. Thymectomy obviously does 
not remove immunocompetent cells which have already seeded 
into the peripheral lymphoid organs. For that reason adult 
thymectomy alone is an ineffective immunosuppressant, 
whereas neonatal thymectomy is severely immunosuppressive. 
Thymectomy of the neonate or the adult has no confirmed 
direct effect on systems other than the immune system. 
Splenectomy removes a mixture of antibody producing 
cells, cells active in cell-mediated immunity and a source 
of red blood cells. Thoracic duct drainage removes 
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circulating lymphocytes, most of which are thymus-derived, 
but also severely affects fluid and electrolyte balance. 
Anti-lymphocyte serum (ALS) can be a very potent and 
specific suppressor of cell-mediated immunity (72, 128, 139, 
140). It is effective in an otherwise nonsuppressed host if 
administered before or shortly after graft placement. It is 
not very effective if given much later than the antigen. 
These antisera are usually prepared in a heterologous species 
against lymphoid tissues of the graft recipient species. 
Anti-lymphocyte sera prepared in the same species as the 
host have not generally prolonged graft survival in normal 
recipients (10, 98, 129). The lymphoid tissue used as 
antigen may be limited by tissue availability and quantity~ 
Whole cells or crude membrane fractions are effective as 
antigens. AIS prepared in a single species and by the same 
method against lymphocytes from different organs or cultured 
lymphoblasts are of different graft prolonging potencies 
(46, 93). ALS prepared against thymocytes is most effective, 
that prepared against lymph node lymphocytes the second most 
effective and the rest are of lesser potency. That thymo-
cytes are the most effective antigen(s) might be expected, 
because thymus-derived lymphocytes are the effective cells 
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in graft rejection and peripheral lymphoid tissues a r e 
mixtures of both thymus-derived and thymus-independent 
lymphocytes. In vivo, ALS does not appear to affect the 
thymus - possibly because of the purported blood- thymus 
barrier. There is, however, a significant but transient 
lymphopenia after administration of ALS. The ALS tar get 
cells in vivo are assumed to be imrnunocompetent thymus -
derived lymphocytes. 
The evaluation of an ALS by comparison of graft sur vival 
times is time consuming, expensive and wasteful of ALS. AI.S 
show a high degree of species specificity - restricting 
tests to the species against which the serum was prepared 
or closely related species. Testing anti-human lymphocyte 
serums would necessitate using mostly subhuman prirnates e 
It is clear that most in vitro assays of ALS do not 
correlate with in vivo suppression of graft rejection . 
Hemagglutination, leukoagglutination, lyrnphocytotoxicity 
or blast transforming assays are of no value in predicting 
ALS activity in vivo (26, 60, 61, 128). This lack of cor-
relation suggests that the sera may contain irrevelant and 
toxic antibodies - including and possibly in addition to 
anti-red cell, anti- platelet and anti-basement membrane 
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antibodies. It is also possible that the effectiveness of 
ALS depends upon more than one antibody population. 
Some correlation with in vivo results has been claimed 
for the indirect globulin test (86), inhibition of rosette 
formation (6) and depression of pertussis induced leuko-
cytosis (103). These results need to be confirmed. 
The method of immunization - i.e., schedule of inject ions 
and use of adjuvant, is important in the apparent balance 
between effective and toxic antibodies. Early antiserum 
prepared without the use of adjuvant is most effective (72). 
Reimmunization of the same animal does not stimulate a 
marked increase in the relevant antibody, but rather the 
appearance of highly cytotoxic antibodies and a loss of 
graft prolonging potency when compared to earlier bleedings. 
Adjuvant, like reimmunization, elicits apparently cytotox•ic 
and undesirable antibodies (62, 67). 
The effective antigen(s) is unknown, but is presumed to 
be a membrane component. Absorption of ALS with red blood 
cells, liver or other nonlymphoid tissues does not absorb 
out the graft prolonging capacity of the serum. Absorption 
with lymphocytes removes immunosuppressive activity from the 
serum. The effective antigen(s) appears to be lymphocyte 
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specific. It is possible, but not established, that this 
antigen(s) is indicative of a particular state of lympho-
cyte differentiation. Because the effective antigen(s) is 
not conserved in widely disparate species, it may not be 
integral to the membrane or even integral to the immune 
functions of lymphocytes. 
Anti-lymphocyte sera prepared by current methods need 
not be considered as acting at only one level of the immune 
response - if only because they contain antibodies of more 
than one specificity. 
Isolated immunoglobulins from ALS retain their in vivo 
. . ' activity, whereas Fab fragments of these molecules are 
almost ineffective (30). Because the antibody combining 
I 
site is in the Fab fragment and the Fe portion of the 
molecule functions in amplifying the immune response, more 
than a simple masking of antigen sites is suggested in ALS 
imrnunosuppression in vivo. The same conclusion was reached 
by Levey and Medawar, who showed a central immune deficit 
after ALS treatment (72). Lymphocytes transferred from an 
ALS-treated animal to a syngeneic x-irradiated recipient 
remained specifically nonreactive although these cells would 
have undergone several division cycles in a neutral environ-
rnent prior to testing. 
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Monaco showed that ALS treatment combined with 
thymectomy prevented recovery of immunity to allogeneic 
histocompatibility antigens (87). Thymectomy apparently 
prevented the generation of new reactive cells which other-
wise would replace those depleted by ALS treatment. These 
results indicate that ALS produces immunosuppression which 
may, because of concurrent antigenic stimulation, show some 
antigen specificity. The duration of immunosuppression 
depends upon the loss of antigen reactive cells. 
AIS preparations do induce a transient depletion of 
circulating lymphocytes. Those preparations which are not 
cytotoxic also do not prolong graft survival, but lympho-
cytotoxicity alone cannot account for suppression of graft 
rejection. Recovery from lymphopenia does not restore 
immunocompetence nor does graft prolongation correlate 
with either in vivo or in vitro cytotoxicity titers for ALS. 
Levey and Medawar noted hyperplasia of lymphoid tissue 
in ALS-treated animals and postulated that ALS might work 
by sterile activation of the lymphocyte population (72). 
This suggestion, however, was controverted by later work in 
the field. Woodruff and colleagues observed atrophy of 
lymphoid tissue after ALS administration and suggested that 
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hypo- or hyperplasia of lymphoid tissues in vivo may depend 
upon the local concentration of ALS ('139). 
Turk and Willoughby observed that ALS preparations are 
anti-complementary - indicating that ALS can suppress the 
peripheral nonspecific inflammatory responses (131). 
Since ALS is prepared against complex antigens and 
mixtures of antigens, its antibody specificities could be 
expected to be similarly complex especially in cross -
species immunization. The total effect must represent a 
balance between the immune system and AI.S, a balance within 
the parts of the immune system and a sum of local concentra-
tion effects. 
ALS-immunosuppression is qualitatively different from 
that 9f other immunosuppressants. After absorption of 
anti-rbc and anti-platelet antibodies, ALS is more specifi-
cally toxic for the immune system than are any of the other 
immunosuppressants (26, 128). Toxicity in humans seems to 
be related mostly to the recipient's immune response against 
heterologous serum proteins in the ALS preparation - i.e., 
an indirect rather than direct toxicity (126). Within the 
immune system it shows high specificity for cell-mediated 
immunity and is effective in controlling both first set and 
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second set graft rejection. Its inhibitory effect on anti-
body production seems limited to the primary antibody 
response. The antigens tested were ones for which there is 
an identified T-cell dependent step prior to antibody 
production. AIS is generally ineffective in inhibiting 
secondary antibody responses. None of the other immuno-
suppressants is as specifically irnmunosuppresive with so 
little toxicity. 
AIS-treated graft recipients demonstrate immunity to 
ALS and become refractory to immunosuppression by AIS. 
Attempts to demonstrate a causal relationship by passive 
transfer of serum have been negative. Pre-immunization 
with gamma globulin fractions results in more rapid clear-
ance of anti - lymphocyte globulin and less prolonged graft 
survival times. 
ALS from two different species when used consecutively 
are more effective in prolonging graft survival than either 
ALS preparation alone (32). These data are consistent with 
the idea that refractoriness to ALS is caused by recipient 
immune response to AI.S - in particular the species-specific 
portions of the immunoglobulin molecule. If other parts of 
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the immune system could compensate for deficiency in 
cellular immunity, then the second ALS would not have 
extended graft survival. 
All five types of immunosuppressants have been used 
to maintain human organ transplant recipients (26, 99, 101). 
The particulars of treatment vary with the institution and 
the individual patient - depending upon the grade of anti-
genic match between recipient and donor, the occurrence of 
rejection crises and individual sensitivity to prescribed 
medication. In human transplant patients the commonly and 
almost universally prescribed immunosuppressants are 
azathioprine and prednisone. Azathioprine (Imuran) is a 
-s- substituted derivative of 6-mercaptopurine (6-mp). 
Both drugs are purine analogs. Normal liver function is 
required for azathioprine to be immunosuppressive. 
Azathioprine presumably is converted to 6-mercaptopurine 
by liver enzymes. Prednisone is a corticosteroid. Other 
antimetabolites, including cyclophosphamide, are being 
tested for their ability to control or prevent rejection. 
The azathioprine-prednisone combination is effective 
because the additive effect of these agents allows a 
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reduction in the dose of each individual agent. Thymectomy 
and splenectomy often but not always supplement this basic 
treatment regimen. 
Whole body x-irradiation is not widely used as an 
immunosuppressive treatment in humans, although irradia-
tion of the graft before implantation may be effective in 
delaying rejection. Local irradiation to the graft in situ 
may be useful in controlling a rejection episode. 
Anti-human lymphocyte serum is commonly prepared in 
horses, although clinical trials are being performed with 
ALS preparations from rabbits. Globulin fractions of ALS 
(ALG) are used in human patients to reduce the amount of 
irrelevant heterologous protein and thereby reduce the 
host's immune response to those serum components. ALG is 
not purified for anti-lymphocyte antibodies and is still a 
nonspecific immunosuppressant. 
All forms of irnmunosuppression which are not antigen 
specific have the direct side effect of reducing the 
organism's resistance to infection. The immediate cause 
of death in these patients has most often been infection 
and sometimes infections which are not life threatening in 
a normally irnmunocompetent individual (1). In evaluation 
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of side effects from long term immunosuppression it may be 
necessary to distinguish between a direct effect of immuno-
suppression and the effect of chronic but unidentified 
infection. 
In those cases where infections have been successfully 
managed and graft survival is maintained with adequate 
function, a long term threat of imrnunosuppression, either 
direct or indirect, has become evident. The immunosup-
pressed transplant patient runs an 80-fold greater risk 
of neoplasia than age matched individuals in the general 
population (99, 101). 
3. Immunosuppression and Neoplasia 
Immune surveillance, the idea that cellular immunity 
evolved to combat transformed cells arising spontaneously 
by somatic mutation, implies that transformed cells and 
the immune system are in balanced opposition (24, 44, 130). 
For this theory to have validity, it is necessary that the 
transformed cell be antigenically distinct from normal 
host cells. With sensitive techniques it is possible to 
demonstrate many tumor-associated antigens. The clearest 
examples of tumor-associated antigens are those of viral 
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origin. Tumors from individuals infected with the same 
virus express the same viral antigens which are identical 
to structural components of the virion. There are also 
cellular antigens characteristic of the virally transformed 
state which are not structural components of the virus. 
An additional class of antigens includes the individually 
unique antigens which are not shared by tumors of the same 
histological type or tumors which result from the same 
oncogenic stimulus. It is anticipated that most tumors 
will prove to be immunogenic and that immunity to auto-
chthonous tumors may be the rule rather than the exception 
(105) . The efficacy of immune surveillance is invoked to 
explain the high incidence of histologically malignant 
foci in human autopsy material compared to the much lower 
incidence of clinically frank neoplasm, occasional sponta-
neous tumor regressions and the low immunogenicity of 
spontaneous mouse tumors. 
There are indications that at least some tumors may 
represent exceptions to or adaptations to immune surveil-
lance. In vitro, cells from many tumors show a greater 
resistance to lysis by immune antibody and/or immune cells 
than do normal cells from the same individual. In some 
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cases this heightened resistance is attributed to increased 
membrane sialomucins. 
The murine virally induced mammary tumor is an example 
of a tumor expressing viral antigens and individually dis-
tinct antigens, but which is highly resistant to immune 
destruction (118). The viral antigens are also present in 
normal mammary cells of infected females prior to malignant 
transformation. These cells are both antigenic and sensi-
tive to immune destruction. The possibility exists that 
cells in the early stages of malignant transformation may 
be antigenic and normally sensitive to immune destruction 
i.eo, immune surveillance could be effective early in 
tumorigenesis. 
Additional data indicate that the mouse mammary tumor 
can be made highly antigenic and subject to immune destruc-
tion in the tumor host if the tumor is injected with 
neuraminidase (116). Neuraminidase presumably removes some 
of the protective coating and bares the antigens of the 
tumor cells to immune recognition and effective immune 
responses. In such treated hosts, however, new tumors 
arise at an accelerated rate: they are believed to be anti-
genically distinct from the original tumor. 
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Another adaptation of oncogenic viruses to the immune 
surveillance function of lymphoid cells may be infection of 
host lymphoid tissue. The murine leukemia and mammary 
tumor viral antigens are normally expressed in the lymphoid 
cells of the infected host (11, 97). Infection at a time 
or in a quantity which would mimic expression of self-
antigens would effectively negate an immune response just 
as immunity against self-antigens is suppressed. The 
balance between the immune system and antigen in some way 
determines the expression of the immune response as immune 
inhibition, tolerance or immune enhancement. The latter 
two would favor viral propagation and malignant transforma-
tion. 
Apparent exceptions to immune surveillance do not 
deny a prior existence of immune sensitive stages during 
transformation nor do they suggest that effective tumor 
immunity cannot be induced. If any of the apparent excep-
tions from immune surveillance are true exceptions, they 
still do not dismiss the participation of immune surveil-
lance in other tumor systems. 
The theory of immune surveillance predicts a high 
incidence of spontaneous tumors in immunologically impaired 
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individuals. A lapse in this defense system combined with 
the superior growth properties of tumors might allow the 
tumor to reach its full growth potential, even if immuno-
suppression were of short duration. High tumor incidences 
are reported for humans with severe immunodeficiencies and 
for immunosuppressed kidney transplant patients when 
compared to normal populations of similar ages. 
The most severely affected congenitally immunodefi-
cient individuals do not survive past infancy. Those who 
do reach childhood exhibit an unusually high frequency of 
spontaneous lymphomas (35). These tumors are common in 
Wiskott-Aldrich syndrome, ataxia telangiectasia and 
Chediak-Higashi syndrome. Patients with these diseases 
exhibit deficiencies in both cell-mediated immunity and 
humeral immunity. Primary involvement of the central 
nervous system (CNS) has been noted in many cases, in 
contrast to lymphoma patients in general where only about 
1% show CNS involvement. The increased tumor frequency, 
lymphatic involvement and unique location are the unusual 
features of these diseases. Dysgammaglobulinemia, which 
occurs much later in life, is a deficiency of immuno-
globulins with variable impairment of cellular immunity. 
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These patients also run a higher than average risk of 
lymphoma. Tumors of the lymphoid system are increased 
even in Bruton's agammaglobulinemia, in which disease all 
classes of irnrnunoglobulins are absent, but the cellular 
immune system appears normal. Individuals with more 
restricted deficiencies of the humoral system have not 
been reported to show an increased tumor incidence. 
Tumor data for imrnunosuppressed transplant recipients 
are available only in the case of kidney transplant recipi-
ents (99, 101). Excluded from these data were tumors 
which were transplanted with the grafted kidney and were 
therefore of donor origin. Tumors of the recipient which 
were present prior to transplantation were also excluded. 
The apparent de !1Q.Y.Q. tumor incidence is BO-fold increased 
compared to overall tumor incidence for the general popula-
tion of similar age. All these patients were subject to 
nonspecific immunosuppression by azathioprine and predni-
sone. Some were additionally splenectomized, thymectomized 
or treated with ALG. There had been 125 tumors reported 
in kidney transplant recipients to the date of reference 
(100). 
1\lmors appeared on an average of 28 months after 
transplantation. Six tumors appeared in less than four 
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months after transplant. 61% of the tumors were epithelial 
tumors: the remainder were meschenyrnal tumors. Three 
instances of multiple tumors were reported. Of the 
meschenyrnal tumors, 86% were lymphomas and of these, 61% 
were reticulum cell sarcomas. Involvement of the central 
nervous system occurred in half the lymphoma cases -
mimicing lymphomas in congenital immunodeficiency diseases. 
Irnrnunosuppression is strongly suggested in the development 
of these tumors. 
There is one unusual report in the literature of an 
immunosuppressed kidney transplant patient who recieved 
ALG and subsequently developed a reticulum cell sarcoma 
near the site of ALG injection (36). The tumor has been 
interpreted as possibly resulting from severe, local 
irnrnunosuppression in the immediate area of the injection 
site. The significance of a single such case is obscure. 
Although ALG supplements other irnrnunosuppressant agents, 
there is no indication that tumor incidence in transplant 
patients has increased since the use of ALG (101). 
In addition to the data for immunodeficient and 
irnrnunocompromised individuals, there is a strong associa-
tion between cancer and spontaneous irnrnunodepression (35). 
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Cancer patients, especially in the advanced stages, show 
a general, nonspecific reduction in immune responsive-
ness. Prognosis after surgical removal of the major tumor 
mass is correlated with delayed hypersensitivity responses 
to skin sensitizing chemicals. Although the immune 
depression observed in malignancy appears to be a second-
ary effect of malignancy, there are no data in these cases 
regarding immunocompetence prior to clinical malignancy. 
The striking almost constant association of immunological 
defect with malignancy does not implicate immunodeficiency 
in a causal way with malignant transformation, but does 
suggest that the immune system may be important in tumor 
control, similar to its role in dealing with exogenous 
pathogens. 
Because (1) immunological defects are common features 
in the preceding examples of malignancies, (2) the immuno-
logical defect preceded malignancy in the case of immuno-
deficient and immunosuppressed patients, (3) tumors are or 
can be antigenic, (4) immunity can have an inhibitory 
effect on tumor growth, and (5) immune surveillance pre-
dicts an increase in tumors in immunologically impaired 
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individuals, suspension of immune surveillance is a 
reasonable mechanism to explain the increased tumor 
incidence in immunosuppressed transplant patients. 
There is, however, some question about the "control" 
population to which tumor incidences were compared. 
Uremic patients without externally induced irnrnunosuppres-
sion show a reduced capacity to reject grafts and a 
reduced activity in mixed leukocyte cultures - i.e., they 
demonstrate an impaired cellular immune response in the 
absence of immunosuppressive treatment (33, 64). 
It has been suggested that they may have an elevated 
tumor incidence over the general population (101). The 
reported tumor increase in transplant recipients does not 
necessarily indicate an increased tumor risk following 
induced immunosuppression. Tumor data on uremic patients 
on dialysis are not adequate as yet to make the necessary 
comparisons (101). 
Assuming that tumor incidence for the transplanted 
patients is increased, the question arises whether the 
tumors were pre-existing or arose de D.Q.Y.Q.. If they were 
pre-existing, an increase in tumor incidence would indicate 
facilitated tumor growth. 
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If the tumors arose de Il.Q.Y.Q. following immunosuppres-
sion, the mechanism of tumor induction is in question. One 
possibility is that somatic mutations normally occur with 
great frequency and some percentage of these are mutations 
to malignancy (24, 44, 130). A second possibility is that 
. the immunosuppressive treatment rnay itself be carcinogenic. 
A third hypothesis is that the partially suppressed immune 
system actually promotes induction of lymphomas. 
Although antirnetabolites may be effective immunosup-
pressants, a subset are definitely carcinogenic in animals. 
All immunosuppressants are not necessarily carcinogenic, 
but all carcinogens are immunosuppressive (35). Azathio-
prine is used in conjunction with steroids in the treat-
ment of human diseases of presumed autoimmune etiology. 
The reports of tumors in these patients are fragmentary_. 
A tumor incidence of less than 3 in 4000 is suggested for 
azathioprine-steroid treated patients and is similar to 
that reported in a placebo control group (76). The tumor 
incidence for both imrnunosuppressed and placebo control 
groups may be higher than for the general population. 
None of the authors of the individual case reports or the 
single control group report are the same. The observed 
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tumor incidence could be strongly affected by diligence 
with which tumors are discovered and reported by different 
individuals or institutions. 
Penn and Starzl point to the occurrence of tumors in 
20 psoriatic patients as a caution against the use of 
immunosuppressants although the tumor incidence in non-
immunosuppressed psoriatic patients is not indicated (100). 
The immunosuppressive agents used to treat psoriasis in 
that report were methotrexate or aminopterin - not aza-
thioprine and steroids. It is certainly not clear that 
all immunosuppressants affect malignant development in 
the same way. The data are at present insufficient to 
define the carcinogenic potential of individual immuno-
suppressive agents, either separately or in combination 
in human populations. 
In mice, azathioprine and 6-mercaptopurine can induce 
lymphomas (27, 28, 37). Two of the three strains of mice 
used were not normally subject to spontaneous lymphomas. 
The third strain was susceptible to x-ray induced leukemia. 
Similar experiments in rats failed to demonstrate a carcino-
genic effect of azathioprine. Azathioprine, as a purine 
analogue, is potentially mutagenic, and may also act to 
facilitate viral transformation. 
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Because lymphomas can be induced in mice by a graft 
versus host reaction, Schwartz has postulated that an 
increase in lymphoma incidence in humans with immunological 
abnormalities may have a similar basis (115). He postu-
lates that humans carry a latent oncogenic virus which may 
be activated in proliferating immunocompetent cells. Such 
proliferation would normally be controlled by a feedback 
inhibition mechanism. Any interference with these 
"immunoregulatory loops" would allow antigen-induced cell 
proliferation and virus activation to procede under less 
stringent control. The subsequent tumor is presumed to 
develop from cells in close proximity to the released 
vir,.ions. 
The most provocative finding in support of this theory 
is the demonstration in mice that leukemia virus is pro-
duced in the spleens from mice subjected simultaneously 
to ALS-immunosuppression and antigenic stimulation (56). 
Mice which were either ALS-treated or grafted showed no 
virus production in the spleen. Schwartz's theory has 
particular merit in that it can explain the elevated 
lymphoma incidence in immunosuppressed transplant patients. 
One would have predicted from the immune surveillance 
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theory that all tumors would be elevated in proportion to 
their usual incidence in the general population. If the 
immunoregulatory theory proves true, immunosuppression 
induced by all methods would be carcinogenic for trans-
plant recipients. 
One comparison of lymphoma incidence in mice ~eceiving 
azathioprine or ALS - either alone or in combination with 
antigenic stimulation -has been reported (68). No lym-
phomas were observed when the mice were treated with 
either agent alone. No lymphomas were observed in ALS 
treated mice receiving antigenic stimulation, but non-
malignant plasmocytosis was noted. Only those mice 
receiving both azathioprine and antigen developed lym-
phomas. These results indicate that the particular immuno-
suppressive agent and antigenic stimulation may be 
important in lymphoma induction. The depth or extent of 
immunosuppression induced by different agents may still 
be the basis of the differential effect on lymphoma 
incidence. 
Reports of tumors in irnmunosuppressed transplant 
recipients have opened up many questions regarding the 
relationship between irnmunosuppression and malignancy, 
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and the specific mechanism of tumor induction in these 
individuals. The answers to these questions may come from 
more extensive experiments in animal models. All the 
common imrnunosuppressive agents, while not proven carcino-
gens, can facilitate tumor growth in animals (99). 
6-mercaptopurine may affect the host reaction to a 
transplanted tumor, aside from its demonstrated carcino-
genicity. It has been observed both to accelerate and to 
inhibit tumor growth. The former may be due to its imrnuno-
suppressive properties and the latter indicative of direct 
toxicity for tumor as well as normal tissue. Both mecha-
nisms depend upon the chemical's toxicity and are probably 
concurrent events in vivo. The end effect observed as 
tumor growth is dose-dependent. 
The corticosteroids are similar/ ly inconsistent in 
i 
their net effect on transplanted tumors. They have been 
demonstrated to facilitate or inhibit carcinogenesis in 
mice. They can induce or cause accelerated metastatic 
growth. They prolong survival of tumor grafts across 
allogeneic and xenogeneic histocompatibility barriers. 
Neonatal thymectomy increases the susceptibility of 
many species of experimental animals to tumors induced by 
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polyoma or adenovirus. Splenectomy, like thymectomy, 
potentiates tumor induction and growth resulting from 
adenovirus infection. Leukemogenesis following neonatal 
infection with Gross or Moloney viruses is inhibited by 
neonatal thymectomy (71, 79). The effect of removing 
lymphocyte target cells overcompensates for the tumor 
promoting effect of thymectomy in these instances. These 
same · mice show an increase in lymphoma incidence after 
neonatal thymectomy. This increase is interpreted as 
rralignant transformation in reticulum cells which are 
secondary target cells for the leukemogenic viruses (114). 
Humans are susceptible to radiation-induced leukemias. 
The immunosuppressed human lacks thymus-derived cells and 
these individuals are particularly susceptible to lym-
phomas. Although the etiology of these two diseases in 
humans is unknown, the parallel with the conditions of 
lymphoma appearance in the mouse system is striking. Both 
the radiation-induced leukemias and the lymphomas in 
immunosuppressed transplant recipients appear starting 
several months after exposure and are significantly 
increased by three years. 
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Neonatal thymectomy in the mammary tumor system in 
mice . inhibits the expression of mammary tumors (71, 75, 
113, 142), although the effect may be strain specific. 
Strain specificity may be a reflection of differences in 
host susceptibility or a property of variant forms of the 
virus carried by the different strains. 
Even in tumor systems, where thymectomy inhibits 
either tumor onset or tumor incidence, the number of 
tumors per mouse may be elevated (25, 54) or the number 
of hormone independent tumors may be increased (122). As 
expected from immune surveillance, more strongly antigenic 
tumors may arise (9). 
Neonatal thymectomy consistently renders the host 
less able to resist allogeneic or xenogeneic tumor 
transplants. The positive thymic contribution to mammary 
tumorigenesis has not been fully explained, although 
immunological interpretations are still possible (see 
section D. Immunity and Murine Mammary Tumors). 
In general, the effects of thymectomy on tumor growth are 
consistent with the immunological functions of the thymus. 
Animals receiving ALS are demonstrably less resistant 
to tumor induction by adenovirus 12, Rauscher leukemia 
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virus, Moloney leukemia virus and polyoma than are RNS-
treated or untreated individuals (57). The magnitude of 
difference between treatment groups is affected by virus 
dose and route of inoculation. In the adenovirus system, 
a large dose of virus can obliterate any difference between 
the control and ALS-treated groups. ALS-immunosuppression 
is generally instituted shortly after virus inoculation 
although the tumor latent period may be several months. 
The affected immune response may be directed either 
against the virus or the transformed cell. The relative 
importance of these two responses depends upon the mecha-
nism of tumor growth -whether additional cells are added 
to the tumor mass after viral infection or the tumor is 
restricted to cells arising by division from the initial 
transformant. The former type of growth has been demon-
strated in rnurine mammary tumors {121), the latter is 
clearly indicated in transplanted tumor systems. 
Transplantation of living tumor tissue can be facili-
tated by ALS-imrnunosuppression. If the tumors are histo-
incornpatible with the host, their survival, like that of 
non-transformed histoincompatible tissue, is favored by 
irnmunosuppression. 
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When spontaneous tumors are transplanted into synge-
neic hosts, ALS treatment may favor, inhibit or have no 
effect on tumor growth (see section C.4 Discussion) . 
Carcinogen induced tumors of demonstrated tumor associated 
antigenicity tend to grow better in the suppressed synge-
neic host than in the non-suppressed syngeneic host. Such 
tumors may even be induced more readily in an ALS-treated 
animal than in control animals (29, 110) Different syn-
geneic tumors almost certainly differ in antigenic strength. 
Only those tumors which are highly antigenic grow better 
under conditions of immunosuppression. 
The interplay between the immune system and tumors 
may be quite complex as a function both of the antigenicity 
of the tumor and the quality of the host's immune response . 
The fact that immunosuppression may in some instances 
inhibit tumor development has led several investigators 
to postulate that immunity may actually stimulate sponta-
neous tumor development (106, 107, 121). 
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C. Retrospective Study on Effect of Anti-Thymocyte 
Serum on Primary Mouse Tumors 
1. Introduction 
Tumor data from immunosuppressed kidney transplant 
recipients indicates that these patients are significantly 
more likely to develop tumors than individuals of similar 
age in the general population (99, 101). All patients 
developing tumors had been immunosuppressed with azathio-
prine and prednisone. The tumors appeared shortly after 
transplantation - as early as several months and averaging 
28 months post-transplantation. The length of the follow-
up period is limited by the recency of kidney transplanta-
tion itself. More tumors may appear as the follow-up 
period is extended. Immunosuppression is strongly sug-
gested in the development of the observed tumors. Because 
of the short time interval between transplantation and 
tumor onset, it is difficult to determine whether some of 
the early tumors were pre-existing or arose de DQ.YQ.. 
There is an additional risk of transplanting tumors inad-
vertently with the grafted tissue. 
Assuming that many of the tumors arise de !lQ.Y.Q., there 
are at least three plausable alternatives which can explain 
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de Il.Q:lQ. tumor induction. The first is somatic mutat i on 
combined with suppression of immune surveillance (24, 44, 
130). The second is that azathioprine, a demonstrated 
carcinogen in mice, may also be carcinogenic in humans 
(27, 28, 37). The third is that an imbalance within the 
immune system may actively contribute to subsequent tumor 
development (115). 
The uncertainties in the human data such as the 
tumor incidence in non-immunosuppressed uremic patients 
and the origin of the observed tumors can be avoided in 
experiments in animal models. Here, too, environmental 
and genetic heterogeneity can be controlled. All the 
common immunosuppressants are capable of facilitating 
tumor growth in animals. Most of these data are based on 
experiments with known oncogenic agents or with trans-
planted living tumor tissue. Oncogenic viruses and their 
resultant tumors are antigenic and immunity to both may be 
affected by immunosuppression. It is difficult to conclude 
that suppression of immune surveillance is more important 
than suppression of an anti-viral response. Experiments 
using transplants of tumor tissue also introduce some 
difficulties in interpretation. One is that the tumor 
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used may be rejected by the host because of histoin-
compatabilities unrelated to the malignant properties of 
the tissue. Second, the irmnune response is greatly 
influenced by the amount and route of antigen presenta-
tion. Some sites of tumor formation may represent 
naturally privileged transplantation sites. Depending 
upon how it is stimulated, the immune system can respond 
to tumor challenge by immune inhibition, tolerance or 
immune enhancement. The best tumor systems for obtain-
ing information relevant to immunity to autochthonous 
tumors are therefore the primary tumors, themselves. 
Data have been collected in the present study on the 
histology, incidence and time of onset of spontaneous 
tumors in virgin, female CBA/J mice in this laboratory. 
These mice fall into four treatment categories immuno-
suppressed with rabbit anti-mouse thymocyte serum (RAMTS), 
treated with normal rabbit serum (RNS), immunized with an 
irrevelant antigen (mouse serum B-lipoprotein) and 
untreated normal mice. The last two categories of mice 
were observed in order to obtain tumor data on mice sub-
jected to other experimental procedures and on untreated 
mice. None of the mice were experimentally exposed to 
known carcinogens or oncogenic viruses. 
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RAMTS was the sole immunosuppressive agent used in 
th is study. Anti-lymphocyte sera are extremely potent 
suppressors of cellular immunity, and have little effect 
on humeral immunity. They can double or triple the mean 
survival times of H-2 incompatible skin grafts, and mice 
tolerate high doses of anti-lymphocyte serum. The sera 
used in this study were prepared by a method which appears 
to maximize the immunosuppressive properties of the sera 
and minimize their toxicity. All rabbit sera were 
absorbed with mouse red blood cells to further minimize 
the amount of irrelevant and possibly toxic antibodies. 
The schedule of ALS administration is important 
relative to the time of antigenic stimulation, but the 
time of antigen stimulation in spontaneous tumor systems 
is unknown. The duration of treatment is effectively 
self-limiting because the host's immune response to the 
ALS, itself, limits its effectiveness. In other tumor 
systems in the mouse (19, 29, 70, 74, 110) a similar 
schedule of injections of RAMTS significantly increased 
tumor growth. This fact combined with significantly 
delayed skin allograft rejection indicate that the 
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severity and duration of immunosuppression in this study 
should have been adequate for tumor promotion. 
A total of 58 mice were observed weekly for the 
presence of tumors until tumors were detected or the 
mice died of other causes. Observations continued over 
a period of three and a half years. Mice from individual 
purchases were the same age and used in the same experi-
ments. Each purchase is referred to as a group and each 
group may be subdivided for experimental and control 
purposes. 
Groups I and II were grafted with skin from another 
inbred line or given isografts. The groups were divided 
into subgroups treated either with rabbit anti-mouse 
thymocyte serum (RAMTS) or rabbit normal serum (RNS). 
Group I mice received subcutaneous injections of 0.5 .ml 
of rabbit serum on days 2 and 5 after grafting and 0.25 ml 
twice a week as long as the allografts were maintained. 
Mice bearing isografts were injected on the same twice 
weekly schedule. The maximum number of injections per 
mouse was 12. 
Group II mice initially received two subcutaneous 
inject ions of rabbit serum as above. At the same time they 
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were injected with 0.5 ml of syngeneic mouse serum from 
normal mice or mice immune to whole rabbit serum. After 
the initial tumors in Group I appeared in the RAMTS-
treated subgroup, Group II mice were injected twice weekly 
with their respective rabbit sera until they had received 
the maximum dose given Group I mice. 
Group III mice were either immunized with mouse 
serum S-lipoprotein in complete Freund's adjuvant or 
untreated. All mice in this group received skin allo-
grafts. 
Group IV mice were used only as normal serum donors. 
2. Methods 
Mice: 
Inbred mice of the CBA/J, A/J, and Balb/c strains 
were purchased from a single supplier (Jackson Laboratory, 
Bar Harbor, Maine) over the limited time period of 14 
months. 
After grafting, the mice were housed individually in 
small metal cages. The untreated blood donors were not 
individually housed until they were 1-1½ years old. All 
mice were fed Purina Rat Chow and water ad libitum. 
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Mice were examined at weekly intervals for the 
presence of tumors. Mice with tumors were sacrificed 
for histological examination of the tumors. Dead mice 
were autopsied for gross pathology. Mice which could 
not be accounted for at any point in the observations and 
one mouse which died within 24 hours of injection have 
been excluded from the data. 
Skin Grafting: 
Each graft recipient was anesthesized with an intra-
peritoneal injection of Nembutal (65 micrograms/kilogram). 
Full thickness grafts of back skin were transplanted 
according to the procedure of Billingham and Medawar (16). 
Bandages were removed after seven days and graft survival 
was evaluated daily or every other day. End point graft 
survival was reached when the entire graft was necrotic 
and could be peeled off without bleeding. 
Rabbit Anti-Mouse Thymocyte Sera (RAMTS): 
Rabbit anti-mouse thyrnocyte sera were prepared fol-
lowing the standard procedure of Levey and Medawar (72). 
New Zealand white female rabbits were injected intra-
venously with 109 living thymocytes from 2 month old CBA/J 
female mice. Two injections were made, two weeks apart. 
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Rabbits were bled seven days after the last injection and 
exsanguinated the following day. Sera from the same 
rabbit were pooled and stored at - 20°C. All sera were 
heat inactivated at 56°C for 20 minutes and absorbed with 
1/2 or 1/3 volume of washed, packed mouse red blood cells 
for 10 minutes at room temperature and at 4°C. Normal 
rabbit sera were treated identically. 
Rabbit Normal Serum (RNS): 
Sera from untreated rabbits or sera from ALS rabbits 
taken prior to immunization were used as normal rabbit 
serum controls. 
Serum Injections: 
All serum injections were subcutaneous. Group I mice 
received injections only on the same side as the grafted 
skin (left). Group II mice were injected on both sides. 
Injections were made on days 2 and 5 after grafting and 
twice a week thereafter if additional injections were 
called for in the protocol. 
Normal Mouse Serum (NMS): 
Untreated young adult CBA/J female mice were tail 
bled into siliconized tubes. The blood was allowed to 
clot and the serum was removed, pooled and stored at - 20°C 
until use. 
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Immune Mouse Serum (IMS): 
Mice from Group I which had received RAMTS were 
.,re-immunized" 7 months later with 0.5 ml of RAMTS 
intraperitoneally, followed by an injection of 0.2 ml of 
a 1:5 dilution of RAMTS subcutaneously six days later. 
Serum was collected and pooled every other day beginning 
two days after the last RAMTS injection. 
#-lipoprotein Isolation (~-Lp): 
Pooled sera from young adult A/J female mice were 
adjusted to a density of 1.063 gm/ml with a stock solu-
tion of NaCl and KBr and centrifuged at 38,000 rpm for 
18 hours at 13°C (138). The ~-lipoprotein fraction was 
removed from the top of the serum and stored at 4°C. 
~-lipoprotein Immunization: 
A fresh preparation of A/J fi-lipoprotein was mixed 
with an equal volume of Freund's complete adjuvant (FCA). 
Some mice were injected with 1 mg protein in FCA one week 
before grafting. In a later experiment, injections were 
nade 11 days and 4 days prior to grafting and 4 days after 
grafting. 
Immunoelectrophoresis: 
A layer of 1% agar in barbital buffer, ionic 
strength= 0.078, pH~ 8.6 was allowed to solidify on a 
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microscope slide. Antigen was placed in a well cut in the 
agar. The slide was electrophoresed at 6 ma per slide 
(about 60 volts) for two hours. Troughs parallel to the 
direction of electrophoresis were filled with antiserum 
and allowed to diffuse in a moist chamber for at least 
24 hours. 
Thymic Extracts: 
#1. Fresh thymuses from young adult CBA female mice 
were homogenized in a ground glass homogenizer with a 
minimal amount of distilled water and frozen and thawed 
three times. The supernatant was retained and stored at 
- 20° C. 
#2. Minced fresh thymuses from young adult CBA 
female mice were sonicated in saline for 2 minutes (in 
30 second intervals) at 20 Kc/sec. The supernatant was 
retained and stored at - 20°C. 
Tumor Histology: 
Histological preparations and identification of 
mouse tumors were done by Dr. Raymond L. Teplitz (City of 
Hope National Medical Center, Duarte, California). Tis-
sues were fixed in buffered formalin, dehydrated and 
embedded in parafin by standard techniques. The sections 
were stained with hematoxylin and eosin. 
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3. Results 
The rabbit anti-mouse thymocyte serum {RAMTS) used for 
Group I mice substantially inhibited cellular immunity as 
indicated by its ability to prolong skin allograft survival 
{Table 1). The RAMTS preparation used for Group II mice 
after only two injections was not as strongly immunosup-
pressive {Table 2). These mice subsequently received 
additional injections of RAMTS. The degree of immunosup-
pression following these latter injections was not tested. 
This group of mice did not contribute greatly to the tumor 
data because of a low tumor incidence {Table 4). 
Passive transfer of syngeneic mouse serum, either 
immune or normal serum, to Group II mice did not abrogate 
or prolong the observed RAMTS immunosuppression {Table 2). 
The immune mouse serum contained antibodies to a large 
number of rabbit serum components including gamma globulin. 
The precipitating activity of this mouse serum was weaker 
against gamma globulin that against the other serum compo-
nents, but nevertheless present. 
Immunization with S-lipoprotein has no significant 
effect on allograft survival {Table 3), and therefore is 
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Graft Number 
Graft of mls of serum Survival-days a b 
Donor Mice RNS RAMTS (MST + SD) 
CBA/J 3 4.0 00 
A/J 3 1.0-2.0 12.0 + 
A/J 2 1.0 17.5 + 
A/J 3 0. 0-1. 0 2. 0 24 .0 + -
A/J 3 2.75-4.0 33.7 + 
a. rabbit normal serum 
b. rabbit anti-mouse thymocyte serum 
c. mean survival times+ standard deviation 
TABLE 1. Skin Graft Survival in RNS and RAMTS Treated 
CBA/J Mice - Data fr om Gr oup I Animals* 
* ,The skin grafting experiment was performed by Jill 
Fabricant, Charles Novitski and Bob Sellent as part 







Number mls of Serum 
Graft 
Graft of Survival-days 
Donor Mice RNSa RAMTSb IMSc NMSd (MST ±. SD)e 
CBA/J 2 1.0 1.0 CD 
BALB/c 2 10.5 + 0.5 
BALB/C 4 1.0 1.0 11. 2 + 0.4 -
BALB/c 4 1.0 1.0 14.0 + 1.2 
BALB/c 4 1.0 1.0 13.3 + 1.4 
a. rabbit normal serum 
b. rabbit anti-mouse thymocyte serum 
c. serum from CBA/J mice immune to rabbit serum 
d. normal mouse serum 
e. mean survival time+ standard deviation 
TABLE 2. Skin Graft Survival in RNS and RAMTS Treated 
CBA/J Mice Given Immune or Normal Mouse Serum 
Treatment 










(MST + SD)a 
12 + 0.4 
11.75+ 0.4 
a. mean survival time+ standard deviation 
b. serum S-Lipoprotein 
TABLE 3. Survival of Allogeneic Skin Grafts in S-Lipopro-
tein Immunized and Untreated CBA/J Mice* 
* Grafting experiment was performed by Jonathan Fuhrman 

















































































































































































































































































































































































































































































































































































































































not suppressive for cellular immunity nor cross reactive 
with histocompatibility antigens of the mouse. 
Humeral irnrnunocompetence as judged by the mouse's 
ability to form precipitating antibodies to rabbit serum 
proteins was not affected when the rabbit serum was irnrnuno-
suppressive anti-thymocyte serum. Serum from mice injected 
with RAMTS gave irnrnunoelectrophoresis patterns against rabbit 
normal serum components similar to the patterns observed 
with serum from mice injected with RNS. The reactivity in 
both cases was weak. AS-globulin component of rabbit serum 
was recognized in every case. The number of rabbit serum 
components and the strength with which they were recognized 
were similar for the two classes of mice. The anti-thymocyte 
sera suppressed the cellular immune response and had little 
or no effect on humoral immunity as has been often demon-
strated {72, 139). 
The unabsorbed rabbit anti-mouse thymocyte sera contain 
strong ~emagglutinins as observed by red cell agglutination 
when absorbed with mouse red blood cells. The absorbed sera 
are also lymphocytotoxic in in vitro, complement dependent, 
cytotoxicity assays, {Tommy C. Douglas - personal communica-
tion). The absorbed RAMTS precipitates a component of mouse 
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thymus extracts, but that component appears identical by 
immunoelectrophoresis to a S-globulin region component of 
normal mouse plasma. The component is not present in 
extracts of thymus cells which have been extensively washed 
in saline prior to preparing the extract. RAMTS when 
tested against normal mouse serum shows as many as three 
precipitin bands. Immunization against mouse serum com-
ponents probably occurred as a result of serum contamina-
tion of the original thymocyte inocula. No thymus-specific 
component was identified in immunodiffusion or immuno-
electrophoresis tests of thymus extracts. 
Although prolonged survival of H-2 incompatible skin 
grafts indicated severe suppression of cellular immunity, 
no mouse showed any evidence of tumors or other gross 
pathology during the six weeks of RAMTS treatment or up to 
six months after cessation of RAMTS treatment. Observa-
tions on tumors are summarized in Table 4. 
Nontumor bearing mice lived at least as long as, or 
longer than, tumor bearing mice. Tumors developed in both 
immunosuppressed and non-irnmunosuppressed mice. Fluctua-
tions in incidence were noted; but tumor incidence was the 
same in matched RAMTS and RNS-treated mice. Incidence 
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within ·any group (purchase) of mice appears independent of 
the type of treatment which the mice within the group 
received. 
The following account of the histology of the tumors 
is included through the courtesy of Dr. Raymond L. Teplitz, 
who collaborated in this part of the investigation. 
Of the tumors observed, the most frequent tumor type 
was the typical mammary tumor (Figures la, lb, 2a and 2b). 
Mammary tumors of mice are fundamentally of adenomatous 
nature. They recapitulate more or less faithfully the 
glandular components of the breast. Thus, most tumors 
show groups of small round or ovoid acini, lined by cuboi-
dal or columnar epithelial cells. Nuclei, normally central 
or basal depending upon estrus, are of variable location. 
Likewise, nuclear size varies, as does the chromatin 
staining. Proliferative activity as monitored by mitotic 
index differs from case to case. 
Distortion of structures follow upon obstruction and 
ectasia of ducts, leads to micro- or macrocysts. Hemor-
rhage and necrosis may occur, usually the result of vascu-
lar occlusion. All of these mammary tumors exhibit some or 




This tumor is from a Group I mouse that received 
only two injections of rabbit anti-thymocyte serum. 
The tumor was first observed when the mouse was 
520 days of age. The predominant structures in 
this tumor are small round acini. They are lined 
by a single layer of cuboidal (or low columnar) 
epithelium. A band of fibrocollagenous tissue 
separates two aggregates of these acini, forming 
a pseudo-capsule. Acinar size varies somewhat, but 
at X, cystic dilatation of a duct occurs, coincident 







Photograph adjacent to the pseudo-capsule. vari-
ability in nuclear size, shape and chromatin 
distribution are hallmarks of the malignant 
character of. these glands. No basement membrane 
is visible. Occasionally nucleoli are present , 






This tumor is from a Group I mouse that received 
three inject ions of rabbit normal serum. The tumor 
was first noted when the mouse was 540 days old. 
The glands of this tumor are so compressed tha_t a 
lobular pattern is produced. Acinar configuration 
is difficult to perceive, but cords of epithelium 
are more characteristic. Some duct ectasia is 
present (at Y), again associated with inspissated 
contents. Infiltration of connective tissue (Z) 







At this magnification, the solid cord-like archi-
tecture is emphasized. Cells tend to pile upon 
themselves. No basement membranes are seen and at 
least one mitotic figure (M) is present. At V, 
destruction of a vessel is shown, with tumor cells 
forming the wall. Greater irregularity of nuclear 
structure and chromatin than in Figure 1, together 
with more frequent mitoses, vascular involvement 
and poorer differentiation indicate that this 





one portion of the tumor to another, a common feature of 
neoplasia. 
Invasiveness is manifested first by perforation of 
the basement membrane juxtaposing the glandular epithe-
lium. Vascular, lymphatic and adjacent structures are 
then involved, although not necessarily in the order pre-
sented. Metastasis to distant parts is generally slow in 
mice, showing a more benign course than in humans. 
Of the three tumors of the series not of mammary 
type, two were classified as fibrosarcoma - one because 
of its location and the second was identified histologi-
cally as a low-grade fibrosarcoma. It displayed bundles 
or sheets of parallel, fusiform cells embedded in a deeply 
eosinophilic matrix. Bundles of cells intersect, but 
within each bundle the cells tend to be arranged parallel 
to one another. Nuclear size varies with cell size. 
Chromocenters tend to be distinct and range from 3-6/cell. 
Mitoses are rare, thus the characterization of "low-grade". 
The cell type and the fibrocollagenous matrix indicate the 
histogenesis: fibrosarcoma. The suspected fibrosarcoma was 
found in a Group I mouse that had received four injections 
of rabbit normal serum. The tumor first appeared at 
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507 days of age. The second fibrosarcoma occurred in 
an untreated mouse from Group IV at 682 days of age. 
The third tumor was a ventral tumor which did not display 
the characteristic adenomatous features of mammary tumors. 
Sheets of round or ovoid cells form the basic pattern with 
occasional cords of cells or adenomatous structures. The 
latter are lined with columnar or cuboidal cells, displaying 
small round nuclei. Nuclear chromatin is dense and dis-
tributed peripherally. Strornal connective tissue is loose. 
Mitotic figures are not encountered. Differential diag-
nosis: 1. 
N£C~DSrs 
Skin adnexal tumor with me±os=ts, and 2. Necro-
tizing (poorly preserved?) mammary carcinoma. This tumor 
occurred in a Group II mouse that had received RAMTS and 
normal mouse serum. The tumor appeared at 337 days of age. 
Groups I and III have high tumor incidence equivalent 
to that reported for normal virgin females of this strain, 
whereas Groups II and IV have lower tumor incidences. 
Tumor onset in immunosuppressed mice tends to be 
earlier than in the RNS-treated mice, but the mean time of 
onset does not differ significantly between the two treat-
ment classes. The difference between the mean time of tumor 
onset in experimental and matched control mice was greater 
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within Group III than within the groups where imrnunosup-
pression was a factor, but the difference still was not 
significant. 
The first tumor observed in any of these mice was in 
a RAMTS treated mouse and was located near the site of 
injection. No other mouse developed a tumor at or near 
the site of injection. 
The anterior: posterior ratio of mammary tumors from 
the combined data for all these mice is 5.5:4, which corre-
sponds to a random distribution of mammary tumors among 
the mammary glands rather than to the distribution of 
hyperplastic nodules (108). 
Mammary tumors from Group I mice showed some preference 
for the left side over the right. The preference was not 
biased by the nature of the rabbit serum injected. 
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4. Discuss ion 
For experiments evaluating the effectiveness of anti-
lymphocyte serum (ALS) in prolonging graft survival, rabbit 
normal serum (RNS) treated animals are the appropriate 
controls. In these experiments one is interested in the 
antibody specific effects of ALS. 
In experiments investigating the association of irnmuno-
suppression and tumor development, the appropriate controls 
should not be irnmunosuppressed. There is some evidence 
that RNS might be irnmunosuppressive. Unabsorbed RNS is 
cytoto.xic for mouse thymocytes in vitro. In vivo, RNS 
causes a transient depletion of circulating lymphocytes 
(see also below). Some unabsorbed RNS may actually cause 
an immunosuppression which may be reflected by prolonged 
survival of histoincompatible skin grafts (41). Absorption 
of ALS or RNS with mouse tissue, like red blood cells 
(RNS [mrbc]) should remove many of the irrelevant anti-
bodies such as species-specific antibody, anti-H-2 anti-
body and hemagglutinating antibodies. Absorptions should 
reduce the toxicity and non-specific effects of both sera. 
Immunosuppressive effects which are unrelated to natural 
antibody or irrelevant antibodies will not be removed. 
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Nehlson and Simpson have published observations on 
mice injected with RNS [mrbc] twice weekly beginning one 
day after birth and continuing for life (95). Prolonged 
administration of RNS [mrbc] did not depress immune respon-
siveness to allografts, xenografts, sheep, rbc, bovine serum 
albumin or Keyhole limpet hemocyanin. RNS[mrbc] treatment 
did not affect graft versus host reactivity or response to 
oxazolone, but did induce lymphopenia. Although no 
specific deficit in immunity was demonstrable in either 
cell-mediated or antibody responses, a reduction in the 
number of lymphocytes suggests some small possibility of 
impaired immunity. RNS[mrbc] is assumed to have no effect 
on adult irnmunocompetence when given over a much shorter 
interval, as in this experiment. 
In published experiments on a number of mouse tumor 
systems, tumor development was not significantly different 
in RNS-treated and untreated controls (39, 63). 
Because there are a number of reports of apparent 
contamination of ALS with oncogenic virus, RNS treated 
animals may be preferrable to untreated animals as controls. 
The suggested source of viral contamination is the red cells 
used to absorb out the irrelevant antibodies (95). If ALS 
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and RNS used in the same experiment are identically 
absorbed, the contamination by viruses and other potential 
pathogens introduced by the absorption should be identical. 
This procedure may be the only valid control as it is not 
possible to identify all the oncogenic agents nor other-
wise control for the secondary effects of unidentified 
pathogens. 
The most common viral contaminant is polyoma (95). 
Polyoma causes a variety of tumors in mice including 
mammary tumors, salivary gland tumors and osteosarcomas 
(43, 95). Although mammary tumors are common in these 
mice, none of these other tumor types were found. Mammary 
tumor incidence and onset is similar for that reported in 
CBA/J mice as a function of their natural infection with 
mammary tumor virus (MTV). There is no evidence that the 
sera used in these experiments were contaminated with 
polyoma. 
Antigens associated with mammary tumorigenesis 
reportedly exist in sera of infected animals (12-14). 
MTV as detected by infectivity of various tissues is 
relatively ubiquitous. MTV is present in whole blood, 
generally cell associated (94). Immunization with virus 
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positive mammary tumor tissue in Freund's complete adjuvant 
enhances growth of subsequent tumor inoculations. The 
adjuvant alone had no effect on tumor incidence, onset or 
survival time. The strain of mice from which the S-
lipoprotein was isolated does carry a low tumorigenic 
variant of MTV. If the S-lipoprotein preparation were 
contaminated with virus or the tumor associated plasma 
antigen, it is possible that immunization with this material 
could affect tumor growth. Since S-lipoprotein is isolated 
by its special density and whole virions are much denser, 
whole virions are assumed not to be present in the isolated 
material. The tumor associated plasma antigen is an alpha-
globulin, not a S-lipoprotein, although 8-lipoproteins 
and alpha-globulins are immunologically cross reactive. 
The reported mammary tumor associated antigen is not a 
viral antigen, but may be indicative of a hormonal state 
which is important is mammary tumorigenesis. CBA/J mice 
apparently lack the antigen and therefore it could not play 
a role in mammary tumorigenesis in these animals. 
There is no direct evidence that serum S-lipoprotein 
contains either infectious mammary tumor agents or tumor 
antigens. Blood associated tumorigenicity is reportedly 
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cell associated and is lost in cell free preparations 
(94). Mouse milk, which is the means of transmission of 
the standard mammary tumor virus (MTV-S), may contain 
infectious mammary tumor agent in a fraction of approxi-
mately the same density as R-lipoprotein (84). B-type 
virus particles, which are generally considered to include 
MTV-S, were not tumorigenic when isolated from the same 
milk samples. These findings are in contradiction to 
previous reports that it is the B-particle fraction from 
mouse milk which is tumorigenic (34, 49, 88). 
Since there is no direct evidence that immunization 
with serum S-lipoprotein should have any effect on mammary 
tumorigenesis, B-lipoprotein is considered an irrelevant 
treatment in the context of this study. Data on skin 
graft survival indicate that 8-lipoprotein immunization 
is not immunosuppressive. These injections should have 
no effect on tumor development either through immunosup-
pression or inadvertent immunization to tumor associated 
antigens. 
There are marked variations in tumor incidence among 
the groups of mice. Mice in the same purchase, regardless 
of treatment, show the same tumor incidence. The murine 
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mammary tumor system is highly susceptible to environ-
mental influences and to, as yet, undefined fluctuations 
There are numerous examples of unexplained variations in 
murine mammary tumor incidence in the literature (111, 119, 
127). Because of the association by purchase, some of 
this variability may have been introduced before the mice 
were received in our laboratory. 
While in our laboratory the mice, except for Group IV, 
were housed and fed identically. These factors should 
therefore not have contributed to the fluctuations in 
tumor incidence in the Groups I-III. Group IV mice were 
not housed separately. Andervont and Muhl.bock showed 
that mammary tumor incidence was highest in female mice 
housed individually and decreased as the number of mice 
housed together increased (3, 91). These results were 
obtained with C3H and DBA strains of mice. No comparable 
studies have been carried out for the CBA strain, but it 
is presumed that CBA would show similar results. CBA 
mice are closely related to both C3H and DBA mice. They 
are assumed to carry the same mammary tumor virus (MTV-S) 
(20). They show a similarly high susceptibility to the 
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virus and their endogenous hormonal milieux are similar by 
several criteria (21, 42). 
The numbers of tumors and the description of their 
locations are too few and incomplete to determine whether 
injections of anti-lymphocyte serum can influence the loca-
tion of a subsequent tumor. Data are available from the 
literature on the site preference for mammary tumors in 
some strains of mice (108). CBA is not one of those 
strains and the observed age at tumor onset for this 
strain is in between the prototype patterns observed. 
Although CBA would not be the strain of choice, the 
observation that the first tumor to appear was located 
near the site of RAMTS injection suggests that the mammary 
tumor system is a possible modelin which to examine the 
influence of serum injection on tumor location. 
The results from this study differ from observations 
in immunosuppressed humans. No mouse tumors appear during 
or immediately following immunosuppression. The tumors 
which do appear later are predominantly mammary tumors 
and not lymphomas. 
The absence of tumors during imrnunosuppression can be 
explained in several ways. If somatic mutation is the 
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mechanism of tumor induction, the frequency of malignant 
mutations ~y not be great enough to be observed in this 
study even though observations continued for the life of 
the animal. Since azathioprine was not used on any of 
these animals, the data only show that lymphomas do not 
appear in nontreated CBA/J mice. There is no positive 
control, i.eo, that this strain would get lymphomas in the 
presence of azathioprine. Implicit in these arguments is 
the suggestion that a malignant tumor is the product of 
two processes - an inductive and a tumor promoting step. 
If either one of these steps is absent, then cancer is not 
manifested. 
CBA mice are quite susceptible to lymphoma induction 
by estrogen (42), suggesting not only susceptibility but 
also the possibility of a latent lymphoma (leukemia) 
agent. Other investigators have reported a low incidence 
of spontaneous lymphomas in this strain of mice (119). 
There are many well documented examples of reciprocal 
viral interference between the mammary tumor agent and 
leukemogenic viruses (20, 48). Viral interference must 
be overcome or reversed in order to provide positive 
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evidence for the immunoregulation theory. Failure to do 
so does not negate the theory. 
In the case of virally caused mouse mammary tumors 
where 100% of the individuals are presumed infected and 
the tumor frequency may be normally about 75% (1, 27), 
failure to observe an effect of immunosuppression requires 
additional explanation. Of the demonstrated naturally 
occurring tumors that have been well studied, virus infec-
tion occurs either prenatally or neonatally (11, 17). 
Infection is followed by a latent period of months or 
years during which tumor associated antigens are expressed 
on tissues accessible to the circulating immune cells. 
The tissues expressing the antigens may be normal untrans-
formed target issue or tissues which are never known to be 
transformed by that particular virus. They may even be 
circulating cells of the immune system itself. In the 
face of this abundance of expressed and displayed foreign 
antigen, the immune system is not effectively stimulated. 
The developing mammary tumor in situ may stimulate the 
immune system differently than does the mammary tumor trans-
planted to an extramamrnary site (22). The role of the 
immune system in these examples of naturally occurring 
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vertically transmitted oncogenic viruses may be quite dif-
ferent from that observed in adult infection by the same 
or another oncogenic virus or in challenge by transplanted 
antigenic tumors. 
Young adult mice which were neonatally infected with 
the mammary tumor virus are reported to be tolerant when 
challenged with syngeneic virus positive tumors (89, 90). 
By the time a primary tumor is detected, both humeral 
and cellular immunity exist coincident with the growing 
tumor (51, 92). Humoral factors,either free antibody, 
antigen or antigen-antibody complex, at this time are 
claimed to protect the tumor from immune destruction by 
sensitized lymphocytes (51, 53). As a result, the cellular 
immune system is specifically ineffective against the tumor 
and ALS-irnmunosuppression should not alter tumor progres-
sion. 
Although the results of this study are consistent 
with both specific tolerance and enhancing serum factors, 
other investigators have found that short term ALS-
imrnunosuppression can enhance or inhibit MTV tumorigenesis. 
Blair and co-workers reported that ALS treatment had no 
significant effect on the preneoplastic lesions in C3H 
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or BALB/cf~3H parous mice (19, 72). A definite inhibition 
of spontaneous mammary tumor onset was noted in the ALS-
treated mice compared to RNS-treated mice. The role of 
immunosuppression in tumor inhibition is in doubt, however, 
because the ALS preparation used also inhibited the growth 
of transplanted normal mammary tissue. Inhibition of 
tumor development like the inhibition of normal tissue 
growth may have been a direct effect of the ALS on the 
mammary tissue itself. Since normal rabbit serum had no 
effect on spontaneous mammary tumor development, the ALS 
effect may have been due to an antibody population induced 
by lymphoid tissue, but not specific for lymphocytes. In 
that study, ALS was prepared by using Freund's incomplete 
adjuvant in the immunization followed by 3-4 challenge 
inoculations. The use of Freund's complete adjuvant and/or 
hyperimmunization have been noted previously to induce 
toxic antibodies, unrelated to those which induce immuno-
suppression (62, 67). Although the mechanism of mammary 
· tumor inhibition is unknown, inhibition of tumor onset is 
also noted after neonatal thymectomy in C3H mice (75, 113). 
An alternative immunological mechanism of ALS tumor 
inhibition is suggested by the fact that ALS-treated mice 
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developed circulating antibody to mammary tumor virus 
whereas control mice did not (18, 19). Syngeneic mammary 
tumor transplants to these two groups of mice failed to 
show any effective tumor immunity in the ALS-treated group. 
Humoral antibody would not be expected to be effective 
protection against the tumor challenge, but should be 
indicative of an altered state of immunity. If recovery 
from ALS alters the immune status of the animal, it could 
be as important in determining tumor development as the 
immunosuppressive phase of ALS treatment. 
Fisher et al. reported that ALS treatment increases 
the growth of syngeneic transplanted mammary tumors in 
C3H mice (39). The ALS was prepared according to a method 
which used Freund's complete adjuvant. 
Woodruff and Smith observed that ALS treatment 
inhibited the growth of intrastrain transplants of mammary 
carcinoma (141). Although their ALS preparation was pre-
pared with Freund's complete adjuvant, it was 
absorbed with mouse red blood cells. The absorbed sera 
were still bound by and were cytotoxic for both lympho-
cytes and tumor cells. Absorption with spleen cells or 
thymocytes or tumor cells indicated the presence of 
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separate antibody populations directed against lymphocytes 
and tumor cells. Similar absorptions with methyl cholan-
threne induce sarcoma indicated that enhanced growth of 
this tumor in ALS-treated mice was partially due to a 
/ 
direct enhancing effect of ALS on the tumor. 
Inconsistencies have also been noted in the effects 
of different ALS preparations on murine leukemias (8, 63). 
The differences have been ascribed to the presence or 
absence of anti-viral antibodies in the anti-lymphocyte 
sera (8). Anti-viral antibodies which inhibited leukemia 
development were detected in ALS. When no activity was 
detected against the virus, the ALS had no effect on tumor 
growth or development. Since the lymphocytes are both the 
immunogens for ALS preparation and the presumptive tumor 
target tissue, and infected nontransformed normal lympho-
cytes express the antigen, the presence of anti-viral anti-
bodies in the ALS should not be surprising. A comparable 
situation may exist in the mammary tumor system where viral 
antigens are expressed on lymphocytes, but not on the red 
blood cells used for absorptions. 
It also seems reasonable that some of the differences 
can be accounted for by qualitatively different immune 
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responses elicited by the primary tumor in situ and by the 
tumor transplanted to an abnormal site. Evidence from 
transplantation studies in the marranary tumor system indi-
cate that the mammary fat pad may be a privileged trans-
plantation site (22). The presence of an intact basement 
membrane may confer this advantage on the spontaneous 
tumor (118). Other evidence suggests that normal mammary 
tissue components may be required for tumor growth and/or 
may sequester neoplastic cells from immune destruction 
(118). Although ALS is a relatively specific suppressor 
of cellular immunity, the facts that the relevant antigen 
is unidentified and that the sera are not rendered lympho-
cyte specific leave open many interpretations and may 
account for inconsistencies noted in the effect of ALS on 
tumor development. 
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D. Immunity and Murine Mammary 'rumors 
The murine mammary tumor must undergo a long develop-
mental progression from the time of virus infection until 
a truly neoplastic, invasive tumor exists (20, 21, 118). 
Following infection, which occurs either in the neonate or 
earlier, viral antigens are present on otherwise normal 
tissues. The antigen is not restricted to presumptive 
target tissue, but appears to be ubiquitous. It is not 
until after puberty, when hormonal stimulation is adequate, 
that the mammary tissue may undergo preneoplastic changes. 
Hyperplastic alveolar nodules or plaque structures are 
indicative of this change. These tissues are higly anti-
genic and are sensitive to immune destruction (118). They 
are not themselves neoplastic and may persist in this 
condition for long periods of time. Frank neoplasia with 
its characteristic invasive growth properties and resistance 
to immune destruction may eventually occur. Since all 
forms of this developmental sequence are antigenically 
distinct from the host, the stages, whether they display 
viral or individually distinct antigens (132, 134) must 
have some special relationship to the immune system. 
230 
The immune system in the young adult female is specifi-
cally nonreactive to mammary tumor viral antigens as illus-
trated by the increased susceptibility of virus carrying 
females to mammary tumor transplants (89, 90). Suscepti-
bility is ascribed to toleranc~ not to the presence of 
enhancing antibodies. This observation has led to the sug-
gestion that the distinction between susceptible strains and 
nonsusceptible strains is based on the relative ease in 
which immune tolerance can be induced in different mouse 
strains (21). Studies from Mintz's and Prehn's laboratories 
indicate that mammary tumor susceptibility is a character~ 
istic of the genotype of the presumptive target tissue and 
not the internal environment of the mouse (81-83). Trans -
plantation of preneoplastic lesions from allophenics or 
mosaics, in which the lesion is a mixture of cells from both 
high and low tumor strains, demonstrate that the neoplastic 
cells most generally originate from the high tumor strain. 
On the strength of these data, the immune response seems 
not to determine strain susceptibility to mammary tumors. 
If classical immunological tolerance to mammary tumor 
virus and associated antigens exists in susceptible strains, 
then i mmunosuppression should not in any way alter tumor 
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development. Neonatally thymectomized mice neonatally 
infected with mammary tumor virus develop tumors less fre-
quently than do sham thymectomized littermates. This 
observation has caused speculation that the thymus plays 
a positive and possibly a nonimmunological role in the 
development of the mammary tissue (113) or that thymus-
dependent immune functions contribute to the expression of 
malignant potential (52, 77, 106, 107). 
Some investigators have noted that neonatal thymectomy 
adversely affects subsequent development of the mammary 
glands (71, 75, 113, 142). The most direct mechanism sug-
gested by these observations is that the .thymus is a source 
of hormone which promotes normal mammary tissue develop-
ment (75, 115). An inhibitory effect on the presumptive 
tumor target tissue would naturally have an adverse effect 
on tumor incidence and development. Other investigators 
have noted that neonatally thymectornized mice fail to 
develop normally in a great number of respects (79). Neo-
natally thymectomized germ free mice do not exhibit gener-
alized growth defects, and the wasting syndrome of 
conventionally raised neonatally thymectomized mice has 
been attributed to infectious agents (79). In the absence 
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of data on the effect of neonatal thymectomy on tumor 
development in germ free mice, it may not be necessary to 
postulate the existence of a mammotrophic hormone. 
Another mechanism to explain the decreased tumor 
incidence is that the thymus-derived lymphocytes may be 
requisite intermediate cell hosts for the virus. The mam-
mary tumor virus is certainly present in these cells in a 
fully infectious state and the viral antigens are detect-
able on the surface of peripheral blood lymphocytes from 
infected mice (11, 94). Measurements of virus levels in 
neonatally thymectomized mice have failed to show a diminu-
tion from control values in sham treated mice (55). 
Even if this virus infection and expression is not 
required for the eventual malignant transformation, it may 
be important in inducing immunological tolerance. Continued 
tolerance to cellular antigens requires that the host be 
chimeric in its lymphoid tissues for the specific cellular 
antigens. Host tolerance may be advantageous for the host 
in preventing an autoimmune reaction. Since the virus is 
expressed in numerous body tissues, in normal as well as in 
premalignant and malignant tissues and in tissues which 
have never been observed to be transformed by the oncogenic 
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virus, antiviral immunity could be extremely detrimental to 
the host in the absence of malignant transformation. Virus 
and host are symbionts at least during host reproduction 
and viral transmission to the progeny. For tolerance to 
explain the results of neonatal thymectomy, this type of 
tolerance must be an active process and require the presence 
of a thymus at least during tolerance induction. An 
example of required thymus presence during tolerance induc-
tion has been reported in mice made tolerant to bovine 
serum albumin (102). In both instances, spleen cells were 
unable to substitute for thymus (102, 142). Studies with 
milk-transmitted murine leukemia virus suggest that the 
.virus carrier state may mimic, but is different from clas-
sical tolerance (109). 
If MTV infection is delayed, neonatal thymectomy 
increases tumor incidence. That neonatal thymectomy has 
opposite effects depending upon the time of infection could 
be explained as an immunological phenomenon. Neonates are 
much more susceptible to tolerance induction than are older 
individuals or adults. Early infection could cause toler-
ance, whereas later infection could result in immunity. 
Heppner has evidence from in vitro studies that serum 
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blocking factors to mammary tumors are not produced in mice 
which were neonatally thymectomized (52). Such blocking 
factors are present in the serum of normal control mice. 
Leukocytes from thymectomized and control mice are equally 
capable of inhibiting tumor cell growth. These results 
suggest that the mammary tumor antigens are thymus dependent 
antigens. Thymus cells are required in a cooperative step 
with antibody forming cell precursors before formation of 
specific antibody against a number of heterologous serum 
proteins and red blood cells (31, 80, 85). Thymus dependence 
of enhancing antibody formation has not yet been established 
by other techniques or independent confirmation. 
Immunosuppressive treatments, other than thymectomy, 
have profound effects on mammary tumor incidence or trans-
plantability. Splenectomy decreases tumor incidence, but 
splenectomy combined with neonatal thymectomy restores a 
normally high tumor incidence (122). 
Cortisone and x-irradiation both decrease the trans-
plantability of virus-positive tumors (194, 107, 121). In 
most of these examples, immunosuppressive procedures also 
inhibit growth of virus positive tumors. 
Virus-negative mammary tumors possess individually 
unique antigens (132-134). X-rayed recipients of virus 
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negative tumors show more tumor takes than do control mice. 
Splenectomy prior to transplantation of virus negative 
tumors decreases tumor incidence. In contrast to results 
with virus-positive tumors, immunosuppression generally 
facilitates the transplantation of virus-negative tumors 
(104, 107). Interpretation of the data may be tempered 
somewhat with the recognition that all imrnunosuppressive 
procedures may also be toxic for nonlymphoid tissues and 
that experiments with virus-positive and virus-negative 
tumors are rarely done in parallel. 
Agents which nonspecifically stimulate the immune 
response may decrease mammary tumor development (20, 21). 
The result of specific immunization with mammary tumor 
tissue is, however, unpredictable in that either immune 
enhancement or inhibition of tumor growth may occur (20, 
21). 
Dissecting the immune response to mammary tumors is 
complicated by the different classes of antigens -- viral, 
tumor associated nonviral and individually unique antigens. 
The virion itself is not a single antigen, but a group of 
distinct antigens (96). The net immune response as measured 
by tumor development is the sum of the immune responses to 
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all the separate antigens and a product of the animal's 
past antigenic history with respect to these antigens or 
cross-reacting antigens. Weiss reports that the enhancing 
antibody in murine mammary tumor systems is directed 
against, not a viral or tumor associated antigen, but a 
normal constituent of mammary tissue (137). If this 
claim is confirmed, the antibody may have an important 
function in normal physiological responses by the mammary 
tissue to hormonal changes. Elimination of enhancing anti-




The immune surveillance theory postulates that neo-
plastic transformation continually occurs within an indi-
vidual and that the immune system is the body's primary 
defense against tumors. A lapse in this defense system 
combined with the superior growth potential of tumors might 
allow the tumor to outgrow and overcome the immune system 
even if irnmunosuppression were of short duration. 
In humans, generalized immunosuppression is used 
therapeutically to delay rejection of allografts of vital 
organs. Therapeutic immunosuppression is induced and 
maintained by a combination of antimetabolites and steroids. 
Other, more direct manipulation of the immune system may 
supplement this treatment. Sufficient numbers of long term 
survivors are available only in the case of kidney trans-
plant recipients. Higher than normal cancer frequencies 
are observed in these patients -with lymphoma being the 
most frequent tumor type. Tumors appear relatively soon 
after the start of irnmunosuppressive therapy. Almost ten 
percent of the reported tumors appear within four months 
from the time of transplantation and the mean time of onset 
is twenty-eight months. 
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Although imrnunosuppression is assumed to be the major 
factor in the tumor increase, suppression of immune surveil-
lance is not the only mechanism whereby these tumors might 
arise. There are at least three alternatives. One is 
that uremia may predispose humans to cancer. The second is 
a possible carcinogenic effect of the antimetabolites used 
in irnmunosuppressive therapy. Third, a direct toxic effect 
on the immune system coupled with constant antigenic stimula-
tion might actively promote tumors of the lymphoid system. 
The contribution of irnmunosuppression to primary tumor 
induction and short tumor latency is therefore not corn-
pletely clear. 
The effect of immunosuppression in the absence of 
chemical toxicity or disease induced stresses can be 
evaluated in animal models where genetic and environmental 
heterogeneity are also controlled and where there is less 
chance of inadvertently transplanting a tumor with the 
graft. 
Virgin female mice of the CBA/J strain were observed 
I 
I 
until tumor onset or death after short term (anti-thymocyte 
serum induced) immunosuppression or a variety of non-
immunosuppressive treatments. The first few tumors were 
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observed in rabbit anti-mouse thymocyte serum (RAMTS) 
treated mice while control rabbit normal serum (RNS) 
treated mice were tumor free. Additional mice of the same 
strain were collected from other experiments, to obtain 
tumor data for untreated mice and mice subjected to other 
experimental procedures. None of the mice were experimen-
tally exposed to known carcinogens or oncogenic viruses. 
RAMTS was the only immunosuppressive agent used in this 
study. Anti-lymphocyte serum is often used in human trans-
plant patients to supplement other immunosuppressive treat-
ments. Mice tolerate high doses of anti-lymphocyte serum 
(ALS) without toxic side effects. ALS shows greater in 
vivo inhibition of the cell-mediated immune reactions, such 
as graft rejection, than of humoral immunity. The prepara-
tions of RAMTS used significantly prolonged survival of H-2 
incompatible skin grafts without grossly affecting humoral 
antibody. 
In mice, ALS-immunosuppression similar to that used in 
this study can significantly affect tumor growth when tumors 
are primary tumors or transplanted tumors. These facts sug-
gest that the severity and duration of immunosuppression in 
this study should have been adequate for tumor promotion. 
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No tumors appeared in any of the mice during or in a 
relatively long interval after immunosuppression. Tumors 
subsequently developed in both immunosuppressed and non-
immunosuppressed mice. Neither tumor incidence nor onset 
were affected significantly by immunosuppression. Fluctua-
tions in incidence were noted, but incidence was the same 
in matched RAMTS and RNS-treated mice. Cause of the varia-
tion in tumor incidence is not known. 
The results of this study on mice differ in two major 
respects from the reports of tumors in irnmunosuppressed 
transplant patients. First, no tumors appeared during 
immunosuppression and second, the predominant tumors which 
appeared later were not tumors of the lymphoreticular 
system. During immunosuppression, the frequency of spon-
taneous tumors in CBA mice in the absence of a carcinogen 
must be low even under conditions favorable for tumor 
growth. 
The most frequent tumor type was the typical mammary 
tumor. CBA/J mice carry the mammary tumor virus (MTV). 
100 percent of the mice are assumed to be infected, and 
normally as high as 75 percent of the females will manifest 
tumors. 
241 
Failure to observe an effect of immunosuppression on 
mammary tumor development requires explanation. Infection 
with MTV occurs in the neonatal period when mice are most 
susceptible to induction of immunological tolerance. Young 
adult mice neonatally infected with the virus are reported 
to be tolerant when challenged with syngeneic, virus posi-
tive tumors . By the time a primary tumor is detected, both 
humoral and cellular immunity exist coincident with the 
growing tumor. Humoral factors, either as antibody, anti-
gen or antigen-antibody complexes, at this time can protect 
tumor cells from immune destruction by sensitized lympho-
cytes. As a result, the cellular immune system may be 
specifically ineffective against the tumor and ALS-
immunosuppression should not alter tumor progression. 
Although the results of this study are consistent with 
the existence of specific tolerance and enhancing serum 
factors, other investigators have found that short term 
ALS-immunosuppression can enhance or inhibit MTV tumori-
genesis. The reason for these differences is probably that 
ALS is a class of reagents, not a monospecific or even a 
lymphocyte specific reagent. ALS can affect tumor growth by 
three different mechanisms depending in part on the anti-
body specificities present in the ALS preparation. It can 
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facilitate tumor growth by suppressing the immune response 
against the tumor. It can inhibit (or enhance) tumor growth 
by a direct toxic (or enhancing) effect of ALS antibodies 
directed against presumptive tumor or target organ. It can 
alter tumor growth by the generation of new reactive lympho-
cytes during the recovery phase, providing that the host's 
anti-tumor capabilities are thereby changed. 
ALS prepared using Freund's complete adjuvant or from 
hyperimrnune animals are more broadly toxic than ALS prepared 
without adjuvant. The RAMTS in this study was prepared by 
a standard method without adjuvant in contrast to the ALS 
preparations shown to inhibit primary mammary tumor growth 
or facilitate growth of transplanted mammary tumors. 
Since the thymus is the source of the peripheral 
lymphocytes involved in cell-mediated immunity, thymectomy 
should affect mammary tumor development in the same way as 
does ALS-immunosuppression. Under normal conditions of 
early vertical transmission of MTV, neonatal thyrnectomy 
decreases tumor incidence - quite the opposite from the 
effect expected from a suspension of immune surveillance. 
This observation has caused speculation that the role of the 
thymus in murine mammary tumor system may be more than just 
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immunological. There is some evidence that the thymus may 
provide a hormone which promotes mammary gland development 
directly. Another proposal is that the thymus-derived 
lymphocytes are necessary sites for MTV replication. 
If MTV infection is delayed, neonatal thymectomy 
increases tumor incidence. That thymectomy increases or 
decreases tumor incidence depending upon the time of infec-
tion, suggests an immunological phenomenon. The murine 
mammary tumor system is a prime example of immunological 
enhancement of tumor growth. Neonatal thymectomy does not 
detectably affect viral (MTV) replication, but can prevent 
the development of enhancing serum factors. Thymus derived 
lymphocytes are necessary in a cooperative step with bone 
marrow derived lymphocytes for production of antibody 
directed against some antigens. The effect of neonatal 
thymectomy on murine mammary tumors could be explained if 
relevant tumor antigens were in this group of thymus 
dependent antigens. The proposed role of the thymus in the 
production of enhancing antibody does not preclude other 
mechanisms of "active II tolerance. Because MTV is a group 
of associated antigens, the immunological response to each 
individual antigen may be different and the eventual outcome 
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of infection depends upon superimposing the immunological 
responses to the individual antigens. 
In the end, the effect of immunosuppression on primary 
tumor growth depends very much on the particular tumor 
system. There may be exceptions to immune surveillance, 
causing immunosuppression to be without effect or possibly 
to inhibit tumor growth. The effect of immunosuppression 
on spontaneous neoplasms would depend on four factors: 
(a) the presence of tumor associated antigens, (b) the 
past antigenic history of the tumor host, (c) the relative 
importance of nonimmune growth regulation, and (d) the 
mechanism of tumor induction. If there are no effective 
tumor-associated antigens or if the hos.tis "tolerant" to 
those antigens or if other control mechanisms constitute 
the body's primary tumor defense, immunosuppression should 
have no effect on the various parameters of tumor growth. 
If immunostimulation of tumors exists, a lapse in immunity 
will retard tumor development. It is only when tumors are 
antigenic, when the host is capable of responding immuno-
logically and in an inhibitory fashion, and when other con-
trol mechanisms are circumvented or secondary, that immuno-
suppression should significantly increase tumor expression. 
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The case for immune surveillance against tumors nay be very 
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